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SUMMARY
It is now recognised that a vast number of peptides are 
present in the central nervous system and that like classical 
transmitters some of these peptides may participate in the 
central regulation of the cardiovascular system. These 
neuropeptides may be colocalised in neurones with other
transmitters, such as catecholamines, in brain areas which
include the important cardiovascular regulatory region, the
medulla oblongata. The peptides reputedly act either 
independently or they undertake a neuromodulatory role where they 
may interact with the function of the costored transmitters. 
Delineation of the cardiovascular actions and possible 
interactions of peptides found in regions of cardiovascular 
significance may assist in the understanding of the labyrinthe 
mechanisms involved in centrally-mediated haemodynamics.
In this respect the ' first series of investigations 
(Chapter Three) examined the potential cardiovascular role of 
neuropeptide Y (NPY). Previous immunohistochemical studies have 
demonstrated the presence of this peptide in many brain regions. 
Of particular interest was the existence of NPY-immunoreactive 
cell bodies and terminals in two regions of the medulla 
oblongata, namely, the noradrenergic cell group in the caudal 
ventrolateral medulla and the adrenergic cell group of the 
rostral ventrolateral medulla. These regions are of considerable 
haemodynamic importance since they participate in the tonic and 
reflex regulation of blood pressure. Discrete microinjection of 
NPY (25 and 50 pmol) in the caudal region of the anaesthetised
rat produced a dose-related decrease in blood pressure. It is 
proposed that in the caudal region NPY may be involved in the 
mechanisms controlling blood pressure and that this peptide 
stimulates the (vasodepressor) cell group to elicit the
observed haemodynamic response. A fall in heart rate also 
proceeded the injection of NPY into this area. This response was 
not dose-related, and may indicate that a maximum response had 
already been reached at the lower dose. If this is the case, it 
would suggest that the mechanisms involved in the regulation of 
heart rate in this region are more sensitive to NPY than those of 
blood pressure, resulting in a similar magnitude of bradycardia 
at both doses of the peptide. Injection of NPY (25 and 50 pmol) 
into the more rostral (C^) area did not evoke any significant 
haemodynamic response.
The functional implications of the reported coexistence of 
NPY with catecholamines in the A^ and cell groups were
investigated in Chapter Four. It has been purported that the 
endogenous catecholamines of these regions (noradrenaline in the 
A^ region and adrenaline in the region) alter cardiovascular 
function principally through -adrenoceptors therefore the 
possible interaction between NPY receptors and C^-adrenoceptors 
was investigated by simultaneous injection of NPY and the OL^- 
adrenoceptor agonist clonidine into these discrete regions. 
Clonidine (10 and 20 nmol) alone evoked a dose-related 
hypotension and bradycardia in both the caudal and rostral 
ventrolateral medulla (Chapter Three). Coadministration of NPY
2
(25 or 50 pmol) together with a submaximal dose of clonidine 
(10 nmol) in these regions however, produced a hypotensive 
response which was comparable to the sum of their individual 
responses. These results indicate that although NPY and 
catecholamines have been shown to be colocalised in the caudal 
and rostral ventrolateral medulla a functional interaction 
pertaining to blood pressure regulation was not evident. The 
significance of their costorage with regard to this haemodynamic 
parameter may therefore reflect a provision for separate 
functions which are required or evoked under different 
physiological conditions. It is interesting that in the caudal 
but not the rostral area, the coadministration of NPY (25 pmol) 
and clonidine (10 nmol) elicited a fall in heart rate which was 
significantly less than the sum of the individual heart rate 
responses.
Chapters Five and Six deal with the molecular mechanisms 
involved in the central effects of NPY. In particular, the 
effect of NPY on cAMP levels in slices of the rat medulla 
oblongata was examined, since studies in other tissues have 
indicated that the functioning of this second messenger system 
was altered by NPY. In agreement with such studies, NPY was 
shown to reduce the forskolin-stimulated cAMP levels in slices of 
the medulla oblongata and cortex. Moreover the ability of NPY to 
inhibit forskolin-stimulated cAMP levels in medullary slices was 
abolished subsequent to intracisternal pretreatment with
pertussis toxin. These results support the involvement of the
\
cAMP system in the central actions of NPY, since this toxin is
known to inactivate a G-protein necessary for receptor-mediated 
reduction in adenylate cyclase activity and consequently cAMP
levels.
Although interactions between the haemodynamic responses to 
NPY and the C^-^renoceptor agonist clonidine were generally 
absent in the ventrolateral medulla, one study has observed a 
functional interaction between NPY receptors and
adrenoceptors in another important region of the medulla, namely, 
the nucleus of the solitary tract. The next series of
experiments therefore examined the possibility of an interaction 
being ■ evident in the medulla oblongata between NPY and '
adrenoceptors at the level of the cAMP system. The effects of 
C^-sdrenoceptor agonists alone were initially investigated. 
Clonidine did not significantly alter the levels of forskolin- 
stimulated cAMP in slices of the medulla whereas another 
antihypertensive agent moxonidine, with more selective G^ ~  
adrenoceptor properties, produced a significant reduction in this 
parameter. Further studies also revealed that the inhibitory 
action of NPY on forskolin-stimulated cAMP levels was attenuated 
in the presence of moxonidine suggesting the existence of an 
antagonistic interaction between the respective receptors. An
interaction between NPY and j3"adrenoceptors at t*16 level of the 
cAMP system was not apparent in the present study.
In the final chapter, the central haemodynamic actions of 
the recently discovered peptide endothelin-1 (ET-1) were 
investigated. Intracisternal administration of ET-1 (0.01 -
4
0.03 nmol) in the conscious rat produced a marked haemodynamic 
response at the highest doses of the peptide studied. A 
pronounced increase in blood pressure was observed accompanied in 
some cases by intense motor activity, but no consistant change in 
heart rate. The cardiovascular profile following this route of 
administration differed qualitatively from the response obtained 
following intravenous administration of the peptide. 
Furthermore, a haemodynamic response was elicited at lower doses 
of ET-1 subsequent to intracisternal administration of ET-1 than 
those necessary to produce a response following intravenous 
administration. These data would suggest that the haemodynamic 
response following was centrally-mediated and not due to leakage 
of the peptide into the peripheral nervous system. The 
hypothesis that the hypertensive event observed after 
intracisternal ET.-l administration was due to an action on 
cerebral blood vessels rather than an action on brain parenchyma 
was also investigated in this final chapter. Regional cerebral 
blood flow was measured using the [^C]-Iodoantipyrene 
autoradiographic technique and the data obtained clearly 
demonstrated that the dramatic increase in blood pressure after 
intracisternal ET-1 (0.03 nmol) administration in the conscious 
rat was associated with a widespread and profound reduction in 
cerebral blood flow throughout the medulla. Although an action 
of ET-1 on central neural mechanisms regulating vasomotor outflow 
cannot be excluded, it is propounded that the first line of 
action of this peptide following intracisternal administration 
occurs at the level of the cerebral vasculature.
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CHAPTER ONE
INTRODUCTION AND GENERAL BACKGROUND
6
Chapter One 
Introduction and General Background
In the attempts to understand the mechanisms underlying the 
central control of blood pressure much attention has been focused 
on the role of the medulla oblongata. This extensive field of 
research has included identifying the neurotransmitters present 
within this brain region. Indeed the recognition that 
catecholamine neurone groups exist in the medulla oblongata and 
are associated with blood pressure regulation, has formed a basis 
for efforts to examine the function of other putative 
transmitters in this region. The recent discovery of a pervasive 
distribution of peptides in the mammalian nervous system has 
raised the question of their functional significance. Encouraged 
in some cases by haemodynamic studies in the peripheral nervous 
system, evidence has now accumulated that several peptides may 
participate in central cardiovascular regulatory mechanisms. In 
this respect two newly identified peptides, neuropeptide Y and 
endothelin-1, both with documented evidence of haemodynamic 
actions in the peripheral nervous system will be considered, with 
the aim of examining their possible centrally-mediated 
cardiovascular activities. In particular, attention will be 
centred on the effects and mode of action of neuropeptide Y in 
the medulla oblongata. In addition the central haemodynamic 
actions of endothelin-1 and its possible role in cerebrovascular 
function will also be examined. As a milieu to this work the 
organisation of the central nervous system with regard to the
7
regulation of blood pressure will be briefly discussed in this 
first chapter, followed by an overview of the central
transmitters and peptides considered important in the central 
neural control of the cardiovascular system. The role of the 
medulla oblongata will then be examined in more detail
concentrating on the neurocircuitry and transmitters associated 
with the various nuclei of this brain region. Next the second 
messengers which may serve as the final biochemical end-point for 
the action of these and other putative neurotransmitters will be 
reviewed. Finally the short history of the two peptides
neuropeptide Y and endothelin will be discussed with reference to 
their peripheral as well as central distribution and activities.
1.1 Brain Regions Involved in the Control of the
Cardiovascular System-overview
It is now well appreciated that neural and hormonal systems 
at all levels of the central nervous system participate in the 
maintenance of blood pressure homeostasis. Thus, various
portions of the central neuroaxis are recognised as able to 
regulate the function of the heart (cardiac output), blood 
vessels (peripheral resistance) and consequently blood pressure, 
by the release of key humoral factors in concert with altering 
the level of activity conveyed over the parasympathetic and 
sympathetic branches of the autonomic nervous system.
The location of the general regions associated with 
cardiovascular control are shown in Figure 1.1 and will be 
discussed briefly.
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Figure 1.1
Sagittal cross-section of the rat brain showing 
important brain areas known to be involved in cardio­
vascular control
The brainstem, which comprises the medulla oblongata and 
pons, can be regarded as the most caudal link in the series of 
longitudinal systems extending from the cerebral cortex which are 
involved in this central control of the cardiovascular system. 
The medullary portion of the brainstem contains the nucleus of 
the solitary tract which serves as the major terminus for 
afferent input, from systemic baroreceptors and chemoreceptors, 
concerning the state of the cardiovascular system. This nucleus 
integrates and then relays this information to a wide variety of 
regions including the ventrolateral aspects of the medulla (Howe, 
1985). Axons from neurones in the latter area descend in the 
intermediolateral cell columns of the spinal cord to innervate 
the sympathetic preganglionic neurones situated in the spinal 
cord (Ross et al, 1981a). The balance of stimulation and 
inhibition provides the control of vasomotor tone by modulating 
the activity of the preganglionic neurones. These neurones are 
known to project to the paravertebral ganglia where they regulate 
the activity of the sympathetic postganglionic neurones which
innervate the heart and blood vessels. Stimulation of these
nerves causes vasoconstriction of resistance vessels and veins, 
vasodilation largely being achieved by fewer vasoconstrictor 
impulses. Most of the parasympathetic (vagal) fibres which
influence heart rate and balance sympathetic tone to the heart
originate in a region of the medulla termed the nucleus ambiguus. 
This nucleus receives an input from and is influenced by the 
nucleus of the solitary tract (Thomas and Calaresu, 1974). The 
paramedian reticular nucleus of the medulla as well as the
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fastigial nucleus of the cerebellum receive communication from 
the vestibular apparatus and make up the network responsible for 
changes in sympathetic tone during changes in posture (Miura and 
Reis, 1971). The area postrema, a circumventricular organ 
located in the caudal medulla, also reputedly influences the 
central neural output to cardiovascular effectors. This 
important area receives afferent input from cardiovascular 
receptors and projects to brain regions associated with 
cardiovascular control including the nucleus of the solitary 
tract and the parabrachial nucleus (Shapiro and Miselis, 1985). 
It is devoid of a blood brain barrier and this allows neural 
elements within and perhaps subjacent to this region to be 
directly exposed to circulating hormones such as vasopressin and 
angiotensin. The more rostrally located parabrachial nucleus of 
the pons also plays a significant role in the neural and humoral 
modulation of the cardiovascular system. This nucleus has 
widespread connections with other cardiovascular centres, in 
particular the nucleus of the solitary tract and the hypothalamus 
and when stimulated evokes an increase in arterial pressure and 
heart rate (Mraovitch et al, 1982).
The hypothalamus, and related structures which lie along the 
lamina terminalis, have been implicated as sites of higher 
cardiovascular control for a number of years. These areas 
provide for the integration of somatic, endocrine and autonomic 
functions and can modulate these functions according to emotional 
situations. Activation of the various hypothalamic centres
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results in a myraid of vasopressor and depressor states, some of 
which are closely involved with the activity of the important 
cardiovascular nuclei in the medulla oblongata. These pathways 
therefore provide a means for higher centres to conduct 
cardiovascular regulation. Electrical stimulation of the 
paraventricular nucleus, anterior (AV3V), or posterior 
hypothalamic regions evoke an increase in blood pressure. In the 
latter region an inhibitory action on baroreceptor reflexes was 
also observed and these effects have been associated with the 
preparation for the 'flight or fight' reaction (Cirello and 
Calaresu, 1980a; Brody et al, 1980). In contrast, stimulation of 
the dorsal anterior hypothalamic region appears to elicit a 
vasodepressor response (Gauther et al, 1981).
Higher centres, such as the cerebral cortex have been shown 
to be involved in conditioned and learned cardiovascular 
responses. It is possible that cortical perceptions such as 
stress can be transmitted to centres responsible for 
cardiovascular regulation and may chronically influence blood 
pressure (Ganten and Pfaff, 1983). A close anatomical and
functional integration between the hypothalamic and cortical 
regions is provided by the limbic system. This area is 
particularly associated with cardiovascular adaptation in 
response to fear and rage.
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1.2 Neurotransmitter Associated with the Central Regulation
of the Cardiovascular System Overview of the 
Classical Transmitters and Neuropeptides
1.2.1 Classical Transmitters
Although the participation of humoral mechanisms in the 
central control of blood pressure has been recognised since the 
beginning of the century, the knowledge that processing in the 
brain involves communication among neurones - through the release 
of chemical messengers at synapses - was only established with 
certainty much later (Eccles, 1954). Acetylcholine was the only 
generally accepted transmitter in the central nervous system for 
some time, however, with the development of histochemical and 
neuroanatomical techniques, a fairly rapid increase in the number 
of candidates ensued. The histochemical fluorescence studies of 
Dahlstom and Fuxe (1964; 1965) demonstrated the presence of
discrete collections of neurones containing catecholamines. This, 
supported earlier biochemical studies which suggested such a role 
for noradrenaline and dopamine in central neurotransmission 
(Vogt, 1954; Carlsson et al, 1958).
Histochemical analysis further revealed that noradrenergic 
cell groups were located in the brainstem and these were 
subsequently labelled A^ - Ay (Figure 1.2). It was considered at 
that time that the most caudally situated noradrenergic cell 
groups in the ventrolateral and dorsomedial medulla (A^/A^) 
provided the descending projections to the spinal cord whereas
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Figure 1.2
Schematic drawing of a sagittal section of rat brain showing 
the location of noradrenaline, adrenaline and dopamine cell 
groups.
The nomenclature of the different cell groups according to 
Dahlstrom et al (1964; 1965); Hokfelt et al (1974).
the other rostral groups, for instance the A6 group in the 
pontine locus coeruleus, ascended to more rostral areas to 
terminate in the cerebral hemispheres, the cerebellum and the 
hypothalamus. Dopamine (Ag - A-^ g) cells were found mainly in mid 
and rostral parts of the brain in areas such as the 
mesencephalon, the hypothalamus, and the olfactory bulb, with 
scattered cells in other brain regions (Figure 1.2). Serotonin 
neurones were also described by these authors with descending 
spinal neurones arising from the B^ - Bg groups in the medulla 
and the more rostrally located cell groups (B^ - B^) providing 
ascending projections. The later discovery of adrenaline in 
central neurones led to the modification of the original 
descriptions by Dahlstrom and colleagues. Hokfelt et al (1974), 
using immunofluorescence to demonstrate the presence of the 
enzyme phenylethanolamine-N-methyltransferase (PNMT) which
catalyses the conversion of noradrenaline to adrenaline 
established the presence of 2 medullary groups of adrenaline 
cells. These neurones designated and C2  were situated in the 
ventrolateral and dorsomedial medulla within the rostral portions 
of the noradrenergic A^ and A 2  cell groups, respectively 
(Figure 1.2).
Thus it was postulated that central neurones could utilise 
adrenaline as well as noradrenaline and dopamine as 
neurotransmitters. Although a third group of adrenaline- 
containing neurones and a dopamine cell group were described 
recently in the medulla by Howe et al (1980) and Armstrong et al 
(1982) respectively, a more significant modification to the
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orginal work of Dahlstrom and Fuxe stemmed from the development 
of neuroanatomical techniques such as the retrograde transport of 
horseradish peroxidase to map central pathways. It was realised 
that projections from the catecholamine cell groups were more 
complicated than originally envisaged with some of the pathways 
long and often diffuse. Ascending pathways were shown from the 
most caudal noradrenergic groups (A^/Ag) as well as descending 
projections from the more rostral nuclei. Moreover some 
investigators now believed that the descending catecholamine 
projections did not arise exclusively (if at all) from the 
noradrenergic located in the medulla but that more
rostrally located medullary neurones including the adrenergic 
cell group and the serotonergic B^, B2  and B^ provided that 
innervation (Ross et al, 1981a; Dahlstrom and Fuxe, 1964; 1965). 
At the level of the medulla oblongata, the main adrenergic 
projection group is the group which was shown to give rise to 
both ascending and descending pathways. The ascending adrenergic 
pathways may run in the medullary catecholamine bundle or as 
recent studies suggest more ventrally along the ventromedial edge 
of the brainstem (Palkovits and Brownstein, 1989). The 
descending spinal adrenergic projections run in the dorsal part 
of the lateral funiculus and innervate almost exclusively the 
lateral sympathetic column.
Axons of the medullary noradrenergic neurones run in the 
medullary catecholamine bundle (also known as the tegmental 
tract) which carries both ascending axons from the A^ and A 2
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groups and descending axons from the Ag and cell groups
(Palkovits and Brownstein, 1989; Hokfelt et al, 1974).
It is of considerable interest that the distribution of 
these central catecholamine neurones, in particular those located 
in the brainstem, are similar to the location of the central 
regions and pathways involved in cardiovascular regulation 
(Figure 1.1, Chalmers, 1975) - a concept that will be discussed 
in more detail in Section 1.3. Moreover it has been demonstrated 
that chemical inhibition or destruction of central 
catecholaminergic or serotonergic nerves has marked effects on 
blood pressure (Haeusler et al, 1972; Saavedra et al, 1976; Wing 
and Chalmers, 1974). While these central monaminergic systems 
apparently participate in the regulation of blood pressure under 
normal conditions, it has also been shown that their function may 
be altered under conditions of high blood pressure. Thus, 
changes in the metabolism and activity of these monoamine 
neurones have been reported in a number of models of experimental 
hypertension suggesting that these transmitters are involved in 
some way either in the generation of, or response to 
hypertensive states (Nakamura et al, 1971; Wing and Chalmers, 
1974; Reid and Rubin, 1989).
Amino acids came into focus in the 1970s as potential 
inhibitory and excitatory transmitters in the central nervous 
system. As reviewed by Hokfelt et al (1984b) autoradiographical 
studies describe the presence of the amino acids gamma- 
aminobutyric acid (GABA), glycine and glutamate within neuronal 
systems. Quantitative and immunohistochemical studies have
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further confirmed that extensive neuronal systems containing the 
inhibitory amino acid GABA exist in the central nervous system. 
While some of these GABA neurones have long projections, for 
instance from the posterior hypothalamus to cortical or 
subcortical areas, a large majority of these systems represent 
local neuronal networks (Jessell et al, 1978). These 
interneurones have been observed in the ventrolateral medulla 
where pharmacological evidence suggests that they play a tonic 
inhibitory role in the regulation of blood pressure (Ruggiero 
et al, 1985a; Reis, 1987). A pressor action of glutamate has 
been observed in the medulla. Indeed this putative transmitter 
has been proposed as a candidate for excitatory input to 
cardiovascular regulation at various levels of the medulla 
including the NTS and the regions (Sun et al, 1986).
1.2.2 Neuropeptides
In addition to the 'classical transmitters' described above 
an explosion in the number of possible chemical messengers 
resulted from the appreciation that peptides were present in 
central neurones and may also serve a neurotransmitter or 
neuromodulator function. Attempts to identify the neuropeptides 
responsible for centrally-mediated cardiovascular functions are 
impeded by their sheer number and pervasive distribution. 
Moreover complications arise from the finding that a peptide may 
have varied effects on a particular function at different levels 
within the central nervous system. Indeed elucidation of their 
respective roles has often followed their neuroanatomical
16
localisation. While many of these peptides fulfil some of the 
essential criteria suggested by Burnstock et al (1979) for 
establishing chemical messengers as neurotransmitters, most 
peptides have not yet been tested for all of these criteria. 
However, a number of peptides with established or putative 
central cardiovascular regulatory functions have been described 
in the last few years following biochemical, immunohistochemical 
and physiological investigations and have been reviewed very 
recently by Reid and Rubin (1987) and Gardiner and Bennett 
(1989). Some of these putative neuropeptides are shown in 
Table 1.1. While it is outside the scope of this discourse to 
consider all of these peptides, the central cardiovascular 
significance of a selected few will be discussed.
The opioid peptides methionine-enkephalin and leucine- 
enkephalin have attracted considerable attention not least 
because of their wide central distribution. Another opioid 
peptide ^-endorphin is also extensively located but is distinct 
from the enkephalin peptides (Lang et al, 1984). The 
hypothalamus and brainstem, cardiovascular regulatory regions, 
contain substantial amounts of opioid peptides. However, central 
administration of these peptides has revealed contradictory 
results with pressor and depressor responses observed depending 
on the area, species and specific peptide investigated. In 
general, leucine and methionine-enkephalin appear to evoke a 
central pressor response in conscious animals although depressor 
effects have been described in anaesthetised animals (Schaz
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Table 1.1
A List of Peptides with Established or Putative Influences 
on Central Cardiovascular Control Selected Examples
j(3 -endorphin 
Leucine-enkephalin 
Methionine-enkephalin
Angiotensin II
Vasopressin
Oxytocin
Corticotrophin-releasing hormone 
Thyrotrophin-releasing hormone 
Somatostatin
Substance P 
Bradykinin 
Neurotensin 
Galanin
Neuropeptide Y 
Atrial natriuretic factor 
Vasoactive intestinal polypeptide 
Calcitonin-gene related peptide 
Bombesin
Endothelin (?)
Data taken from Gardiner and Bennett (1989); Reid and Rubin 
(1987); Yanagisawa and Masaki (1989a).
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et al,, 1980; Yakimura et al, 1981). endorphin elicits
primarily a hypotensive effect when administered centrally. In 
particular this peptide has a depressor effect in the medulla and 
within this area may participate in the reflex regulation of 
blood pressure (Petty and Reid, 1981). A role for the peptide 
substance P in central cardiovascular mechanisms has been 
suggested by several studies. Substance P is found in abundance 
within the hypothalmus where this peptide has been observed to 
exert a potent pressor response (Unger et al, 1981). In 
contrast, in the medulla this peptide has been observed to 
produce either a fall in blood pressure, or have no effect (Kubo 
and Kihara, 1987; Carter and Lightman, 1986). Two other peptides 
with established influence in cardiovascular regulation are 
angiotensin II and vasopressin. In addition to the purported 
centrally-mediated haemodynamic (pressor) activity of circulating 
systemic angiotensin II and vasopressin, recent studies have
identified neuronal systems containing these peptides in the
central parenchyma, suggesting an intrinsic central 
neurotransmitter role for these peptides (Ferrario et al, 1970; 
De Wied and Jolles, 1982). Although these systems have been
observed in a variety of discrete central regions including the 
brainstem, angiotensin II and vasopressinergic nerves are most 
prominent in hypothalmic regions. Administration, either into 
the cerebrospinal fluid or into discrete brain regions have
confirmed a pressor response to angiotensin II and vasopressin 
(Reid and Rubin, 1987). An important role in cardiovascular 
control mechanisms is also proposed for the peptides
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neuropeptide Y and the very recently identified peptide 
endothelin-1. A function for these peptides in the peripheral 
cardiovascular system has been described and this together with 
their imputed central activity will be considered in detail in 
Sections 1.5 and 1.6.
1.2.3 Cotransmission
It is now apparent that peptides are present in well-defined 
central neuronal systems and effect the mechanisms involved in 
cardiovascular control. While these peptides may be present in 
distinct systems with an independent function, 
immunohistochemical analysis of the distribution of various 
peptides has revealed that in many cases both in the peripheral 
and central nervous systems, peptides could be observed in a 
neurone containing another transmitter. Several types of co­
existing situations have emerged: (1) classical transmitter plus
peptide(s); (2) more than one classical transmitter and (3) more 
than one peptide (Hokfelt et al, 1986). The functional 
significance of co-existing messengers has not been fully 
resolved. However, that the various types of compounds differ in 
parameters such as time course and mechanism of action may be 
utilised if they are co-stored and/or co-released. Indeed amino 
acids have been associated with fast transmission processes 
whereas monoamines and particularly neuropeptides often exert 
effects which are slow on onset and of long duration (Bloom, 
1979; Schmitt, 1984). There are several models which explain how 
co-stored messengers might work. One mechanism would be that the
neurone always releases all of the messenger molecules 
simultaneously and the distribution of receptors provides 
selectivity and specificity (post-synaptic selectivity). These 
messengers may act independently or interact either at the 
postsynaptic or presynaptic level. An alternative would be that 
the neurone has the ability to release the messengers 
differentially under certain conditions (pre-synaptic 
selectivity). ■
Rapid development in the understanding of co-existing 
messengers has focused on the presence of a classical transmitter 
together with a peptide. In the peripheral nervous system 
evidence exists that classical transmitters and peptides are co­
released and in addition to an independent action these agents 
can also interact in a cooperative way on effector cells. For 
instance, vasoactive intestinal polypeptide is co-stored in the 
parasympathetic nerves of the salivary gland with acetylcholine 
and has been shown to enhance the secretory effects of the 
classical transmitter. In contrast, in the rat vas deferens 
where nbradrenaline and neuropeptide Y are co-stored, the peptide 
seems to inhibit the release of noradrenaline via a presynaptic 
action (Lundberg and Hokfelt, 1983; Stjarne et al, 1986). The 
situation is more confusing in the central nervous system because 
of the more complex neuronal organisation and the difficulties 
experienced obtaining suitable preparations for investigation. 
Although numerous co-existing situations do exist between 
classical transmitters and peptides in brain regions the
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functional significance of these is still rudimentary 
(Table 1.2). However the function of the co-storage of the 
classical transmitter serotonin with the peptide substance P in 
the medullary neurones has been investigated. These neurones 
project to the spinal cord and probably innervate motoneurones. 
It has been shown that the peptide ' blocks the presynaptic 
serotonin autoreceptor and consequently enhances serotonin 
release from spinal cord slices. The physiological relevance of 
this action could be to strengthen the serotonin-mediated stretch 
reflex (Mitchell and Fleetwood-Walker, 1981). Another system
that has attracted considerable attention is the differential co­
existence of peptides in central catecholamine neurones. Since 
adrenaline and noradrenaline neurones have been implicated in 
cerebral cardiovascular regulation, a role for colocalised
peptides in central haemodynamic mechanisms has been suggested.
In particular, neuropeptide Y, which is co-stored and interacts 
with noradrenaline in the peripheral nervous system, has been 
shown to be present in central catecholamine neurones and may 
therefore contribute to blood pressure regulation (Section 1.5).
1.3 Importance of the Medulla Oblongata in the Control of
the Cardiovascular System
1.3.1 History
Although the potential for control of the cardiovascular 
system from regions rostral to the brainstem has been 
acknowledged, historically systems within the lower brainstem, 
which comprise the medulla oblongata and pons, have been
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Table 1.2
Coexistence of Classical Transmitters and Peptides in the 
Central Nervous System Selected Examples
Classical Peptide Brain region (species)
Dopamine Neurotensin 
Cholecystokinin
Ventral tegmental area 
Ventral tegmental area 
man)
(rat)
(rat,
Noradrenaline Enkephalin 
Neuropeptide Y
Locus coeruleus (cat) 
Medulla oblongata (man, 
Locus coeruleus (rat)
rat)
Adrenaline Neurotensin 
Neuropeptide Y 
Substance P
Medulla oblongata (rat) 
Medulla oblongata (rat) 
Medulla oblongata (rat)
Serotonin Substance P 
Enkephalin
Medulla oblongata (rat) 
Medulla oblongata, pons (rat)
Achetylcholine Vasoactive 
intestinal 
polypeptide 
Enkephalin 
Substance P
Cortex (rat)
Spinal cord (rat) 
Pons (rat)
GABA Somatostatin Thalmus (rat) 
Cortex (rat)
Data taken from Hokfelt et al (1984a).
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recognised as critical for the tonic as well as reflex 
maintenance of arterial pressure. The first major advance 
towards this concept was the discovery by Bernard (1863) that 
transection of the spinal cord resulted in a substantial fall in 
arterial pressure. Later Dittmar (1873) and Owsjanniko (1871) 
demonstrated that transection of the brainstem from areas that 
lie rostral to it had little effect on the basal level of 
systemic arterial pressure, whereas successive caudal 
transections produced a progressively greater fall in arterial 
pressure, until disconnection at the level of the obex reduced 
arterial pressure to a level comparable to that observed after 
cervical spinal transection. From these classic studies and the 
initial failure of investigators to replicate, by localised 
lesions in the medulla, the effects of spinal cord transection 
arose the hypothesis that the essential neurones for maintenance 
of arterial pressure were distributed throughout the brainstem 
rather than being concentrated in a discrete region. Thus, it 
was considered that a diffuse pool of neurones were responsible 
for receiving all the information regarding cardiovascular 
parameters, transforming it into the provision of sympathetic 
nerve outflow and consequently regulating systemic arterial 
pressure. However, with the introduction of the stereotaxic 
method the brainstem was examined more systematically for sites 
from which alterations in arterial pressure could be elicited by 
electrical stimulation. This led to the description of large 
pressor and depressor areas in the brainstem with a number of 
groups focusing on the dorsolateral reticular formation of the
brainstem as a potential site of a pool of tonically active 
neurones. These neurones would provide the excitatory and 
inhibitory input to sympathetic vasomotor and cardiac nerves 
(Alexander, 1946; Wang and Ranson, 1939). Around the same time 
it was realised that the cardiovascular effects elicited by 
electrical stimulation could result from the excitation of fibres 
of passage rather than cell bodies. Therefore, the extent of the 
pressor as well as depressor regions demonstrated previously may 
reflect the diffuse distribution of axons rather than the 
'cardiovascular' cells themselves. This information suggested 
that the central neurones controlling sympathetic cardiac and 
vasomotor outflow were perhaps situated in a discrete region(s).
The ventral surface of the medulla was next to come under 
scrutiny as a site of vasomotor activity. This was initially 
because of the ‘ observations of Guertzenstein (1973), that 
chemical inhibition, in particular direct application of sodium 
pentobarbitone or glycine resulted in a profound fall in arterial 
pressure similar to spinal cord transection. Since glycine was 
known to hyperpolarise and inactivate neurones by an action on 
the cell bodies rather than axons, it was postulated that the 
neuronal cell bodies near the ventral surface provided the tonic 
excitatory input to the sympathetic preganglionic nerves. These 
neurones regulate the activity of the neurones innervating the 
heart and blood vessels. The availability of neuroanatomical 
techniques such as the use of fluorescent dyes and markers 
(horseradish peroxidase) that provide tracings of pathways
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greatly advanced the knowledge of neuronal connections within the 
central nervous system. Using the latter technique Amendt et al 
(1979) confirmed that a group of neurones located near the
ventral surface of the medulla projected directly to the
intermediolateral cell columns of the spinal cord where the
preganglionic neurones, which regulate the activity of the nerves 
to blood vessels and the heart, are situated.
Altogether the evidence suggested that a group of neurones 
in the ventrolateral medulla were critical for the maintenance of 
vasomotor tone and strengthened the hypothesis that vasomotor 
activity is regulated by functionally discrete medullary neurones 
rather than a general multifunctional neuronal pool. While this 
area is ostensibly of crucial importance in sustaining arterial 
blood pressure, other major areas in the medulla have since been 
observed to have, important functions per se in the tonic and 
reflex control of blood pressure in addition to regulating the 
tonically active neurones in the ventrolateral medulla. The
following sections will discuss in more detail the neuroanatomy, 
physiology and transmitters of these major medullary nuclei 
(incorporating the ventrolateral regions) whose . function and 
interconnections are considered pivotal to the regulation of the 
cardiovascular system.
1.3.2 The Nucleus of the Solitary Tract
The nucleus of the solitary tract (NTS), situated in the 
dorsomedial medulla is the main terminus and relay station for 
cardiovascular afferent information (as well as .other visceral
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information) concerning the status of the peripheral 
cardiovascular function (Figure 1.3). Thus, baroreceptors 
located in the heart, carotid sinus, aortic arch and other large 
vessels, detect changes in blood pressure and transmit this 
information via fibres which travel in the carotid sinus nerve, 
as well as the glossopharyngeal and vagus nerves to the NTS. 
This innervation is bilateral and the fibres terminate in the 
caudal (dorsolateral, medial, commissural) two-thirds of the 
logitudinal Y-shaped nucleus (Calaresu et al, 1975; Wallach and 
Loewy, 1980).
The major role of the NTS is considered to be in the 
mediation of the baroreceptor reflex. This cardiovascular reflex 
is stimulated by increases in arterial blood pressure and evokes 
both a decrease in peripheral vascular resistance as well as a 
negative chronotropic and inotropic effect on the heart. The 
involvement of the NTS in the reflex regulation of cardiovascular 
function is supported by the finding that neurones in the NTS 
respond monosynaptically to stimulation of baroreceptor afferents 
and fire in synchrony with the arterial pulse, indicating that 
they are locked into the baroreceptor reflex chain (Spyer, 1981). 
Moreover, Doba and Reis (1973) demonstrated the lesioning of this 
nucleus abolished baroreflexes and resulted in an acute elevation 
of blood pressure (neurogenic hypertension), whereas electrical 
stimulation of this nucleus elicits the opposite response with a 
reduction in blood pressure (Seller and Illert, 1969). Although 
controversial, the rise in arterial pressure with discrete 
lesions of the NTS has been reported by several groups to return
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Figure 1.3
Schematic diagram showing the location of catecholamine cell groups 
in the medulla involved in the control of blood pressure and heart rate.
NTS, Nucleus of the solitary tract; NA, nucleus ambiguus, A^ noradrenergic 
cell group, adrenergic cell group.
to normal values with time, suggesting that this nucleus is not 
crucial for establishing the long-term set point for blood 
pressure. However, a permanent increase in blood pressure 
lability has been demonstrated (Cowley et al, 1973; Bucholz and 
Nathan, 1984). A prominent feature of the NTS is the number of 
putative neurotransmitter substances that have been localised and 
that produce a haemodynamic response in this region (Malay and 
Elde, 1982; Yamazoe et al, 1984; Leslie, 1985). The transmitter 
of the primary afferent input is uncertain. Substantial evidence 
exists to suggest that afferent fibres may contain the excitatory 
amino acid L-glutamate and that release of this amino acid 
transmits the information from the baroreceptors onto the 
neurones of the NTS. Indeed, local injection of L-glutamate into 
the NTS elicits baroreflex-like responses (Reis et al, 1981). 
That substance P is also present in these afferent fibres 
implicates this peptide as a possible transmitter in the 
baroreflex. However its function in this region is less clear 
since it has been shown to either decrease blood pressure or have 
no effect (Gillis et al, 1980; Kubo and Kihara, 1987; Carter and 
Lightman, 1986). Catecholaminergic neurones and terminals have 
also been located in the NTS. This region contains two notable 
catecholamine cell groups, the noradrenaline A 2  cell group 
located in the caudal region and the more rostral group of 
adrenergic C2  neurones (Section 1.2.1). Morover, several studies 
have shown that catecholamines can function as neurotransmitters 
in the NTS to regulate autonomic function (Zandberg et al, 1979).
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Although the NTS does not have extensive projections to the 
preganglionic sympathetic neurones which control vasomotor 
outflow, it does project to several brainstem and forebrain sites 
that do have direct sympathetic and vagal connections (Loewy and 
Burton, 1978). Indeed the modulation of arterial pressure via 
brainstem nuclei which control preganglionic nerve activity is 
considered to be of critical importance in the regulation of 
arterial pressure in the NTS-mediated baroreflex response. 
Electrophysiological and neuroanatomical studies provide evidence 
of a reciprocal connection between the NTS and the ventrolateral 
medulla, supporting such an involvement (Ciriello and Caverson, 
1986; Dampney et al, 1987; Ruggiero et al, 1985b). Furthermore, 
lesions of the ventrolateral region, in particular the rostral 
portion, abolish baroreceptor and other reflex responses elicited 
from afferent fibres of the vagus (Section 1.3.4). The NTS also 
has neural connections with higher structures in the brain. The 
parvocellular neurons in the paraventricular nucleus of the 
hypothalamus receive an input from the A2 cell group of the NTS. 
Projects from the parvocellular neurones to the autonomic regions 
of the brainstem and spinal cord are thought to contribute to the 
control of cardiovascular function (Sawchenko and Swanson, 1982; 
Ciriello and Calaresu, 1980b; Brody, 1986). It has been 
demonstrated that the NTS can modulate the electrical activity of 
the magnocellular neurones in the hypothalamic supraoptic and 
paraventricular nuclei and thus regulate secretion of the peptide 
vasopressin from the neurohypophysis (Koizumi and Yamashita,
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1978; Harris, 1979; Shade and Share, 1975). Pathways from the 
NTS via the parabrachial nucleus or the cell group of the 
caudal ventrolateral medulla have been implicated in the 
provision of the ascending pathways controlling the secretion of 
this vasoconstrictor and antidiuretic hormone (Norgren, 1978; 
Swachenko and Swanson, 1982). The integrative function of the 
NTS in cardiovascular regulation is further highlighted by the 
diversity of central sites which have inter connections with, and 
are able to modulate the function of, this nucleus. These 
include inputs from the area postrema, parabrachial nucleus of 
the pons, the fastigial nucleus, and the hypothalamus (Ross 
et al, 1981b). A pathway from the NTS to the nucleus ambiguus of 
the medulla is thought to contribute to the reflex regulation of 
heart rate (Steusse and Fish, 1984a). The involvement of the 
latter nucleus in.cardioinhibitory function will be considered in 
the following section.
1.3.3 The Nucleus Ambiguus
The nucleus ambiguus (NA) has been proposed as a site of 
origin of central cardioinhibitory neurones (Figure 1.3). This 
nucleus consists of a thin column of cells in the ventrolateral 
medulla, extending from the caudal pole of the facial nucleus to 
the pyramidal descussation. The first suggestion that this 
nucleus was involved in cardioinhibitory functions was based on 
the finding that lesions of the nucleus produced degeneration in 
the- cardiac branches of the vagus (Szentagothai, 1952). More
recent histochemical studies in the rat have confirmed that the
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nucleus ambiguus sends projections through the vagus to the heart 
and that the majority of preganglionic parasympathetic fibres 
which terminate in the heart originate from the NA (Stuesse, 
1982). Another region in the medulla, the dorsal motor nucleus 
of the vagus is also known to send projections through the vagus 
(Kalia, 1981). However, electrophysiologic functions have failed 
to clarify the role the projections from this nucleus play in 
cardioinhibition. Electrical stimulation has been reported to 
either result in bradycardia or have no effect (Geis and Wurster, 
1980; Steusse and Fish, 1984b). While species' differences may 
account for these discrepancies, recent evidence suggests that 
this area is predominately concerned with altering heart 
contractility but not heart rate (Geis et al, 1981).
Thus, consistent with its purported role as a 
cardioinhibitory centre electrical stimulation of the NA results 
in bradycardia (Ciriello and Calaresu, 1980c). The area of the 
NA which reduces the heart rate has been reported to be confined 
to a small rostral portion of the nucleus (Steusse and Fish, 
1984a). These authors further demonstrated by tracer techniques 
that a major projection to this rostral area was from the NTS, a 
known site of termination of cardiovascular afferent fibres. 
Indeed selective lesions of the NTS were previously shown to 
result in the degeneration of projections to the NA implicating 
the latter nucleus in the pathway mediating reflex cardiac 
control. Moreover, Machado and Brody (1988a; 1988b) have
proposed that this area also has a tonic cardioinhibitory 
function. Electrical stimulation of the NA evoked a bradycardia
that was not reflex in origin since it was maintained in rats 
with sinoaortic deafferation. Other projections to this region 
were derived from the parabrachial complex and the 
paraventricular nucleus of the hypothalamus (Steusse and Fish, 
1984a). Although these areas might be involved in the slowing of 
heart .rate, other autonomic functions may also be subserved. The 
view that the NA may be related to the control not only of heart 
rate but also of arterial pressure was purported by Machado and 
Brody (1988a; 1988b). Since electrolytic, as well as chemical
lesion, facilitated the development of hypertension in rats with 
sinoaortic deafferation. In this respect the functional role of 
the established projections from the NA to the NTS, the 
parabrachial nucleus and the spinal cord have to be further 
investigated. Another potentially important functional
connection is that reported from the NA to the rostral 
ventrolateral medulla (Dampney et al, 1987). The role of this 
input from the NA to this area is as yet unknown. However, the 
importance of the rostral ventrolateral medulla in the regulation 
of blood pressure, which will be discussed in the proceeding 
section, implicates the NA in more widespread , functions than 
cardioinhibition.
1.3.4 The Rostral Ventrolateral Medulla
Following the initial observation that glycine applied to 
the ventral surface of the medulla caused a collapse of arterial 
pressure comparable to spinal cord transection, this general area 
of the medulla has been subjected to extensive investigations as
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a possible site of vasomotor activity (Guertzenstein, 1973). 
Several groups have since demonstrated that electrical or 
chemical lesioning of a discrete region in the rostral 
ventrolateral medulla (RVLM) reduced arterial pressure and heart 
rate to spinal levels. This evidence together with the fact that 
electrical or chemical excitation of this region elevates 
arterial pressure and heart rate, suggests that the neurones of 
this restricted zone are sympathoexcitatory and that their
integrity is necessary for the maintenance of vasomotor tone 
(Dampney et al, 1982; Ross et al, 1984b). *
In a series of experiments combining electrophysiological as 
well as immunohistochemical techniques, Ross al (1984b) 
revealed a tight correlation in the rat between the location of 
the RVLM pressor region and a group of adrenaline-containing cell 
bodies, originally designated the cell group (Hokfelt et al, 
1974; Section 1.2.1). The area of the RVLM in the rat is
located caudal to the facial nucleus of the pons and rostral to
the most precerebellar relay neurones of the lateral reticular 
nucleus (Figure 1.3). It extends rostrocaudally as a cell
column, representing a subdivision of the nucleus 
paragigantocellularis lateralis (Paxinos and Watson, 1986; 
Andrezik et al, 1981). Anatomical studies have shown that this 
adrenaline-synthesising cell group projects to the 
intermedialateral cell column of the spinal cord, where the 
preganglionic neurones are situated, thus supporting a functional 
role for the intrinsic neurones in the area in tonic vasomotor
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tone (Ross et al, 1984a). Indeed the changes in arterial 
pressure subsequent to pharmacological or electrophysiological 
manipulation of the RVLM region are associated with the 
alteration of sympathetic nerve activity and differential 
regulation of vascular resistance (Ross £t al, 1984b; Willette 
et al, 1987). Whether or not adrenaline is the transmitter that 
is released to excite the preganglionic neurones in the spinal 
cord remains to be established. That the microiontophoresis of 
adrenaline in the area of the preganglionic neurones apparently 
inhibits rather than exites the discharge of sympathetic nerve 
activity is a perplexing paradox (Guyenet and Cabot, 1981). It 
is conceivable that microinotophoretically applied adrenaline may 
act on a different population of receptors than those which are 
innervated by the preganglionic sympathetic neurones. Moreover, 
the discovery of coexisting peptides such as neuropeptide Y or 
substance P in the neurones raises the possibility that the 
release of some agent other than adrenaline produces 
sympathoexcitation (Hokfelt et al, 1983a; Lorenz et al, 1985). 
Pilowsky et al (1987) have demonstrated that chemical stimulation 
of neurones results in a pressor response and release of NPY- 
like immunoreactivity from the rabbit spinal cord. The concept 
of co-existing transmitters in relation to the catecholamine 
neurones of the ventrolateral medulla will be discussed in 
Section 1.5. However, the controversy surrounding the
transmitter released from the neurones onto the preganglionic 
neurones does not detract from the ostensible importance of these 
neurones in tonic vasomotor control. It has been suggested that
ultimate tonic control over the sympathetic nerves is 
synchronised by central mechanisms that generate the periodicity 
of sympathetic activity (Gebber, 1984). On this basis two 
regions, including the RVLM, have been proposed as mediating 
basal vasomotor tone. Electrophysiological studies have 
demonstrated that neurones in the dorsomedial medulla whose 
activity is time locked to the slow wave of sympathetic nerve 
activity, discharge earlier than neurones in the RVLM. This 
implies that although both regions participate in the generation 
of spontaneous vasomotor outflow, the former area may 
predominate. However, since neurones in the RVLM project to the 
intermediolateral cord whereas the dorsomedial neurones do not, 
it has been postulated that the fall in arterial pressure
produced by interruption of the dorsal medial site results from 
the blockade of RVLM fibres that project through this region
before descending to the spinal cord (Dampney et al, 1982). 
Thus, the RVLM has been proposed as the area providing the tonic 
excitatory input to the spinal sympathetic preganglionic 
neurones, with the dorsal medulla a part of the pathway mediating 
basal vasomotor tone.
RVLM participation in reflex as well as tonic control of tbe 
cardiovascular system (Section 1.3.2) is suggested by the 
existence of a reciprocal connection of this area with the NTS,
upon which afferent fibres mediating baro- and other
cardiopulmonary reflexes terminate (Dampney et al, 1987; Ruggiero 
et al, 1985b; Ciriello and Caverson, 1986). The neurones of
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this area are again implicated since projections from the 
cardiovascular portions of the NTS directly overlap with the 
region of the RVLM containing the neurones. Moreover the 
vasodepressor response elicited by stimulation of the vagus nerve 
or carotid sinus stretch is abolished following bilateral 
chemical blockade of the area (Granata et al, 1983).
Conversely, withdrawal of the baroreceptor input by lesion of the 
NTS results in an elevation of arterial pressure which can be 
abolished by interference with the neurones (Benarroch et al, 
1986). Thus the involvement appears to be that of an inhibitory 
pathway from the NTS to the area which can reduce the 
spontaneous drive imposed by the cell group on the
preganglionic sympathetic neurones. As discussed recently by 
Reis and colleagues (1987; 1988) the area is under the control 
of a variety of proposed neurotransmitters. For instance, 
acetylcholine and glutamate are associated with an excitatory 
input to the neurones whereas noradrenaline and gamma-
aminobutyric acid (GABA) are inhibitory. GABA may be the 
inhibitory transmitter in the NTS-C^ pathway, but it is more 
likely to be present in local interneurones (Meeley et al, 1985; 
Ruggiero et al, 1985b). Neurones in the RVLM, in particular the 
neurones, may mediate another important reflex response. 
Dampney and Moon (1980) reported that the potent reflex response 
to cerebral ischemia is abolished by bilateral lesions of this 
region, a subject that will be discussed in more detail in 
Section 7.3.
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The number of convergent inputs into the RVLM further 
support its integrative function in the cardiovascular system. 
Neuroanatomical studies have described connections from the 
parabrachial and Kolliker-Fuse nuclei of the pons, the nucleus 
ambiguus as well as the paraventricular and lateral hypothalamic 
regions (Dampney et al, 1987). While the exact function of some
of these descending pathways have not been fully defined,
selective inhibition of neurones attenuates the
vasoconstrictor response that can be elicited from the 
hypothalamus. This pathway may therefore be another potential 
route by which the parvocellular neurones of the paraventricular 
nucleus can influence autonomic function, in addition to its 
direct inputs to the spinal cord and dorsomedial medulla (Hilton
et al, 1983; Swanson and Kupers, 1980).
The caudal ventrolateral medulla with connections to the 
hypothalamus reputedly influences the area. This
vasodepressor region is juxtapositioned to the area on the 
rostrocaudal plane and its involvement with the region and 
haemodynamic function per se will be discussed in the next 
section.
1.3.5 The Caudal Ventrolateral Medulla
The caudal ventrolateral medulla (CVLM) at its most rostral 
extent overlaps with the pressor neurones of the RVLM 
(Figure 1.3, Paxinos and Watson, 1986). In contrast to the RVLM, 
electrical or chemical stimulation of the CVLM results in an 
acute fall in arterial pressure and heart rate (Blessing and
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Reis, 1982; Willette et al, 1987). A tonic inhibition of 
vasomotor activity by this region has been proposed, since 
electrical or chemical inhibition elicits a marked increase in 
arterial pressure (Blessing et al, 1982). The cardiovascular 
responses produced by such interventions are reputedly mediated 
through the noradrenergic neurones contained within the CVLM 
(Dahlstrom and Fuxe, 1964, Section 1.2.1). Support for this 
hypothesis derives from anatomical correlations, the 
manipulations being deliberately made in the region coinciding 
with the A^ cell group. Although this association has been 
questioned recently by Day et al (1983), functional studies as 
well as neuroanatomical investigations of the efferent 
connections of the CVLM, have focused on the A^ cell group. The 
pathway through which the vasodepressor area alters arterial 
pressure has not been established with certainty, however most of 
the recent evidence indicates that few, if any, of these 
noradrenergic cells project to the spinal cord (Ross et al, 
1981a; Blessing et al, 1981a). Although non-catecholamine 
neurones in the CVLM are known to project to the spinal cord, it 
is generally considered that the sympathoinhibition exerted by 
activation of the A^ neurones is relayed via other structures. 
The principal efferent connections from the A^ neurones that have 
been anatomically established include projections to the 
paraventricular and supraoptic nuclei of the hypothalamus as well 
as the NTS (Sawchencho and Swanson, 1982; Blessing et al, 1981b). 
Since neurones from the parvocellular component of the
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paraventricular nucleus project directly and indirectly to the 
spinal cord to influence sympathetic nerve activity, the 
neurones could potentially regulate cardiovascular function 
through these areas. However, close proximity of region to 
the RVLM, has tempted some investigators to suggest an inhibitory 
input from A^ to the cell group. Pharmacological evidence for 
such a mechanism has been accrued recently. The hypertensive 
response evoked by microinjection of muscimol or kainic acid into 
the CVLM was abolished by chemical inhibition • of the RVLM 
(Willette et al, 1984; Granata et al, 1986). In contrast, the 
latter study also demonstrated that the hypertensive response was 
not altered by interruption of the two other major projections of 
the A p  namely to the hypothalamus or to the NTS. Moreover■, 
hypotension evoked by CVLM stimulation in the rat, which should 
according to the. hypothesis release noradrenaline onto the C^ 
neurones is mimicked by local application into the C^ area of the 
Of-agonist alpha-methyl noradrenaline (Granata et al, 1986).
Although the C^ area contains noradrenaline synthesising 
nerve terminals, the neuroanatomical evidence that these derive 
from A^ projections in nebulous. Chan et al (1986) attest, on 
the basis of horseradish peroxidase tracer techniques in the rat, 
that a direct projection exists from the CVLM to the RVLM whereas 
in the rabbit, Blessing et al (1987a) maintain that neither a 
direct nor indirect (via other noradrenergic pathways in the 
brainstem) noradrenergic projections exist between these 
medullary areas. Species variation may account for these 
discrepant reports. However it is possible that a non-
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noradrenergic inhibitory projection from the CVLM to the RVLM may
\
exist and contribute to the functional interaction between the 
regions. Indeed Urbanski and Sapru (1988) have pharmacological 
evidence for a GABAergic pathway between the CVLM and RVLM. 
Another potential mechanism by which the A^ region could 
influence the C^ area and cardiovascular function is by the 
release of co-existing transmitters in this area. In this 
respect the putative role of the colocalised neuropeptide Y is of 
particular interest.
Sawchenko and Swanson (1982) have demonstrated an ascending 
projection from the A^ neurones to the magnocellular division of 
supraoptic and paraventricular nuclei, where vasopressinergic 
cell bodies are concentrated. Thus it was proposed that the A^
neurones may regulate the release of vasopressin (AVP), a potent 
vasoconstrictor and antidiuretic hormone, with a homeostatic 
function in situations (haemorrhage) where blood volume is 
threatened (Johnston, 1985).
Blessing et al (1982) originally postulated that A^ neurones 
tonically inhibit AVP release since electrolytic lesioning of 
this area resulted in an increase in AVP. However, controversy 
surrounds the contribution that this elevation in AVP made to the 
accompanying hypertension. Although Blessing et al (1982)
suggested that the rise in AVP was responsible for the effect on 
blood pressure, Minson and Chalmers (1983) have proposed that AVP 
makes a greater contribution to the bradycardia than to the
hypertension after A^ lesions. More specific studies by Blessing
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and Willoughby (1985) have since demonstrated that chemical 
inhibition of the CVLM prevents the release of AVP induced by 
haemorrhage whereas chemical stimulation elevates the plasma AVP 
levels. These authors thus concluded that contrary to the 
original hypothesis by Blessing et al (1982), the A^ 
noradrenergic pathway to the hypothalamus facilitate the 
secretion of AVP. While the significance of the A^ neurones in 
reflex (haemorrahagic) regulation of AVP release and heart rate 
have been confirmed, the involvement of these neurones in the 
reflex control of blood pressure is controversial (Head et al, 
1987a). Lesions of the A^ area, in contrast to the area, do 
not substantially alter the magnitude of the vasodepressor 
response to stimulation of vagal afferent fibres or to carotid 
sinus stretch, implying that the caudal region does not affect 
reflex arterial . pressure. However, participation in the 
vasodepressor response elicited after aortic nerve stimulation 
has been reported suggesting that the central mechanisms 
mediating reflex blood pressure control differ depending on the 
afferent input (Granata et al, 1985; Gordon, 1987).
1.4 Second Messenger Systems Mediating Neurotransmitter or
Hormonal Actions 
Neurotransmitters and hormones act upon specific recognition 
sites located on cell membranes and it is considered that 
activation of these sites modifies cellular activity and can 
potentially elicit a vast array of physiological responses. The 
initial stage in this process, transmitter recognition, is
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translated into altered cellular function through a coupling 
between the recognition site and an effector mechanism. In some 
cases, the recognition site is directly associated with an ion 
channel, whereas in others the effector is a membrane-associated 
enzyme that generates the production of a second messenger. 
There are two major receptor-regulated second messengers 
currently thought to be present in the brain; the adenylate 
cyclase system and the phosphoinositide cycle. The mechanisms 
whereby these systems modulate synaptic transmission following 
receptor activation will be outlined below. Special emphasis 
will be given to the adenylate cyclase system since studies 
within this thesis examine the role of this system in central 
peptidergic cardiovascular regulatory mechanisms.
1.4.1 Adenylate Cyclase System
The more established of the two second messenger systems is 
associated with the enzyme adenylate cyclase and involves the 
generation of cyclic adenosine 3'5-monophosphate (cAMP) from 
adenosine triphosphate (ATP) as depicted in Figure 1.4. cAMP 
then acts as an intracellular second messenger to activate 
protein kinases and subsequently modify cellular activity. A 
role for cAMP in mediating cellular events has been known since 
the late 1950s when Sutherland and coworkers suggested it was a 
cofactor enabling adrenaline to initiate glycogen breakdown in 
the liver (Sutherland and Rail, 1960). A feature common to both 
the adenylate cyclase system and the phosphoinositide cycle is 
the involvement of guanine nucleotide binding proteins (G-
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Figure 1.4
Dual regulation of adenylate cyclase 
Rs = stimulatory receptor 
Ri = inhibitory G-protein 
Gs = stimulatory receptor 
Gi = inhibitory G-protein 
GTP = guanosine triphosphate 
GDP = guanosine diphosphate 
ATP = adenosine triphosphate 
AMP = adenosine monophosphate
See text for details of this system
proteins). G-proteins, which consist of three subunits, OL ,f$  
and T  , transduce and amplify the extracellular signal into 
enzymatic activity. Receptors that stimulate adenylate cyclase, 
such as (3 -adrenergic and A 2 -adenosine receptors, do so by 
activation of a specific G-protein (Gs), (Figure 1.4). Prior to 
receptor activation Gs is complexed with guanosine diphosphate 
(GDP) and is unable to stimulate adenylate cyclase. Receptor 
activation of GS enhances the affinity of the OL subunit for
ganosine triphophate (GTP) relative to GDP. In turn, the
activated OL subunit-GTP dissociates from the f i l f  subunit and
stimulates adenylate cyclase activity, which then catalyses the
conversion of ATP to cAMP. Termination of the transmitter signal 
involves hydrolysis of GTP to GDP by GTPase activity of the OL- 
subunit and possibly by reassociation of the subunits. The 
continued presence of a hormone at the receptor permits the
repetition of this cycle of events (Levitzki, 1987).
{ •
Another distinct G protein (Gi) is involved in the 
inhibition of adenylate cyclase by receptors such as
angiotensin II, dopamine (^2 ), opiate (ju) and O'adrenoceptors 
(Figure 1.4). The mechanisms involved in the hormonal inhibition 
of adenylate cyclase are not as well understood as hormonal 
stimulation. Activated Gi was initially thought to * inhibit 
adenylate cyclase activity directly and thus reduce cAMP 
production. However, unlike the stimulatory branch, the OL 
subunit of Gi does not form a strong complex with adenylate 
cyclase. This led to the suggestion the the j(3Y -subunit of Gi 
plays an important role in the inhibitory regulation of adenylate
cyclase possibly by indirectly reducing the activity of Gs. The 
exact roles of the f i y  subunits in this mechanism, however, 
remain to be elucidated (Gilman, 1984; Levitzki, 1987).
Thus, according to the receptor type occupied, the 
production of cAMP will either increase or decrease. The 
consequences of this modulation of cAMP levels are diverse. This 
cyclic nucleotide can activate phosphorylating enzyme(s) (protein 
kinase A) which regulate a variety of cellular responses
including metabolic, contractile and secretory events. In a 
number of these situations cAMP acts to regulate another second 
messenger, namely calcium ions. Modulation of the calcium 
pathway by the cAMP system has emerged in cardiac and other 
muscle cells with a resultant alteration in contractile events. 
Ion channels in neuronal membranes are also key targets of cAMP 
action, with secretion of transmitters and neuronal activity 
being affected. The cAMP-mediated control of calcium and 
potassium conductance through ion channels involved in neuronal 
secretory processes, can either facilitate or suppress
transmitter release depending on the receptor type activated and
the system studied (Illes, 1986). Neuronal activity of the locus 
coeruleus cells is affected by the regulation of one type of 
potassium channel by cAMP. A reduction in cAMP levels
facilitates the opening of potassium channels causing 
hyperpolarisation and depression of neuronal firing (Andrade 
et al, 1985).
Useful tools in the study of the cyclic nucleotide system
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include agents which can interact with the different G-proteins. 
Pertussis toxin blocks the inhibitory action of Gi whereas 
cholera toxin blocks the GTPase activity of Gs causing its 
persistent activation (Figure 1.4). The diterpene forskolin, 
which at high concentrations directly activates adenylate cyclase 
thereby increasing cAMP, is useful in the examination and 
detection of inhibitory influences on adenylate cyclase activity. 
Phophodiesterase inhibitors such as theophylline are effective in 
studies involving the measurement of cAMP levels since they 
prevent the breakdown of cAMP to 5'-adenosine monophosphate.
1.4.2 Phosphoinositide Cycle
The more recently discovered second messenger system 
involved in neurotransmitter and hormonal actions, the 
phosphoinositide cycle, has been reviewed recently by Berridge 
and Irvine (1989) and will be discussed briefly. Currently 
accepted views purport that the neurotransmitter interaction with 
receptors activates a phosphodiesterase (phospholipase C) that 
specifically hydrolyses the membrane phospholipid, 
phosphotidylinositol 4, 5-bisphosphate (PIP2 ) (Figure 1.5). 
Hydrolysis of produces at least two second messengers
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3 )• 
This process is analogous to the receptor stimulation of 
adenylate cyclase, in that transmitters act at receptors, a G 
protein transduces this extracellular signal activates an enzyme 
that generates second messengers (Cockcroft and Gomperts, 1985). 
The involvement of Gi-like proteins has been demonstrated in non-
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Figure 1.5
Receptor mediated phosphoinositide turnover
R = receptor
G = G-protein
PLC = phospholipase C
PKC - protein kinase C
DAG = diacylglycerol
PIP2 = phosphotidyl inositol 4,5-biphosphate
IP3 = inositol 1,4,5-triphosphate
See text for details of this system.
neuronal systems, where phosphoinositide turnover is blocked by 
pertussis toxin or by GTP analogs that inactivate G-proteins. 
Although several G-proteins have been identified in the brain 
including Gs, Gi, Go and Gp, the G-protein(s) that mediate 
stimulation of the phosphoinositide system in the brain remains 
to be clarified.
Transmitters known to stimulate the phosphoinositide system
in the central nervous system include serotonin (5 -HT2
receptors), noradrenaline ( OL^-adrenoceptors) and vasopressin
(V^) . The messengers generated by phosphoinositide turnover, IP^
and DAG, modulate a plethora of cellular processes including
metabolism, secretion, contraction, neural activity and cell
proliferation. The messenger functions of IP^ involve the
interacting with a specific receptor causing the release of
calcium from nonmitochondrial, internal stores. The IP^ signal
is terminated by the cleavage of the 5-phosphate, generating
inositol 1,4-bisphosphate which is less active (Berridge and
Irvine, 1989). In nonneural tissues the action of IP0 mediates• o
contractile activity. The mechanisms of pharmacomechanical- 
coupling in smooth muscle and excitation-contraction coupling in 
skeletal muscle both appear to involve phosphoinositide turnover. 
At present, the role of IP^ in the central nervous system has not 
been fully established, however a participation in neuronal 
activity and perhaps secretory mechanisms have been suggested. 
Diacylglycerol, the other major second messenger generated by 
hydrolysis of PIP2  activates a phosphorylating enzyme(s) known as 
protein kinase C which in turn phosphorylates several cellular
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proteins (Figure 1.5). The activation of protein kinase C is 
complex and apparently requires calcium and phospholipid for 
activity (Nishizuka, 1988). Protein kinase C can act 
synergistically with calcium pathways to affect a range of 
physiological responses. A negative feedback regulation of 
agonist-induced IP^ production has also been reported for this 
enzyme. Important functions of protein kinase C include 
neurotransmitter release, smooth muscle contraction, gene 
expression and cell proliferation. Protein kinase C also affects 
neuronal activity. In the hippocampus, activation of this enzyme 
blocks a calcium-activated potassium channel resulting in 
enhanced neuronal excitation (Baraban et al, 1985).
In conclusion, there are two major second messenger systems, 
the adenylate cyclase system and the phosphoinositide cycle, both 
of which have been identified in the brain and are considered to 
play a role in the mediation of neurotransmitter function. The 
participation of the former system in the central haemodynamic 
effects of neuropeptide Y will be investigated during the course 
of this thesis.
1.5 Neuropeptide Y
1.5.1 Isolation and Identification of Neuropeptide Y
Neuropeptide Y (NPY), was originally isolated from the 
porcine brain by Tatemoto et al (1982) and subsequently shown by 
Tatemoto (1982) to exhibit a sequence of 36 amino acids with an 
N-terminal tyrosine (Y) and a C-terminal tyrosine amide residue.
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This peptide belongs to the biologically active pancreatic 
peptide (PP) family and as such displays considerable C-terminal 
amino acid sequence homology, as depicted in Table 1.3, to both 
bovine PP (17 amino acids in common) and avian PP (20 amino acids 
in common) as well as to the other cognate peptide, peptide YY 
(Tatemoto et al, 1982). Investigation of the molecular origins 
of this peptide has resulted in the determination of the 
structure and expression of the NPY gene in the rat. The 
predicted amino acid sequence of mature rat NPY is identical to 
the human sequence (Larhammar et al, 1987). No precursor has yet 
been isolated from tissue extracts, however the structure of the 
human NPY precursor has been deduced from cloning experiments to 
be a 97 amino acid residue. This putative precursor consists of 
three peptide segments, a leader sequence of 28 amino acids, an 
active neuropeptide Y sequence of 36 amino acids and a 30 amino 
acid carboxyterminal peptide (Minth et al, 1984).
Although NPY was first described in the porcine brain, 
immunohistochemical as well as radioimmunoassay studies using 
antibodies raised towards this peptide, have revealed a pervasive 
distribution of NPY-like peptide in both the peripheral and 
central nervous systems. This wide but discrete distribution of 
NPY resembles that of the previously mapped pancreatic 
polypeptides (Lundberg et al, 1984; Allen et al, 1983a). While 
radioimmunoassay techniques confirmed the presence of NPY, this 
analysis could not detect PP-like immunoreactivity. Indeed it 
has- now been established that cross-reactivity to NPY of the 
avian-PP and bovine-PP directed antisera had occurred in the
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Table 1.3
Amino Acid Sequences of Neuropeptide Y and Three Cognate Peptides
Amino acid 
sequence NPY APP BPP PYY
1 Tyr Gly Ala
2 Pro — — -
3 Ser = Leu Ala
4 Lys Gin Glu =
5 Pro — — . -
6 Asp Thr Glu Glu
7 Asn Tyr Tyr Ala
8 Pro = • = =
9 Gly = - - •
1 0 Glu Asp Asp -
1 1 Asp = Ala =
1 2 Ala = = = .
13 Pro - Thr Ser
14 Ala Val Pro Pro
15 Glu - - -
16 Asp Gin Glu
17 Leu Met —
18 Ala H e - Ser
19 Arg - Gin -
2 0 Tyr Phe = - =
2 1 Tyr - Ala -
2 2 Ser Asp Ala Ala
23 Ala Asn Glu Ser
24 Leu = = =
25 Arg Gin - -
26 His Gin Arg -
27 Tyr - - - -
28 H e Leu = Leu
29 Asn = -=
30 Leu Val Met w
31 lie Val Leu Val
32 Thr = = —
33 Arg = = =
34 Gin His Pro
35 Arg - - -
36 Tyr* *= *= —
Ala -, Alanine; Arg - Arginine; Asn - Asparginine; Asp - Asparti<
acid; Glu - Glutamic acid; Gin - Glutamine; Gly - Glycine; His
Histidine; lie - Isoleucine; Leu - Leucine; Lys - Lysine; Meth
Methionine; Phe - Phenylalanine; Pro - Proline; Ser - Serine; Thr 
- ‘Threonine; Tyr - Throsine; Val - Valine.
* - Amidation of Y terminal; - Identical amino acid to NPY 
From Tatemoto et al (1982) and Tatemoto (1982).
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previous investigations and that the preponderance of PP-like 
immunoreactivity hitherto observed, was actually due to NPY 
(Lundberg et al, 1984; DiMaggio et al, 1985; Allen et al, 1983a). 
That NPY is the predominant pancreatic peptide in the central 
nervous system is further supported by evidence that the other 
structurally related peptide, peptide YY is largely confined to 
the gut (Lundberg et al, 1984).
1.5.2 Distribution of Neuropeptide Y in the Peripheral 
Nervous System
In the peripheral nervous system, high levels of NPY (up to 
80 pmol g"^)have been identified in the sympathetic ganglia and 
the heart with significant levels in other tissues such as the 
spleen, bladder and respiratory system. This peptide has been 
localised immunohistochemically in the perivascular nerves 
innervating the blood vessels of the heart, kidney, liver, 
spleen, skeletal muscle and in the gastrointestinal tract with 
the concentration in each area generally reflecting the density 
of innervation for that organ. These findings have been reported 
in a number of species including rat and man (Gu et al, 1983; 
Lundberg et al, 1983; 1984; Ekblad et al, 1984; Uddman et al,
1985).
A salient feature of the location of NPY in the periphery is 
its occurrence predominately with noradrenaline in sympathetic 
ganglia and sympathetic neurones in many tissues. 
Immunohistochemical studies have also shown that colocalisation 
of this peptide and noradrenaline is a hallmark of a certain
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population of sympathetic neurones, namely those that innervate 
the cardiovascular system (Lundberg et al, 1983; Ekblad et al, 
1984; McLachlan and LIewellyn-Smith, 1986). In addition, NPY has 
been closely associated or colocalised with noradrenaline in 
chromaffin cells of the adrenal medulla reportedly in 
concentrations greater than in the rat brain (Allen et al, 1983a; 
1983b). At the ultrastructural level, it has been observed that 
noradrenaline and NPY may be colocalised not only within the same 
nerve cells or fibres but within the same vesicle, namely in 
large dense-cored vesicles. Most noradrenaline however, is 
stored in small dense-cored vesicles which do not contain NPY 
(Fried et al, 1985a; 1985b). A functional significance of these 
histochemical observations is implied by the finding that these 
messengers can be differentially released. Continuous low 
frequency stimulation has been shown to release noradrenaline 
preferentially from small vesicles in the spleen where as high 
frequency stimulation releases both noradrenaline and NPY from 
large vesicles (Lundberg et al, 1986). NPY has also been 
localised in non-vascular neurones which do not contain 
noradrenaline, for instance, in the heart and in the 
gastrointestinal tract (Hassal and Burnstock, 1984; Sundler 
et al, 1983).
1.5.3 Distribution of Neuropeptide Y in the Central Nervous 
System
• The presence of NPY-like immunoreactive material has been 
observed throughout the rostrocaudal extent of the mammalian
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(including rat, cat and human) neuroaxis (Allen et al, 1983a;
Chronwall et al, 1985; Gibson et al, 1984; Adrian et al, 1983).
NPY is present in amounts which exceed (in picomole/gram of
tissue quantities) those of other known peptides in the mammalian 
central nervous system including cholecystokinin (Allen et al,
1983a). Although reports differ regarding the absolute values of 
NPY in each of the central areas, the concentration of peptide 
measured by radioimmunoassay is not uniform between regions and 
may also be dependent on the species examined. As demonstrated 
for the rat and human central nervous system in Table 1.4, 
overall the distribution of NPY exhibits a characteristic pattern 
of high levels in forebrain regions such as the hypothalamus, 
cerebral cortex and the caudate nucleus tending towards lower 
levels in the direction of the brainstem and spinal cord. High 
concentrations of NPY-like immunoreactivity (IR) has also been 
detected in the sympathetic nerve fibres innervating cerebral 
arteries (Edvinsson et al, 1987). In general, fibres are dense 
around arteries and few or moderate in number around veins 
(Uddman et al, 1985).
Central Neuropeptide Y Pathways
Several studies have examined the central distribution 
(origin and projections) of the NPY-like immunoreactive neurones. 
Some of the more pertinent systems in the rat brain will be 
considered. In the hypothalamus, numerous NPY perikarya were 
found in the arcuate nucleus with a lower number in the 
paraventricular and preoptic areas (A.^ an<i ^-^) . Moderate to
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Table 1.4
Distribution of Neuropeptide Y-like Immunoreactivity within
Regions of the Rat and Human Central Nervous Systems
Concentration
Region (pmol g wet tissue)
rat human
Hyp o thalamus 730 + 164 182 ± 21
Cerebral cortex 179 + 24 1 2 0 ±  13
Caudate nucleus 313 + 69 534 + 170
Cerebellum < 0 .75 1.3 + 0 . 2
Pons 113 + 23 7 + 1
Medulla oblongata 15 + 3 nd
Spinal cord - thoracic 2 1 + 3 34 ± 5
Spinal cord - sacral 92 + 9 47 ± 11
Data taken from Allen et al (1983a; 1984); Adrian et al (1983);
Chronwall et al (1985); Gibson et al (1984); nd = not determined.
53
high densities of NPY fibre networks and terminals were also 
located in these hypothalamic regions (Chronwall £t al, 1985). 
NPY-positive neurones have been observed to project from the 
arcuate nucleus to the paraventricular nucleus and from the 
dorsomedial hypothalamic region to the nucleus tractus solitarius 
(Bai et al, 1985;. Gray and Morley, 1986). The number of NPY 
perikarya and extent of fibre networks in the cerebral cortex is 
high especially compared to other peptides previously mentioned. 
In contrast, the cerebellum contains no NPY-positive cell bodies 
or terminals in agreement with the low levels of NPY measured by 
radioimmunoassay techniques (Chronwall et al, 1985).
The medulla and pons embody three major NPY-immunoreactive 
neuronal systems which closely parallel the catecholamine- 
containing cell bodies and fibre systems of these regions. These 
are the A^/C^ cell groups of the ventrolateral medulla and the 
A 2 /C2  cell groups of the dorsal medulla as well as the Ag region 
of the locus coeruleus (Chronwall et al, 1985). Indeed, using 
sequential staining techniques with antisera against NPY and the 
enzyme markers for noradrenaline (tyrosine hydroxylase) and 
adrenaline (phenylethanolamine-N-Methyltransferase),
immunohistochemical studies have shown colocalisation of NPY with 
catecholamines in some of these brainstem neurones as well as in 
other central regions. The extent of the colocalisation depends 
on the region, pathway and neurotransmitter examined. However, a 
general feature observed is that only a subpopulation of the 
neuronal groups contain both NPY and a catecholamine. There is 
evidence to suggest that NPY is colocalised in the vast majority
of adrenergic cell groups (C^ - C^) but is colo.calised only in a 
subset (A^, A 2 , A^, Ag) of the total noradrenergic cell
population. The findings of these immunohistochemical studies in 
the medulla oblongata (rat, human and rabbit) have been
summarised in Table 1.5. These data demonstrate that
differential proportions of noradrenergic and adrenergic neurones 
of the ventrolateral and the dorsomedial k ^ / Q ^ cell groups
of the medulla contain NPY-IR. Differences apparently exist 
between species ostensibly in the A ^ cell group where major 
colocalisation was only observed in the human medulla. However, 
methodological differences between studies cannot be excluded. 
Maps of NPY-IR show that low to moderate density fibre and
terminal networks surrounding these cell bodies. In particular, 
terminals around the A^/C^ neurones show a close overlap with 
catecholamine positive fibres in these regions (Everitt et al, 
1984; Harfstrand et al, 1987a).
The involvement of these catecholamine cell groups in 
central cardiovascular regulation and neuroendocrine function 
(Section 1.3) also implicates NPY and points to the possibility 
that NPY may have a modulatory role in this region, interacting 
with the endogenous catecholamines - a concept that will be 
examined in subsequent chapters. The postulated involvement of 
NPY in neuroendocrine and autonomic regulation is further 
supported by the finding that cells which contain both NPY and 
catecholamines have been shown to project to the hypothalamus 
(Sawchenko et al, 1985). Moreover NPY fibre systems and
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Table 1.5
Summary of Differential Coexistence Patterns of NPY-like Immunoreactivity 
in Brainstem Catecholamine Groups
Area Catecholamine rat
Coexistence
human rabbit
CVLM NA (Ai group) Y e s , major Y e s , minor Y e s , partial
RVLM A (Ci group) Y e s , complete Y e s , partial Y e s , maj or
Dorsal medulla NA (A, group) Y e s , minor Y e s , maj or No
oblongata z
(NTS; Dorsal vagal A (C2 group) Y e s , major Y e s , partial Y e s , maj or
complex)
z
DA No nd nd
Area postrema NA No nd nd
Pons, locus coeruleus NA
<A 6
group) Y e s , partial No nd
A - adrenaline major > 7 5 %
NA — ■ noradrenaline partial > 50%
DA - dopamine minor > 25%
nd - not determined
CVLM - caudal ventrolateral medulla 
RVLM - rostral ventrolateral medulla 
NTS - nucleus of the solitary tract
From Data of Everitt et al (1984); Halliday et al (1988); Blessing et al (1986)
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terminals, but not cell bodies, have been located in the dorsal 
horn at all levels of the spinal cord (Gibson et: al, 1984; Allen 
et al, 1984). In particular, NPY-immunoreactive nerve fibres and 
terminals were evident in the intermediolateral cell columns of
the thoracic segment, where they closely parallel, and are
possibly associated with, the site of termination of descending 
catecholamine neurones (Chiba and Murata, 1981; Blessing et al, 
1987b; Gibson et al, 1984).
Not all neurones in the regions described contain both a
catecholamine and NPY. Indeed the complexity of the situation is
highlighted by the finding that a proportion of catecholamine 
neurones may contain other peptides such as substance P (C^, ,
neurotensin, cholecystokinin (C£ dorsal) or galanin (A^, A 2 , Ag) 
(Lorenz et al, 1985; Hokfelt, 1984b; 1985; Melander et al, 1986). 
Moreover, NPY has been shown to be present in neurones containing 
other putative transmitters, such as somatostatin, FMRF-amide, 
gamma-amihobutyric acid and serotonin in several discrete 
locations throughout the central nervous system (Chronwall et al, 
1984; Hokfelt et al, 1983a; Hendry et al, 1984; Blessing et al, 
1986). Neurons containing NPY alone have been observed in the 
medulla and hypothalamus (Everitt et al, 1984). In addition to 
the immunohistochemical evidence of NPY-containing cell bodies 
and fibre systems, receptor binding studies have shown high 
affinity binding sites in rat brain membrane preparations, 
suggesting the existence of NPY receptors (Saria et al, 1984; 
Unden et al, 1984). These putative receptors have been widely 
but discretely located in the brain. Areas enriched in both NPY
receptors and fibres have been demonstrated (nucleus of the 
solitary tract, ventral tegmental area). However, there is 
evidently a lack of correspondence in the pattern of distribution 
between the NPY receptors and NPY fibre systems in certain 
regions. Numerous structures have been observed to have NPY 
innervation but few or undetectable receptors. This situation 
exists in the preoptic area, hypothalamus (suprachiasmatic 
nucleus) and the ventrolateral medulla. In contrast, in areas of 
dense binding such as the cortical layers I-IV and the area 
postrema, fibres are either sparsely scattered or not detected 
(Martel et al, 1986; Nakajima et al, 1986; Harfstrand et al,
1986). The mismatch of receptors and NPY-containing neuronal 
systems is not restricted to NPY or indeed to peptide 
transmitters and has been observed to some degree for all 
categories of transmitters including monoamines and amino acids. 
This phenomenon, which has been reviewed recently by Herkenham 
(1987) with several possible explanations propounded, does not 
detract from the substantial evidence described above suggesting 
an important function within the central nervous system.
1.5.4 Effects of Neuropeptide Y in the Peripheral Nervous 
System
Systemic administration of NPY per se has pronounced 
cardiovascular effects characterised by an increase in arterial 
pressure and a reduction in heart rate. Other notable peripheral 
actions of NPY are summarised in Table 1.6.
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Table 1.6
Proposed Peripheral Effects of Neuropeptide Y
Peripheral Effects
Increase in systemic blood pressure
Vasoconstriction
Potentiation of vasoconstriction
Presynaptic inhibition of transmitter release
Positive and/or negative chronotropic action
Negative inotropic action
Inhibition of cardiac vagal action
Relaxation of colon smooth muscle and 
inhibition of colonic motility
Suppression of insulin release
Na.tr iures is
Reduction of circulating atrial natriuretic factor 
and vasopressin
Suppression of renin secretion
Enhancement of stimulated thyroid hormone secretion
See text, Gray and Morley (1986) and Higuchi (1989) for details 
and references
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In the peripheral circulation, NPY has been reported to 
cause vasoconstriction which is unrelated to alpha-adrenoceptors 
(Lundberg and Tatemoto, 1982). This evidence combined with its 
observed potent contractile effects in the renal and coronary 
circulation support the view that a major part of the systemic 
pressor response to NPY may be mediated by direct 
vasoconstriction (Allen et al, 1985; Franco-Cereceda et al,
1985). This contractile activity, which can also be observed 
with the structurally related PYY is typically slow on onset and 
has a prolonged duration of action. In the intact animal these 
effects may be related to the relatively long ( 2 0  minute) plasma 
half-life of NPY (Pernow et al, 1987). However NPY has weak 
contractile effects in a number of isolated peripheral vessels, 
an effect that is dependent on the vessel (precise segment) and 
species examined.- The rabbit gastro-epiploic artery responds to 
NPY with a weak contraction whereas the rat femoral artery 
responds with a stronger contraction (Edvinsson et al, 1984a; 
Lundberg et al, 1985). NPY can also modify vascular resistance 
by enhancing the contriction elicited by other agents such as 
noradrenaline or histamine. Evidence of the functional 
interaction with the peripheral sympathetic nervous system is 
supported by a number of studies. In tissues which include the 
rabbit femoral artery and vein, NPY can act postsynaptically to 
potentiate the vasoconstriction evoked by nerve stimulation or by 
noradrenaline (Edvinsson et al, 1984a; Dahlof et al, 1985; 
Wahlestedt et al, 1985). This potentiating effect is manifest at 
nanomolar concentrations, far below the concentrations required
to evoke a direct vasoconstrictor response.
NPY can also act presynaptically to reduce the release of 
noradrenaline from sympathetic nerve terminals (rat vas deferens) 
indicating the existence of a presynaptic interaction between NPY 
in the sympathetic nervous system (Stjarne et al, 1986). 
Consistent with the investigations on isolated tissues, it has 
been demonstrated that in intact rats the pressor response to 
alpha-adrenoceptor agonists are potentiated by NPY to a greater 
extent than the response to sympathetic nerve stimulation 
(Zukowska-Grojec et al, 1986). This data implies that NPY can 
enhance pressor responses postjunctionally while attenuating 
transmitter release by a prejunctional action.
The possible consequences of these diverse actions of NPY at 
the sympathetic neuroeffector junction may be to improve the 
transmitter economy, reflected in a reduced noradrenaline demand 
and an ( attenuation or shortening of noradrenaline release 
(Glover, 1985; Stjarne, 1986). It should be considered that NPY 
may not produce all three effects at all neuroeffector junctions 
and it is possible that the distribution of receptor subtypes may 
be the limiting factor. Indeed, in contrast to the post 
junctional effects of NPY previously discussed, the C-terminal 
fragment of NPY^ bas been observed to mimic the effects of 
NPY at the presynaptic receptors in the vas deferens. Thus 
peripheral post- and prejunctional receptors are suggested by 
some to be structurally distinct and have been classified as Y^ 
and Y 2  respectively, ^ ^ 1 3 - 3 6  being selective for Y 2  receptors
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(Wahlestedt et al, 1986). These subtypes of NPY receptors, based 
of fragment selectivity, are not however observed in all systems 
and their existence may only be established with certainty 
following the development of selective antagonists (Lundberg, 
1988).
1.5.5 Effects of Neuropeptide Y in the Central Nervous System 
In accordance with its contractile activity in peripheral 
blood vessels, NPY evokes a potent vasoconstriction in cerebral 
blood vessels of several species which is not modified by 
adrenoceptor blockade. Microapplication of NPY around cerebral 
arteries and arterioles in the anaesthetised cat produced a 
constriction of commensurate magnitude as that produced by 
noradrenaline. However the response to NPY was more prolonged. 
Perivascular application of NPY also constricts cerebral veins 
but generally higher concentrations are necessary to produce a 
significant effect (Edvinsson et al, 1983; 1984b). Although NPY 
potentiates the vasoconstriction evoked by transmural nerve 
stimulation and exogenous noradrenaline in numerous peripheral 
arteries, this effect was not observed in cerebral vessels of the 
rat. Furthermore NPY did not significantly alter the nerve 
stimulated release of noradrenaline from cat cerebral vessels. 
Thus it would appear that a direct vasoconstriction is the 
predominant response to NPY in cerebral blood vessels (Edvinsson 
et al, 1987). In addition to its effect on cerebral blood 
vessels, localised injections of NPY into brain parenchyma or 
administration into the cerebral ventricles elicits changes in a
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variety of behavioural and physiological parameters (Table 1.7). 
A role for NPY in the regulation of food and water ingestion has 
been implicated by several studies. Administration of NPY into 
the paraventricular nucleus results in an increased food and 
water ingestion as well as reducing the time the animal spends on 
grooming (Stanley and Leibowitz, 1984). The former behavioural 
response was associated with a preference for carbohydrates and 
was localised to the hypothalamus (Stanley et al, 1985). 
Although NPY is colocalised with catecholamines in a number of 
discrete neuronal systems which include brainstem 
catecholaminergic projections to the paraventricular nucleus of 
the hypolthalamus, NPY produces its effects on ingestive 
behaviours independently from noradrenaline (Gray and Morley,
1986). NPY also had marked effects on the hypothalamo-pituitary 
axis, including.modulating the release of gonadotropin-releasing 
hormone and subsequently luteinizing hormone secretion with 
suppressed lordosis in the estradiol and progesterone primed 
ovariectomised rat (Gray and Morley, 1986). Other noteworthy 
effects of centrally administered NPY include behavioural and EEG 
signs (Synchronisation) of sedation similar to the effects 
produced by the alpl^-agonist clonidine (Fuxe et al, 1983).
The diverse nature of the effects produced by NPY is most 
likely a reflection of its widespread distribution in the central 
nervous system. Potentially the most interesting and important 
findings however, are that NPY is localised in central regions 
associated with cardiovascular regulation (Section 1.5.3). 
Moreover it has been shown that administration of this peptide
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Table 1.7
Reported Central Effects of Neuropeptide Y
Central Effects 
Increased food intake 
Increased drinking
Enhancement of gonadotropin-releasing hormone 
Modulation of luteinizing hormone 
Reduction of circulating growth hormone 
Reduction of circulating thyrotropin,
Elevation of circulating prolactin
Elevation of circulating vasopressin
Shift of circadian rhythms
Hypothermia
Bradypnea
Sedation
Synchronization of EEG activity 
Decreased lordosis 
Decreased grooming 
Suppression of sexual behaviour 
Inhibition of memory
Reduction in blood pressure and heart rate
See text, Gray and Morley (1986) and Higuchi (1989) for details 
and references
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into the cerebrospinal fluid results in alterations in a variety 
of cardiovascular parameters including reduction in blood 
pressure and heart rate (Fuxe et al, 1983; Macrae and Reid, 
1988) . The putative role of NPY in central cardiovascular 
function is the subject of examination in subsequent chapters 
within this thesis and will be discussed in detail therein.
1.5.6 Proposed Mechanisms of Action for Neuropeptide Y
For the purposes of this thesis, the present account will
confine itself to the mechanisms underlying the purported
cardiovascular functions of NPY. Several studies have shown that
the vasoconstrictor response produced by NPY can be blocked by
calcium channel antagonists both in vitro (peripheral and central
blood vessels) and in vivo suggesting that an influx of
extracellular calcium is necessary for the response (Lundberg and
Tatemoto, 1982; Edvinsson et al, 1985). In contrast to this
effect on vascular smooth muscle, calcium entry blockers do not
influence the direct contraction evoked by NPY in the mouse vas
deferens implying that the mechanism may be tissue dependent
(Stjarne et al, 1986). The potentiating effect of NPY in
peripheral blood vessels has been reported by Nield (1987) to
reflect a general change in smooth muscle reactivity (partial
depolarisation). While some believe this effect is caused by NPY
2+increasing the permeability to Ca of partially depolarised
smooth muscle, others purport that the potentiation depends on 
+ 2+Na ■ but not Ca influx and that an intracellular sequestered 
2+pool of Ca participates (Glover, 1986; Wahlestedt et al, 1985).
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Stjarne et al (1986) proposed that the presynaptic action of
NPY on transmitter release at the sympathetic neuroeffector
junction is associated with a depression of the stimulus-
secretion coupling (invasion of varicosities by action
potentials) rather than an effect on the secretory process
itself. In central nervous tissue the inhibition of
neurotransmitter release by NPY may be a consequence of the
2+inhibition of neuronal Ca currents (Walker et al, 1988a; 
Colmers et al, 1987).
It is of considerable interest that NPY has been shown to 
attenuate the forskolin-induced formation of cAMP or adenylate 
cyclase in several tissues which include some peripheral and 
cerebral blood vessels (Lundberg et al, 1988; Fredholm et: al, 
1985; Haggblad and Fredholm, 1987). This inhibitory action of
NPY on cAMP formation may mediate at least some of the reported
functional activities of the peptide. Evidence favouring the 
direct involvement of the other second messenger system, 
phosphoinositide hydrolysis, in this peptide's action on smooth 
muscle is less convincing. Although inositol phosphates may 
participate in the enhancement of NPY on agonist-induced 
contractions (Haggblad and Fredholm, 1987; Lundberg et al, 1988).
1.6 Endothelin-1
1.6.1 Identification of Endothelin-1
Endothelin-1 (ET-1) is an endothelial cell-derived peptide, 
which was isolated and sequenced by Yanagisawa and colleagues 
(1988a) from the culture medium of porcine aortic endothelial
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cells. Despite the very recent discovery of this peptide, 
substantial progress has been made concerning its identity and 
origins. Indeed the endothelin gene.was cloned and sequenced 
prior to the pharmacological characterisation of the peptide. 
The peptide consists of 21 amino acid residues with free amino 
and carboxytermini plus two sets of intrachain disulfide bridges 
(Figure 1.6). Sequence analysis of cloned endothelin-1 cDNA 
demonstrated that a precursor peptide of 203 amino acids is 
synthesised which contains a signal sequence which is 
proteolytically cleaved to produce the 39 (porcine) or 38 (human) 
amino acid intermediate big endothelin-1. This precursor is then 
apparently processed to mature endothelin (ET-1) by a putative 
'endothelin converting enzyme'. The sequences of mature ET-1 in 
porcine and human are identically conserved (Yanagisawa et al, 
1988a). The presence of mRNA encoding the prepro-form of 
endothelin in vascular endothelium and the lack of secretory 
granules in which the peptide could be stored in this tissue 
suggest that endothelin is produced by de novo synthesis with 
processing analagous to many hormones and neuropeptides. 
Moreover the level of mRNA expression can be influenced by 
vasoactive agents such as thrombin and adrenaline (Yanagisawa 
et al, 1988a).
The existence of a 'family of endothelins' has been 
indicated by the finding that three genes related to ET-1 are 
present in the human porcine and rat genomes. The amino acid 
sequences of the 21 amino acid peptides predicted by the three
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Endothelln-1
(Human/Porcine/
Dog/Rat)
Endothelln-3
(Human/Ral)
Endothelin-2
(Human)
Sarafotoxln S6b
(A. engaddensis)
Figure 1.6
Amino acid sequences of peptides from the 
endothelin family.
Filled circles represent amino acid residues which differ from 
those in ET-1. Since ET-2 and ET-3 have not yet been identified 
at the peptide level, the bond topologies and the chain lengths of 
these predicted peptides have been drawn by comparison with ET-1.
Adapted from Yanagisawa and Masaki (1989).
genes in humans differed at several amino acid residues. These 
peptides have since been designated endothelin-1 (ET-1 or the 
original porcine/human ET), endothelin-2 (ET-2, with two amino 
acid substitutions from ET-1 and endothelin-3 (ET-3, with six 
amino acid substitutions). ET-3 is identical to a sequence that 
was described earlier in the rat genome (Figure 1. 6, Yanagisawa 
and Masaki, 1989a). The endothelin group display a striking 
sequence homology with a family of 21-residue peptide toxins 
(safarotoxins) newly purified and sequenced from snake venom and 
has prompted some investigators to suggest a common evolutionary 
origin (Figure 1.6). A relationship between these mammalian and 
snake peptides is also indicated by their similar functional 
activities and the finding that they bind competitively to the 
same specific receptor in certain tissues (Kloog and Sokolovsky, 
1989). It is possible that the three endothelin isopeptides are 
produced in many mammalian species and may have different 
functions, possibly by acting at different receptors.
1.6.2 Peripheral Distribution of ET-1
Following the initial report by Yanagisawa et al (1988a) 
showing that genetic markers (mRNA) for the ET-1 precursor were 
present not only in cultured endothelial cells but also in the 
porcine aortic intima in situ, a number of studies have 
investigated the location and distribution of this novel peptide. 
Unlike other peptides including neuropeptide Y which have been 
localised mainly by radioimmunoassay and immunohistochemical 
techniques, studies concerning the distribution of the endothelin
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peptides to date have generally involved indirect methods of 
locating the radiolabelled binding sites using autoradiographic 
techniques or detecting the genetic markers for the peptide. 
Although ET-1 has been detected at the peptide and at the mRNA 
level in vascular endothelial cells, the other cognate peptides 
ET-2 and ET-3 have not been observed in this tissue. Indeed the 
expresion of ET-2 has not yet been conclusively demonstrated in 
any tissues (Yanagisawa et al, 1989a). Several studies have 
demonstrated a wide distribution for ET-1 binding sites. In 
cultured rat vascular smooth muscle cells, a single class of high 
affinity binding sites for ET-1 has been described, supporting a 
role for this peptide in vascular reactivity. Autoradiographic 
studies with iodinated ET-1 have also shown specific binding 
sites of ET-1 in the media of a variety of blood vessels. The 
binding sites in. these blood vessels appeared to be more dense 
towards the adventitia than on the portion of the smooth muscle 
closest to the lumen (Hirata et al, 1988; Koseki et al, 1989a).
Systemic administration of iodinated ET-1 to rats labelled a 
variety of tissues with high concentrations found in the lungs, 
kidneys, adrenal medulla and liver, and lower densities observed 
in heart muscle, stomach, spleen, large blood vessels and renal 
arteries. The autoradiographic features of these tissues 
labelled in vivo were qualitatively similar to the individual 
labelling of tissues in vitro, however the relative densities of 
ET-1 labelling differed (Koseki et al, 1989a). Binding sites for 
ET-1 in peripheral tissues have also been determined in the' 
human, pig, mouse and monkey (Hoyer et al, 1989; Davenport et al,
1989) . The distribution of binding sites in some tissues was not 
homogeneous and was not exclusively associated with vascular 
smooth muscle. In the kidney for instance, the medulla displayed
higher densities of sites than in the cortex. This suggests that
ET-1, as well as influencing blood vessel functioning, may exert 
other physiological effects in these tissues which are not
directly related to vascular reactivity (Koseki et al, 1989a; 
Davenport et al, 1989).
1.6.3 Central Distribution of ET-1
Studies to determine the distribution of ET-1 in the brain 
after systemic administration of the radiolabelled peptide in the 
rat have shown that the peptide bound only to the
circumventricular structures of the median eminence of the
hypothalamus and. subfornical organ located outside the blood 
brain barrier and the choroid plexus (Koseki et al, 1989a).
Although the peptide does not appear to cross the blood brain 
barrier, incubation of brain sections with the radiolabelled 
peptide revealed that as well as brain blood vessels containing 
ET-1 binding sites, many discrete parenchymal regions throughout 
the rat and human brain were labelled with the peptide. High 
levels of binding sites were found in the cerebellum and
hypothalamus with lower levels in the neocortex (Table 1.8). 
Specific binding sites were also found in nuclei-associated with 
cardiovascular regulation in the medulla, pons and the spinal 
cord of the rat (Koseki et al, 1989a; 1989b; Hoyer et al, 1989;
Jones et al, 1989; Davenport et al, 1989). The pattern of
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Table 1.8
125Autoradiographic Distribution of X II-ET-1 Binding Sites in 
Selected Regions of the Rat and Human Brain
Brain Area Rat Human
Cerebellum 882 776
Hypothalamus 727 624
Substantia nigra 651 nd
Thalamus 517 nd
Caudate putamen 255 nd
Neocortex 193 nd
Brain vessels nd 163
- 1Data taken from .Hoyer et al, 1989 and expressed as fmol mg 
tissue.
nd = not determined
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distribution of ET-1 binding sites in the central brain areas is 
distinct from other known peptides including vasopressin and 
neurotensin (Yamamura et al, 1983; Quirion et al, 1982). 
Moreover the non-homogenous pattern of distribution of ET-1 
indicates that in addition to possible vascular activity ET-1 may 
act in the central nervous system in a neurotransmitter or 
neuromodulatory capacity to regulate a variety of neuronal 
functions. ET-3-like immunoreactive material has been located in 
porcine brain homogenates and ET-1-like immunoreactivity 
demonstrated in motor neurones and primary sensory neurones, 
suggesting a neural function for these isopeptides (Yanagisawa 
and Masaki, 1989a). A complete definition of the presence and 
location of ET-1 (and cognate peptides) in the central nervous 
systems, requires further work.
1.6.4 Effects of ET-1 in the Peripheral Nervous System
ET-1 evokes a potent and sustained contraction in isolated 
arterial and venous smooth muscle preparations in almost all 
animal species and vascular regions examined. The effective dose 
of ET-1 on these blood vessels varies, with renal and pulmonary 
arteries being the most sensitive (Yanagisawa et al, 1988a; 
Shigeno et al, 1989; Tomobe et al, 1988). In porcine coronary 
artery strips the dose-response relation of the contractile 
activity of ET showed that the maximum tension developed was 
comparable to those of potassium chloride-induced contractions. 
The dose at which ET-1 was 50% effective (EC,-q ) in this tissue 
was 4.5 x 10 "^M, at least one order of magnitude lower than the
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reported values for neuropeptide Y, angiotensin II and
vasopressin (Edvinsson, 1986; Regoli et al, 1974; Altura, 1970).
In addition values in many other arteries and veins were
also within this range, suggesting that ET-1 is one of the most 
potent vasoconstrictors known to date with important implications 
in vascular regulation (Yanagisawa et al, 1988a).
Intravenous bolus injection of ET-1 in rat provokes a
transient dose-related fall in blood pressure followed by a
sustained dose-dependent elevation in arterial pressure. This 
biphasic response has been associated with differential changes 
in peripheral vascular resistance (Yanagisawa et al, 1988a; 
1988b; Han et.al, 1989). A characteristic feature of the 
response to systemically administered ET-1 is the long duration 
of the pressor phase (2-3 hours) at high doses. The other
members of the endothelian family (ET-2, ET-3) also have
constrictor properties. ET-3, in general, has much weaker 
contractile effects than ET-1 or ET-2 both in isolated tissues 
and in vivo. Furthermore ET-3 has been observed to produce a 
greater initial transient depressor response iji vivo compared to 
the other isopeptides (Inoue et al, 1989). The depressor 
response to ET-1 is also observed in isolated perfused pre­
contracted rat mesenteric arteries and can be attenuated by 
oxyhaemobglobin indicating that the response may be mediated by 
the release of endothelium-derived relaxing factor (de Nucci
et al, 1988). Prostacyclin, another potential vasodilator and 
thromboxane A ^ were also reported by de Nucci et al (1988) to be 
liberated from the perfused isolated rat lung. However the
importance of endothelium-derived relaxing factor and the other 
agents mentioned in the response to ET-1, in vivo remains to be 
established.
Although ET-1 was originally described as a vasoconstrictor 
agent, this peptide has since been recognised to possess a wider 
variety of activities. ET-1 can induce the proliferation of 
vascular smooth muscle cells, which may have important 
implications in the pathogenesis of atherosclerosis (Komura 
et al, 1988). Direct effects of ET-1 on cardiac function have 
been reported. In particular, positive inotropic and 
chronotropic actions, on myocardium of the isolated guinea pig 
atria have been observed (Ishikawa et al, 1988a; 1988b). Another 
cardiac effect which may have physiological significance is the 
secretogogue action of ET-1 on atrial natriuretic peptide in 
isolated atria (Hu et al, 1988). ET-1 is also reputedly involved 
in the regulation of renal function. This is based on the 
finding that ET-1 administered into the renal artery of dogs 
in vivo evoked a pronounced decrease in renal blood flow 
accompanied by a reduction in glomerular filtration rate. These 
actions could potentially lead to the stimulation of renin 
secretion and thus to an increase in blood pressure. However, 
paradoxically ET-1 has also been observed to inhibit renin 
release from isolated glomerular preparations (Yanagisawa and 
Masaki, 1989b).
- In a more recent and very interesting report by Tabuchi 
et al (1989) low doses of ET-1 inhibited the release of nerve-
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stimulated noradrenaline from presynaptic nerve endings in the 
rat mesenteric artery. At higher doses in the same tissue this 
peptide was also observed to enhance the pressor response to 
nerve stimulation. These differential effects of ET-1 are 
similar to the results discussed previously for NPY at the
sympathetic neuroeffector junction. Thus, as for NPY, in
addition to a direct vasoconstrictor response, the above results
support a role for ET-1 in the regulation of local vascular tone 
in association with the sympathetic nervous system.
1.6.5 Effects of ET-1 in the Central Nervous System
The pervasive distribution of specific high affinity binding 
sites for ET-1 in the brain advocates an involvement of this 
peptide in a wide variety of central functions. Since the
binding sites for this peptide were only identified very 
recently, there are few published studies on the potential 
central activities of this peptide. However, a putative role in 
the regulation of cerebral vascular function is inferred by the 
presence of ET-1 binding sites on brain blood vessles (Hoyer 
et al, 1989). In addition, the non-homogenous pattern of
distribution in parenchymal tissue supports a neuronal function 
for this peptide either as a neurotransmitter or a 
neuromodulator. Indeed, very recent evidence which may support
both a central neuronal and vascular function for ET-1 will be 
considered in the context of the studies in Chapter seven which 
investigates the potential central cardiovascular actions of
ET-1.
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1.6.6 Possible Mechanism of Action
The original hypothesis for the contractile activity of ET-1
24-in isolated tissues at least, was the influx of Ca through
voltage-dependent calcium channels in smooth muscle. This view
was based on the finding that vasoconstriction produced by ET-1
in the porcine coronary artery was inhibited dihydropyridine
calcium entry blocker or in the absence of extracellular calcium
(Yanagisawa et al, 1988a). Furthermore, ET-1 markedly augments
2+dihydropyridine-sensitive voltage-dependent Ca channel currents
in whole-cell clamped smooth muscle cells from porcine coronary
artery suggesting a close association with the activation of the 
24-Ca channel (Goto et al, 1989). However, in the cultured
vascular smooth muscle cell of the rat, the binding of
radiolabelled ET-1 was not displaced by dihydropyridine calcium
entry blockers, implying that the specific receptors for ET-1 are
distinct from those of the calcium channel antagonists (Hirata
et al, 1988). In the same report, these authors further
demonstrated that ET-1 produced an initial transient as well as a
24-sustained increase in intracellular Ca concentration in
vascular smooth muscle cells, with only the second phase of the 
24-Ca elevation sensitive to calcium channel antagonists. The
24-initial ET-1 stimulated increase in intracellular Ca levels may 
be mediated by an increase in inositol phosphate production which 
was also observed in vascular smooth muscle cells following ET-1 
(Marsden et al, 1989). It has been postulated that this initial 
elevation in inositol phosphate production mediates an influx of
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2+ 2+ Ca ions resulting in the secondary sustained elevation of Ca
observed in the vascular smooth muscle cell (Van Renterghem
et al, 1988). Therefore it appears that in some tissues,
although ET-1 does not act directly on the dihydropyridine- 
2+sensitive Ca channel, a close association with these voltage
operated channels exists.
In other systems ET-1 has been observed to act almost
2 +completely independently of the voltage-dependent Ca channel.
In the coronary artery strip, high concentrations of ET-1 can
elicit a contraction which does not require extracellular calcium
but is associated with an increase in inositol trisphosphate as
well as another product of phospholipid breakdown, 1, 2-
diacylglycerol (Kasuya et al, 1989). This data suggests that
ET-1 can evoke a potent vasoconstriction which may involve
intracellular calcium mobilisation (inositol trisphosphate) and
stimulation of protein kinase C by 1,2-diacylglycerol. These
second messengers could potentially lead to the activation of the
contractile machinery. This view is consistent with the previous
work of Auguet £t al (1988), who observed that in the rat aorta,
the contraction elicited by ET-1 did not involve the voltage-
dependent calcium channels. Thus, the increased intracellular 
2+Ca levels and vasoconstriction subsequent to ET-1 does not 
necessarily involve direct activation of voltage-dependent 
calcium channels and in some systems ET-1 can act independently 
of extracellular calcium.
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Chapter Two 
General Methods and Materials
2.1 Introduction
This chapter details the general methods ulitised in this 
thesis, more specific methodology is described within the 
individual chapters. All animal studies were carried out using 
male, normotensive, Wistar-Kyoto rats (250 - 350 g).
2.2 Blood Pressure and Heart Rate Measurement in 
Chronically Anaesthetised Rats
Animals were anaesthetised with pentobarbitone sodium 
(60 mgs kg \  i.p.) and a polyethylene catheter, filled with
heparinised saline (8 units ml ^), placed in the abdominal aorta 
or femoral artery. The catheter was then sealed and tunneled 
s.c. to be exteriorised at the back of the neck between the 
shoulder blades. Patency was ensured by filling the catheter 
with a polyvinyl pyrrolidone saline solution (0.5 mgs ml 
containing 200 units ml  ^of heparin. The animals were then 
allowed to recover from the surgery for a period of 24 hours. On 
the study day anaesthesia was induced with a combination of
urethane (1 g kg i.p.) and alpha chloralose suspension (60 mgs
-1 -1 kg , i.p.) and maintained with urethane (300 mgs kg , i.v.).
Rectal temperature was kept constant at 37°C with an automated
heating blanket. After a stabilisation period of one hour,
arterial pressure (mmHg) was recorded via the catheter by a
Statham pressure transducer connected to a Grass Polygraph (7D)
and heart rate was monitored by a cardiotachograph triggered by
the arterial pulses.
2.3 Intraparenchymal Irrj ections into the Medulla Oblongata
of Anaesthetised Rats Coordinates 
Anaesthesia was maintained and arterial blood pressure and 
heart rate and temperature monitored as previously described in 
section 2.2. The rats were placed in a David Kopf stereotaxic 
frame for small animals. A midline incision was made from the 
level of bregma to the lambdoid suture, the fascia retracted and 
the skull exposed.
For microinjections into the caudal ventrolateral medulla, 
the incisor bar was set at 5 mm above the intra-aural line (IAL) 
using the following stereotaxic coordinates: 4.5 mm rostral to
the IAL; 1.7 mm lateral to the midline and 9.9 mm ventral to the 
cerebellar surface. The rostral ventrolateral medulla was 
located with the incisor bar set at 5 mm below the IAL and using 
the following coordinates: 3.5 mm rostral to the IAL; 2.5 mm
lateral to the midline and 8.5 mm ventral to the cerebellar 
surface (Paxinos and Watson, 1986). A small craniotomy (2 mm 
diameter) was performed using a standard dental drill with size 
16 burr. An incision was then made in the dura using the tip of 
an 18 g needle. Unilateral microinjections of drug or vehicle 
(0.9% saline), were delivered via a 30 g needle using a 1 jil 
microsyringe, mounted on a micromanipulator. All injections were 
delivered in a total volume of 0.1 jul over a 20 second interval.
Pilot experiments were performed for both sets of 
coordinates to check the accuracy of the needle placement. This
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involved stereotaxic microinjection of 0.1 [ i l  methylene blue 
followed by histological examination of brain sections (see 
following section). It was demonstrated that the stain never 
diffused beyond a radius of 0.05 mm from the point of injection 
in the coronal plane and 0.2 mm in the saggital plane.
2.4 Histology
At the end of each experiment the animals were killed by an 
overdose of pentobarbitone sodium. The brains were then fixed by 
transcardiac perfusion with FAGLU (formaldehyde 4% and 
gluteraldehyde 0.5% in 0.1 M sodium phosphate buffer pH 7.0), 
excised and 50jum sections cut and mounted for verification of 
the injection site. Needle tracts were clearly visible even in 
unstained sections.
Figures 2.1 and 2.2 illustrate the site of injection for the 
caudal and rostral ventrolateral medulla, respectively. 
Experiments where the injection site was not within the caudal or 
rostral areas were excluded from the study.
2.5 Blood Pressure and Heart Rate Measurement in Conscious 
Rats
The animals were anaesthetised with the short-acting 
anaesthetic methohexitone sodium (60 mg kg i.p.). Catheters 
were then placed in the femoral artery (and vein if necessary), 
the wound infiltrated with the local anaesthetic lignocaine and 
the catheters exteriorised as described in section 2.2. A small 
jacket was fitted to the animal and the catheters passed through
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Figure 2.1
Diagram illustrating the site of microinjection in the caudal 
ventrolateral medulla (CVLM) of the rat.
Af = A^ adrenaline cell group as described by Hokfelt et al,
(1974).
AP = area postrema
V —
\
Figure 2.2 '
Diagram illustrating the site of microinjection in the rostral vento- 
lateral medulla (RVLM) of the rat.
Cf = C, noradrenaline cell group as described by Dahlstrom et al (1964), 
NTS = nucleus of the solitary tract 
4V = fourth ventrical
an attached metal spring plus swivel to protect the catheters and 
allow the animal unrestrained movement. A recovery period of 
three hours was allowed before continuation of the study. 
Arterial pressure and heart rate were monitored as discussed 
previously in section 2.2.
2.6 Intracisternal Cannulation
Animals were anaesthetised with the short acting anaesthetic 
methohexitone sodium (60 mgs kg i.p.). The animal's head was 
fixed in a David Kopf stereotaxic frame with the incisor bar set 
at 3.3 mm below the intra-aural line so that the dorsal surface 
of the skull was horizontal. A midline incision was made from
bregma to the lambdoid suture, the fascia retracted and the skull
exposed. Using an electric hand drill and a dental burr, two 
holes were drilled; one drilled partially through the skull for 
placement of a steel self-tapping screw for anchorage of a dental 
cement and one drilled entirely through the skull for placement 
of the cannula (Figure 2.3). The latter was positioned on the 
midline 1 mm rostal to the lambdoid suture. The guide cannula 
was then advanced caudally 7 mm, at an angle of about 45° to the 
horizontal, so that the bevelled surface of the cannula tip was 
lying approximately horizontal above the surface of the medulla. 
Acrylic dental cement was applied around the screw and cannula to 
fix the cannula to the skull. The cement was allowed to harden, 
the cannula tested to ensure that the cerebral spinal fluid had 
been accessed by the cannula. This was achieved by attaching a
saline filled tube to a needle which was then inserted into the
82
< — 7mm - X r 5mm
17 mm
5mm
5mm
Figure 2.3
Diagram showing dimensions of the intracisternal 
cannula and stylette.
guide cannula. When the tube was raised and lowered the meniscus 
should rise and fall. The cannula was then sealed with a 
stylette (Figure 2.3), cicatrin powder (antibiotic) and the local 
anaesthetic lignocaine were then applied to the wound before 
suturing. On completion of surgery ampicillin sodium (30 mg kg 
i.m.) was given for two days as prophylaxis against infection. 
The animals were allowed seven days to recover before proceeding 
with the study.
2.7 Determination of Plasma Catecholamine Levels
Plasma catecholamine levels were determined as an indirect 
method of measuring sympathetic nerve activity before and after 
intravenous or intracisternal injection of endothelin in rats.
Arterial blood samples (300 ;ul) were removed into lithium 
heparin tubes for the measurement of plasma noradrenaline and 
adrenaline levels. The blood samples were centrifuged 
immediately at 1000 g for ten minutes at 4°C, plasma harvested 
and stored at -70°C. Catecholamine levels were measured by a 
sensitive radio-enzymatic assay modified from the methods of 
Peuler and Johnston (1977) with inter-assay coefficients of 
variation of 10% and 13% for noradrenaline and adrenaline 
respectively. After separation of plasma, the red blood cells 
(150 jul) were resuspended in the same volume sterile saline 
(0.9% w/v) to be returned to the animal after the next sample.
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2.8 Measurement of cAMP Accummulation in Brain Slices
2.8.1 Preparation and Preincubation of Brain Slices
Circadian rhythms have been shown to significantly affect 
basal levels of cyclic adenosine monophosphate (cAMP) in rat 
brain as well as the synthesis and hydrolysis of this enzyme 
(Lemmer et al, 1987). Therefore the present experiments were 
always performed between 9 - 10 a.m. The general protocol for 
these experiments is shown in Figure 2.4. The animals were 
killed by decapitation, the brain removed and the medulla or 
frontal cortex quickly dissected out on ice. The medulla was cut 
again with a scalpel horizontally into two parallel slabs (3 mm 
thick). Slices of medulla or cortex (500 x 500 ;um) were then 
cross-cut on a Mcllwain tissue chopper. Each brain was 
transferred to a separate glass tube containing physiological 
buffer solution A (Table 2.1). Gentle vortexing was used to 
separate the slices. Consistent with other studies, the samples 
were then incubated at 37°C for 30 minutes and gassed with 95% 
02/5% CO2  (Al-Gadi and Hill, 1985). The slices from two brains 
were then pooled and transferred to 13 mis of buffer B which 
consisted of the buffer A solution plus theophylline 
(1.08 mg ml ^), a phosphodiesterase inhibitor to prevent the 
hydrolysis of cAMP to 5 '-AMP.' Where necessary bacitracin (0.1 mg 
ml ^), and/or ascorbic acid (0.2 mg ml )^ was added to this 
buffer■ to prevent the breakdown and oxidation of NPY and 
isoprenaline, respectively. Four aliquots (2 mis slice/buffer
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Brain slices incubated in buffer A at 
37°C (30 minutes)
\
Slices from two brains pooled into buffer B 
and incubated at 37°C (10 minutes)
\
Slices aliquoted into 4, allowing 1 basal and -3 treatments 
and drugs or vehicle control added (15 minutes)
I
Reaction terminated (100 C/4 minutes)
\
tissue homogenised (10 seconds)i
tissue debris removed by 
centrigugation (2800 g/15 minutes/4°C)
I
Supernatant removed and stored for subsequent cAMP
determination
Figure 2.4
General protocol for the incubation of rat brain slices
Table 2.1
Composition of Buffer used in the Incubation of Brain Slices
mM g/litre
NaCl 118 6.85
KC1 5 0.37
k h 2po4 2 0.27
MgS04/7H20 2 0.49
NaHC03 25 2.10
EDTA disodium salt 0.002 0.05
Glucose 11 2.00
CaCl2 2.5 2.5 mis of a 
1M solution
The pH of the buffer was adjusted to 7.4.
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solution) from each pooled sample, which allowed for one control 
and three treatments, were incubated for a further ten minutes.
2.8.2 Drug Treatment of Slices
At the end of the preliminary incubation stage drugs were 
added in two stages and incubated for a total of fifteen minutes 
(Figure 2.4). Specific protocols for the drug additions are 
given in the appropriate chapters (Section 5.2 and Section 6.2).
Following incubation with drugs, the reaction was terminated 
and tissue cAMP released by boiling the sample at 100°C for four 
minutes followed by homogenisation (ten seconds). This procedure 
for extracting cAMP has been demonstrated by Uhlen and Wikberg 
(1988) to yield similar recovery of cAMP as the acid extraction 
protocol described by Kelly and Nahorski (1986). Samples 
(200 ul) were then taken for protein determination using the 
method of Lowery and co-workers (1951). Tissue debris was 
removed by centrifugation at 2800 g for 15 minutes at 4°C and 
samples of the supernatant taken and stored at -20°C overnight 
for subsequent cAMP determination the next day (Figure 2.4). 
However, samples could be stored for at least one month without 
any significant deterioration in cAMP levels.
2.8.3 Measurement of cAMP Accummulation
Levels of cAMP in the samples were determined using a 
sensitive radioimmunoassay kit technique (Tovey et al, 1974) The 
assay is based on the competition between unlabelled cAMP and a 
fixed quantity of the tritium labelled compound, for binding to a 
protein which has a high specificity and affinity for cAMP.
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Separation of the protein bound cAMP from the unbound nucleotide 
is achieved by adsorption of the free nucleotide on to coated 
charcoal, followed by centrifugation. An aliquot of the 
supernatant is then removed for liquid scintillation counting. 
The amount of labelled protein-cyclic AMP complex formed is 
inversely related to the amount of unlabelled cAMP present in the 
assay sample. Measurement of the protein-bound radioactivity 
therefore enables the amount of unlabelled cAMP in the sample to 
be calculated.
2.8.4 " cAMP Assay Protocol
The assay protocol is shown in Table 2.2, with all 
procedures carried out, in duplicate, on ice. After the addition 
of the appropriate agents, tubes were mixed for about five 
seconds. The qssay tubes were then incubated in a cold room at 
2°C - 4°C for two hours. Fifteen minutes before the end of the 
incubation time charcoal reagent was stirred continuously to 
ensure a uniform mixture. The charcoal suspension was then added 
to all tubes in batches of eight, vortex mixed, and allowed to 
stand for three minutes. The tubes were then centrifuged at 
2800 g for five minutes at 4°C, to sediment the charcoal. 
Without disturbing the sediment, a 200jul sample from each tube 
was removed and placed in scintillation vials. 10 mis of the
scintillent 'Hydroluma' was added to each vial for subsequent 
determination of radioactivity in a f t -liquid scintillation 
counter.
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DETERMINATION OF THE CO-EFFICIENT OF VARIATION (CV) 
IN BASAL cAMP LEVELS WITHIN SAMPLES
Samples measured after 1,2,7 and 30 days of storage
cAMP Levels ( pmol/mg protein)
SAMPLE K D 2(2) 3(7) 4(30) Mean i  S.E. Mean CV(%)
1 2.47 2.69 2.79 2.42 2.59 + 0.09 6.8
2 2.14 1.95 2.10 2.15 2.09 + 0.05 4.4
There is no change in cAMP levels with time
2.8.5 cAMP Assay ^ Precision and Range
Amersham's cyclic AMP assay kit combines the high 
specificity and affinity for cAMP of a highly purified and 
stabilised binding protein with a charcoal separation step. This 
results in little interference by materials likely to be present 
in crude extracts (Tovey et al, 1974). The kit provides a rapid, 
simple and specific method for the determination of cAMP. 
Typical assay data is shown in Table 2.3 and from this the 
concentration of unlabelled cAMP in the sample is determined from 
a linear standard curve (Figure 2.5) and then converted to pmols 
mg"^ protein. The assay has a co-efficient of variation of less 
than 7% over the range of 0.5 - 14 pmol/50 jul sample.
2.8.6 Preliminary Investigations
As will be discussed later in Sections 5.4 and 6.4 the
inhibitory reponse to various agents including Brener gic
agonists has been observed by Duman and Enna (1986) to be more 
easily detected under conditions of elevated cAMP levels achieved 
by the direct stimulation of the adenylate cyclase enzyme with
the diterpene forskolin. In order to reveal the optimal
conditions for this stage, concentration-response and time- 
response relationships for the effect of forskolin on cAMP
production in the medulla slice were determined. The preparation 
and preincubation of the brain slices was essentially the same as 
detailed in Section 2.5.1 with the following modifications. The 
brain slices from four rats were pooled into 28 mis of buffer B. 
Twelve aliquots (2 mis slice/buffer solution) from the pooled
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Table 2.3 
Typical Assay Data
Tube No. c.p.m. Average
c.p.m.
Average 
c.p.m. - 
blank
Co
Cx
Standard
cAMP
pmol/tube
1 121
120 - - -
2 119
3 5611
5605 5485 1 0.0
4 5600
5 3437
3424 3304 1.66 1.0
6 3411
7 2528
2552 2432 2.26 2.0
8 2576
9 1659
1679 1559 3.52 4.0
10 1699
11 1017
1040 920 5.96 8.0
12 1063
13 627
645 525 10.44 16.0
14 663
c.p.m. -* counts per minute
Co = c.p.m. bound in the absence of
unlabelled cAMP
Cx = c.p.m. bound in the presence of
standard or unknown unlabelled <
90
CO
cx
n =
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0 5 10 15 20
cAMP (pmol/incubation tube)
Figure 2.5 
A typical cAMP standard curve 
radiolabelled cAMP bound in the absence of 
unlabelled cAMP
radiolabelled cAMP bound in the presence of 
standard unlabelled cAMP 
1  (in duplicate)
sample were taken which allowed six treatment or time samples,
each with a separate control. The samples were incubated for a
further ten minutes, as described previously (Section 2.5.1). To
establish the dose-response relationship to forskolin, the
- 8  -5appropriate concentration of forskolin (1 0 - 1 0  M) was added
and incubated for ten minutes. Alternatively, a time-response
curve was constructed by incubating the chosen concentration of
forskolin (10 ^M) for various time intervals (0 - 30 minutes).
The reaction was then terminated and cAMP levels measured as
described in the previous Sections 2.5.2 - 2.5.4.
- 8 - 5Forskolin (10 - 10 M) stimulated the cAMP production in
the medulla oblongata above control levels in a dose-dependent
manner (Figure 2.6). The plateau stage in the dose-response
curve was not reached because of solubility problems encountered
if higher concentrations of forskolin were used under the present
conditions. Ethanol (95%) was used to dissolve forskolin and
this solution remains stable for at least one month. Although
Robberecht et al (1983) have shown that high concentrations of
ethanol inhibit adenylate cyclase activity, the final
concentration of ethanol in the present experiments was less than
0.1% which Kitamura et al (1985) have shown does not affect basal
adenylate cyclase activity. In accordance with numerous other
_ 5
studies a dose of 10 M forskolin was used in the following
experiments. This represented a concentration which obtained a
maximum or near maximum response in studies by Fredholm et al
(1986) and Westlind-Danielsson et al (1987; 1988). In medulla
-5slices forskolin ( 1 0  M) evoked an increase in the production of
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Figure 2.6
-8 -5Dose-response graph of forskolin (10 - 10 M) in
slices of the rat medulla oblongata.
Results are expressed as mean + s.e.mean.
For each point 3 < n < 6 , in duplicate.
* Significant difference from saline control (p < 0.05)
cAMP compared with basal values, reaching a stable level after 
10 - 15 minutes (Figure 2.7). Consequently, and in agreement 
with previous investigations (Daly et al, 1982) a ten minute 
incubation time was chosen for forskolin.
Thus, in the proceeding results (Sections 5.3 and 5.4), 
where the effects of purported inhibitory substances on cAMP 
production have been examined, forskolin ( 1 0  ^M) or vehicle were 
added and incubated for ten minutes subsequent to an initial five 
minute incubation with the proposed inhibitory agents.
2.9 Materials
Wistar-Kyoto rats were supplied by Harlan Olac, Bister, 
England.
Porcine NPY was purchased from Cambridge Research 
Biochemicals. Clonidine, forskolin, isoprenaline, pertussis 
toxin and propranolol were obtained from Sigma Chemical Co., 
Dorset, England. Moxonidine was a generous gift from BDF, 
Hamburg, Germany. Porcine endothelin-1 was supplied by 
Scientific Marketing, London. All drugs were dissolved in 
sterile saline with the exception of forskolin and isoprenaline 
which were dissolved in ethanol (95% v/v) and ascorbic acid 
solution (0.1% w/v), respectively. NPY was dissolved in a bovine 
serum albumin solution (0.5% w/v), aliquoted and stored at -70°C 
in silicone coated tubes (Sigmacoate). These procedures were 
carried out to prevent the absorption of the peptide onto the 
plastic tube. Endothelin-1 was dissolved in sterile saline 
(0.9% w/v), aliquoted and stored at -20°C in silicone coated
cA
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Figure 2.7
-5
Time-response graph of forskolin (10 M) in 
slices of the rat medulla oblongata.
Results are expressed as mean + s.e.mean.
For each point, n = 4 (in duplicate).
O Basal cAMP levels
-5• Forskolin-stimulated (10 M) cAMP levels 
* Significant difference from saline control (p < 0.05)
tubes.
The contents of the buffers used were obtained from BDH,
Dorset, England, with the exception of theophylline and ascorbic
acid which were purchased from Sigma and Koch-Light Laboratories,
Colnbrook, England.
The anaesthetics used and their U.K. sources are as follows:
Methohexitone sodium, Eli Lilly & Co.; Pentobarbitone sodium, May
and Baker Ltd.; Urethane, Sigma Chem. Co.; Halothane, I.C.I.; and
the alpha-chloralose suspension was a kind gift from Glaxo Group
Research, Middlesex. Ampicillin sodium was purchased from
Beecham Research, Brentford, England. The heparin solution and
polyvinyl pryrrolidone were obtained from Leo Laboratories,
3
Risborough and BDH, England, respectively. The H-cAMP
1^4-radioimmunoassay kit was supplied by Amersham, England. C-
Iodoantipyrine was also purchased from Amersham. The liquid 
scintillent Hydroluma was purchased from May and Baker Ltd., 
England. Equipment used and their sources include a blood gas 
analyser, Corning, U.K., a Quantimet 970 densitometer, Cambridge 
Instruments, and Kodak GRL film. The small animal jacket and 
swivel attachment was obtained from Harvard Apparatus, England.
2.10 Statistics
The majority of the statistical analysis was carried out 
using Repeated Measures Analysis of Variance and where 
appropriate, a Bonferroni correction was included for multiple
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comparisons. Alternative statistical tests were used 
Chapter Seven and are described therein. All results 
expressed as mean + standard error of the mean (s.e. mean).
in
are
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Chapter Three
Individual Haemodynamic Actions of Neuropeptide Y and Clonidine 
after Microinj ection into the Ventrolateral Medulla
3.1 Introduction
The central haemodynamic actions of NPY are the subj ect of
continued research, some of which has been stimulated by its co­
storage and functional interaction with catecholamines in the 
peripheral nervous system (Lundberg et al, 1982; Edvinsson et al, 
1984a). NPY-like immunoreactivity and binding sites have also 
been localised in discrete central regions associated with 
cardiovascular control and thus form a morphological basis for an 
action of NPY in these regions (Section 1.5.3). Prior to 
investigating the possible functional interactions between NPY 
receptors and C^-adrenoceptors in the medulla oblongata, it was 
first necessary to establish the individual haemodynamic actions 
of NPY and the OL^ -adrenoceptor agonist, clonidine, in this 
region.
3.1.1 Central Actions of NPY
Intraventricular administration of NPY has been reported to 
cause hypotension, bradycardia and bradypnea in the conscious rat 
(Harfstrand, 1986). In contrast, Vallego and Lightman (1986a) 
demonstrated an increase in blood pressure after administration 
of lower doses of NPY into the ventricles of anaesthetised rats. 
Although the former group attributed the vasodepressor effect of 
NPY to an action at the medulla oblongata, these results are 
complicated by the widespread distribution of the peptide
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following injection via this route and an action at the level of 
the hypothalamus cannot be excluded. Indeed NPY has been found 
to exert varying effects on blood pressure and behaviour 
depending on the specific site of injection within the 
hypothalamus. Martin et al (1988) reported an elevation in blood 
pressure following unilateral injection of NPY in nanomolar 
quantities, into the posterior hypothalamic nucleus.
Microinjection of NPY into the paraventricular nucleus resulted 
in an increased food intake and a separate stimulation of 
drinking (Stanley and Leibowitz, 1984). The former behaviour may 
have cardiovascular consequences since the hypotensive response, 
subsequent to intraventricular NPY administration, was reported 
to be counteracted by an NPY-induced feeding action (Harfstrand, 
1986). These results however, are confused by the finding that 
NPY in the paraventricular nucleus NPY can either reduce blood 
pressure or have no significant effect on blood pressure 
depending on the report (Harland et al, 1988; Harfstrand et al, 
1987a). Furthermore, an increased plasma level of vasopressin 
was observed in response to NPY microinjected into the 
hypothalamic supraoptic nucleus of conscious rats (Willoughby and 
Blessing, 1987). The haemodynamic importance of this elevated 
plasma vasopressin is in contention, since the pressor response 
to intracerebroventricular administration of NPY in anaesthetised 
rats was unaffected by intravenous injection of a specific 
vasopressin antagonist. However, the finding that this pressor 
response was attenuated in vasopressin-deficient rats
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(Brattleboro), indicates that central vasopressin pathways may be 
involved in the response to intracerebroventricular injection of 
NPY (Vallejo and Lightman, 1986a).
The multifarious nature of this peptide is indicated by the 
above observations and highlights the limitations in the amount 
of information that can be obtained from injections into the 
cerebrospinal fluid. Thus, the cardiovascular effects of 
intracisternal injection of NPY, which initially concentrates the 
peptide around the brainstem regions are also difficult to 
interpret. Injection by this route has been shown to reduce 
blood pressure and heart rate (Macrae and Reid, 1988; Fuxe et al, 
1983). However, Petty et al (1984) failed to demonstrate a 
cardiovascular response to intracisternal injection of NPY.
The anaesthetic state and species of the animals used in 
these studies may determine the direction of the response to NPY, 
Alternatively, the variation in the reported haemodynamic effects 
may also arise from the concentration of NPY used as well as the 
indiscriminate circulation of the peptide resulting from the 
volume of injectate or solvent used. These experiments, although 
necessary starting points, demonstrate that further refinement of 
the injection technique is required to define the nuclei 
mediating the central cardiovascular actions of NPY. The 
specific areas chosen for such investigation were the group of 
adrenaline containing neurones in the rostral ventrolateral 
medulla (RVLM) and in the caudal ventrolateral medulla (CVLM), 
the noradrenergic neurones (Hokfelt et al, 1974; Dahlstrom 
et al, 1964). In addition to being important centres for the
tonic and reflex regulation of blood pressure per se, these areas 
contain NPY-like immunoreactivity in the cell bodies and 
terminals, as discussed in previous sections, propounding a 
functional role for NPY.
3.1.2 Central Actions of Clonidine
Clonidine is a centrally acting hypotensive and bradycardic 
agent. On the basis of transection experiments and radioligand 
binding data these haemodynamic effects are considered to be 
mediated primarily through alpt^-adrenoceptors located in the
medulla oblongata (Schmitt and Schmitt, 1969; Unnerstall, 1984), 
although as shown in Table 3.1, other areas have been implicated. 
The mechanism of action has been studied extensively in both 
human and experimental animals with a number of specific nuclei 
in the medulla proposed as the most likely sites of action. 
Rockhold and Caldwell (1979) observed that the fall in blood
pressure and heart rate, subsequent to intravenous clonidine
administration in conscious spontaneously hypertensive rats, was 
reduced following bilateral electrolytic lesions of the nucleus 
of the solitary tract (NTS). In contrast, in anaesthetised cats, 
other investigators have been unable to confirm, by lesioning 
studies, the purported involvement of the NTS in the central
actions of clonidine (Antonaccio and Hailey, 1977). However, 
unilateral microinjection of clonidine (1.25 - 40.0 nmol) into 
the NTS resulted in hypotension and bradycardia in anaesthetised 
rats which was attenuated by NTS pretreatment with yohimbine, an 
OL^r-adrenoceptor antagonist (Rockhold and Caldwell, 1980).
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The ventrolateral medulla has also been investigated as a 
potential site of action of clonidine. Punnen et al (1987) 
demonstrated that microinjection of idazoxan, an 0 ^  adrenoceptor 
antagonist, into a pharmacologically defined pressor area in the 
ventrolateral medulla, attenuated the reduction in blood pressure 
and heart rate, evident in anaesthetised rats, following 
intravenous administration of clonidine. More localised 
microinjections of clonidine into the lateral reticular nucleus 
(which also includes the vasopressor nuclei of the RVLM) 
resulted in hypotension plus bradycardia and suggests that the 
nuclei may participate in the central actions of clonidine 
(Bousquet et al, 1981). More recently, Head et al (1987b) 
investigated the cardiovascular role of the cell group in the 
CVLM of rabbits. Chronic lesions in this area attenuated the 
bradycardia but not hypotension produced by intracisternal 
clonidine administration.
Thus evidence exists, albeit indistinct, that clonidine in 
the medulla oblongata, evokes haemodynamic responses. Further 
characterisation of the cardiovascular effects of clonidine in 
this area is warrented and the present study compared the effects 
of microinjecting clonidine directly into the C-^  plus cell
groups of the rostral and caudal ventrolateral medulla.
3.2 Methods
The animal studies described in this chapter were carried 
out using Wistar-Kyoto rats weighing between 250 - 320 g. Groups 
of 6  - 9 were used in all experiments.
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3.2.1 Preparation of Animals for Intraparenchymal
Microinj ection Studies and Measurement of Arterial 
Pressure and Heart Rate
Anaesthesia was induced with a mixture of urethane 
( 1  g kg i.p.) plus alpha-chloralose suspension (60 mgs kg
i.p.) and maintained where necessary with urethane (300 mgs kg ^ ,
i.p.). The rats were placed in stereotaxic frame and vehicle or 
drug microinjected into either the caudal or rostral 
ventrolateral medulla using the methods and coordinates described 
in Section 2.3. Arterial pressure and heart rate were measured 
from an arterial catheter inserted the previous day 
(Section 2.2). At the end of each experiment the site of 
injection was confirmed by histological examination 
(Section 2.4).
3.2.2 Statistical Analysis
Changes in mean arterial pressure and heart rate from basal 
values are denoted A  MAP and A  HR. All values are quoted as means 
+ s.e.mean. The significant changes in MAP and HR from control 
values following drug injections were determined by Repeated 
Measures Analysis of Variance, with a bonferoni correction 
included where appropriate for multiple comparisons.
3.3 Results
3.3.1 Control Responses in the Caudal and Rostral
Ventrolateral Medulla 
No significant effect on MAP or HR was observed after the
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microinjection of saline into the caudal (CVLM) or rostral (RVLM) 
ventrolateral medulla of anaesthetised rats (Figure 3.1 and 
Figure 3.2). Furthermore injection of neuropeptide Y (NPY) or 
clonidine into nearby control areas lateral or dorsal to these 
regions did not produce any significant haemodynamic response.
3.3.2 Effect of Neuropeptide Y Microinjected into the Caudal 
Ventrolateral Medulla
The haemodynamic profile obtained after microinjection of 
NPY (25 and 50 pmol) into the CVLM is shown in Figure 3.1. Both 
doses of NPY microinjected into this area produced a fall in MAP. 
This hypotensive response reached statistical significance, with 
the higher dose of NPY (50 pmol), after five minutes. The 
maximum decrease in MAP was -7.4 + 2.1 mmHg and -12.3 + 3.0 mmHg, 
which occurred at 30 minutes post-injection in response to 25 and 
50 pmol NPY respectively. The MAP returned to control values by 
one hour post-injection. The fall in HR elicited after injection 
of NPY into the CVLM, which was similar for both doses, was 
significantly different from control value for both doses at 30 
minutes and persisted for one hour. Nadir was reached at 45 
minutess and was -91.1 + 21.5 bpm and -94.4 + 28.1 bpm for NPY 25 
and 50 pmol, respectively.
3.3.3 Effect of Neuropeptide Y Microinjected into the Rostral 
Ventrolateral Medulla
In the RVLM, neither concentration of NPY investigated (25 
and 50 pmol) significantly influenced blood pressure or heart 
rate when compared to saline control (Figure 3.2).
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Figure 3.1
Effect of neuropeptide Y (NPY) microinjections into the 
caudal ventrolateral medulla on (a) mean arterial pressure 
(MAP) and (b) heart rate (HR).
O saline 
A  NPY (25 pmol)
▲  NPY (50 pmol)
Points represent mean changes from preinjection value; 
vertical bars show s.e.mean; * significant differences from 
saline control (p <  0.05).
Preinjection values 
(means + s.e.mean)
Saline; n = 6  
25 pmol NPY; n = 9 
50 pmol NPY; n = 9
MAP (mmHg)
96,1 + 2.6
101.0 + 1.9
102.0 + 2.7
HR (bpm)
369 .0 + 14.1 
338 .0 + 11.3 
368 .0 + 4.2
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Figure 3.2
Effect of neuropeptide Y (NPY) microinjections into the 
rostral ventrolateral medulla on (a) mean arterial pressure 
(MAP) and (b) heart rate (HR).
O  Saline
A NPY (25 pmol)
A NPY (50 pmol)
Points represent mean changes from preinjection value; 
vertical bars show s.e.mean;
Preinjection values 
(means + s.e.mean)
Saline; n = 6 
25 pmol NPY; n = 7 
50 pmol N P Y ; n = 6
MAP (mmHg)
89.2 + 3.3 
97.9 + 4.9 
90.0 + 2.6
HR (b p m )
368.8 + 18.3
382.8 + 18.4
360.0 + 1 3 . 9
3.3.4 Effect of Clonidine Microinj ected into the Caudal 
Ventrolateral Medulla
Clonidine (10 and 20 nmol) evoked a significant dose-related 
fall in MAP when microinjected into the CVLM (Figure 3.3). The 
maximum hypotensive effect following injection of clonidine 1 0  
and 20 nmol (-21.0 +4. 6  mmHg; -40.8 + 6 . 5  mmHg, respectively) 
was manifest between 45 and 60 minutes and the reduction 
sustained for 2-3 hours. The bradycardia produced by clonidine 
resembled the response after injection of NPY in this region 
(Figure 3.3), with both concentrations of clonidine producing 
comparable falls in HR. The bradycardia reached the nadir at 45 
minutes with a time course commensurate with the blood pressure 
response.
3.3.5 Effect . of Clonidine Microinjected into the Rostral 
Ventrolateral Medulla
Clonidine (10 and 20 nmol) produced dose-related hypotension 
and bradycardia following microinjection into the RVLM 
(Figure 3.4). The peak hypotensive response of -21.6 + 5 . 9  mmHg 
(10 nmol) and -36.0 +3. 5  mmHg (20 nmol) was observed 30 minutes 
post-injection, with the fall in MAP lasting 2-3 hours at the 
highest dose. In contrast to the effect of clonidine on the HR 
response in the more caudal region (Section 3.3.4), the 
bradycardia induced in this area was dose-related. A similar 
time-course was demonstrated for the bradycardia, compared with
the hypotensive response. The maximum fall in HR was
- 54.6 + 12.2 bpm and -110 +16.2 bpm following injection of
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Figure 3.3
Effect of clonidine microinjections into the caudal 
ventrolateral medulla on (a) mean arterial pressure (MAP) 
and (b) heart rate (HR).
O Saline
□ Clonidine (10 nmol)
■ Clonidine (20 nmol)
Points represent mean changes from preinjections values; 
vertical bars .show s.e.mean; * significant differences 
from saline control (p <  0.05).
Preinjection values 
(means + s.e.mean)
MAP (mmHg)
Saline; n = 6  96.1 + 2.6
10 nmol Clonidine; n = 10 96.8 + 2.5
20 nmol Clonidine; n = 5 9 4 . 4 + 1 . 7
HR (bpm)
369.0 + 14.1
373.0 + 8 . 6
339.0 + 13.3
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Figure 3.4
Effect of clonidine microinjections into the rostral 
ventrolateral medulla on (a) mean arterial pressure (MAP) 
and (b) heart rate (HR).
O Saline
□ Clonidine (10 nmol)
■ Clonidine (20 nmol)
Points represent mean changes from preinjection values, 
vertical bars show s.e.mean; * significant differences 
from saline control (p < 0.05).
Preinjection values 
(means + s.e.mean)
Saline; n = 6  
10 nmol Clonidine; n 
20 nmol Clonidine: n
MAP (mmHg)
81.1 + 3.3
97.3 +1.9 
88-0 + 6.0
HR (bpm)
368.3 +18.3
375.0 + 15.9
347.0 + 29.1
clonidine 1 0  and 2 0  nmol, respectively.
3.4 Discussion
3.4.1 Effects of Neuropeptide Y in the Ventrolateral Medulla
Using a discrete microinjection technique the present study 
demonstrates that NPY evokes cardiovascular effects following 
injection into a specific region of the ventrolateral medulla. 
In the CVLM, injection of NPY results in a dose-related 
hypotension which is analogous with the peptide's effect after 
intracisternal administration (Macrae and Reid, 1988). The 
haemodynamic response in the present study most likely involved 
the group of noradrenergic (A^) neurones located in this caudal 
area (Dahlstrom et al, 1964). The mechanism through which the 
neurones alter arterial pressure is not clear at present. 
However, these cells do not appear to project to the spinal cord 
(Ross et al, 1981a). An inhibitory pathway from the A^ cells to 
the vasopressor (C-^ ) cells of the RVLM, which do project directly 
to the spinal cord, has been implicated, however as discussed 
previously in Section 1.3.5 other pathways may contribute.
Further evidence for an involvement of the sympathetic 
nervous system in the actions of NPY in the CVLM arises from 
experiments carried out by Willette et al (1987). They report 
that chemical excitation of the CVLM in anaesthetised rats using 
the excitatory amino acid L-glutamate, results in a reduction of 
regional vascular resistance via an alteration of sympathetic 
nerve activity. These data together with the localisation of
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NPY-immunoreactive terminals around the nucleus (Harfstrand 
et al, ' 1987a) suggest that NPY in the CVLM stimulates the A^ 
neurones to evoke a reduction in sympathetic outflow and produce 
a fall in blood pressure.
Although NPY elicits a pronounced vasodepressor response in 
the CVLM, no effect was observed after NPY administration in the 
more rostral area. Harfstrand et al (1987a) have shown a low to 
moderate density of NPY-like immunoreactive terminals in the 
RVLM, suggesting the presence of endogenous NPY in this area. 
Therefore the lack of effect of exogenously administered NPY is 
curious. Furthermore, the importance of the area, which includes 
the C^ adrenergic neurones, in tonic and reflex cardiovascular 
regulation is well established. Ross et al (1984b) have shown 
that electrical stimulation of the C^ area results in significant 
increases in arterial pressure, while electricl or chemical 
lesion of these neurones cause a profound fall in arterial 
pressure (Dampney et al, 1982).
The haemodynamic effects of NPY have been investigated in 
another discrete area of the medulla, the NTS (Carter et al, 
1985) . In this region the direction of the blood pressure 
response to NPY was dose-dependent, 470 fmol induced a pressor 
response, 4.7 pmol a fall in blood pressure and the low dose of 
47 fmol was ineffective. Therefore it is possible that an effect, 
of NPY in the RVLM would be observed by extending the dose-range. 
However, this is unlikely since the doses used in the present 
study (NPY; 25 and 50 pmol) are similar to the dose producing 
hypotension in the NTS.
106
Recent evidence indicates that subtypes of receptors for NPY 
may also exist in the central as well as the peripheral nervous 
systems and this may explain the different actions of NPY 
demonstrated in the CVLM and RVLM. Initially it was proposed by 
Wahlestedt et al (1986), that two distinct subtypes of NPY 
receptors were responsible for the pre- and post- junctional 
actions of NPY in the peripheral sympathetic neuroeffector 
junction. This hypothesis was based on the ability to mimic the 
effects of NPY at the presynaptic but not postsynaptic receptor 
with the C-terminal fragment of N PY ^  3 5  (Section 1.5.4). Sheikh 
et al (1989), using monoiodinated radioligands of both the intact 
NPY molecule and the C-terminal fragment NPY ^  human and
porcine brain, has apparently characterised two subtypes of NPY 
binding sites. The Y^ subtype was identified on a human 
neuroblastoma cell line and binds NPY with a dissociation 
constant in the nanomolar range but does not bind N P Y ^  3 5 - In 
agreement with Walker and Miller (1988) who utilised rat 
forebrain membranes, Sheikh et al (1989), also defined a second 
binding site (Y^) which was in the majority, and bound NPY with a 
high affinity plus the C-terminal fragment NPY^g 3 6 * A 
functional role of these binding sites was considered by Fuxe 
et al (1987a) who observed in conscious rats, that 
intraventricular injection of NPY lowered blood pressure whereas 
N P Y ^  3  ^had no significant haemodynamic action. This indicates 
the possible involvement of the Y^ receptor in cardiovascular 
control. Although it would appear from the limited data
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available that the Y 2  subtype of NPY binding site does not 
directly participate in the central control of blood pressure, it 
is possible that this subtype is involved in the central pre- 
synaptic actions of NPY which include the inhibition of 
neurotransmitter release^ from rat sensory neurones (Walker et al, 
1988).
It has not yet been possible to establish the distribution 
of the subtypes of NPY binding sites in the medulla, indeed 
Martel e t al (1986) using radioligand and autoradiographical 
techniques observed only a single class of high-affinity sites in 
rat brain membrane preparations. Further work is therefore 
required to determine whether the above reported differences in 
affinity and specificity represent the expression of two 
different NPY receptor types or reflect two different states of a 
single receptor. The differential synaptic location of the NPY 
binding site(s) may regulate the response to exogenously 
administered NPY in a specific area and explain the lack of 
effect of NPY in the RVLM. Alternatively although NPY- 
immunoreactive terminals have been demonstrated in the rostral 
and caudal ventrolateral medulla (Harfstrand et al, 1987a), 
reports vary . in the ability to determine the presence of NPY- 
binding sites in these regions (Nakajima et al, 1986; Martel 
et al, 1986). Mismatches between the distribution of NPY-like 
immunoreactive terminals and NPY binding sites exist throughout 
the central nervous system (Section 1.5.3). Thus the presence of 
the former may not always be a reliable indicator of a functional 
role for NPY in the region under investigation.
In addition to the hypotensive response, NPY administered 
into the CVLM elicited a fall in HR, which had a similar time 
course to the blood pressure response. These results are similar 
to those of Willette e t al (1987), who observed that the 
vasodepressor response to chemical stimulation of the region 
in rats was accompanied by bradycardia. In the present study, in 
contrast to the effect on arterial pressure, the fall in HR after 
NPY microinjection into the CVLM was not dose-dependent. It is 
possible that the mechanisms involved in the regulation of heart 
rate are more sensitive to NPY than those of blood pressure. 
Thus although the blood pressure response to the lower dose of 
NPY was submaximal, the heart rate response may have been 
maximal. Moreover the nucleus ambiguus is in close proximity to 
the injection site. This area is the origin of most cardio- 
inhibitory vagal projections and may therefore be involved in the 
heart rate response. This area is included in a plexus of NPY-IR 
nerve terminals which surrounds the CVLM. Indeed, Macrae and 
Reid (1988), have demonstrated that the prolonged bradycardia 
elicited by microinjections of NPY into the CVLM is significantly 
reduced, but not abolished, in vagotomised rats. This incomplete 
attenuation of the heart rate response to NPY in vagotomised rats 
probably reflects the participation of cardiac sympathetic, as 
well as vagal pathways in the response.
The results of the present study confirms the role of NPY in 
the central regulation of cardiovascular control with the 
addition of the CVLM to the list of discrete regions where NPY
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has been observed to produce a haemodynamic effect.
3.4.2 Effects of Clonidine in the Ventrolateral Medulla
A prolonged hypotension and bradycardia were demonstrated 
after microinjecting clonidine into the rostral and caudal 
regions of the ventrolateral medulla. In the CVLM, the fall in 
blood pressure resembled the response to electrical or chemical 
(glutamate) stimulation of this region, previously reported in 
rabbits (Blessing and Reis, 1982). The bradycardia produced by 
clonidine in the CVLM was not dose-related and in this respect 
resembled the heart rate response to NPY in the same area. As 
discussed previously (Section 3.4.1), the involvement of the 
nucleus ambiguus in the effects of NPY in the CVLM has been 
reported. Thus, the bradycardic response to clonidine may also 
be a result of diffusion of the peptide to the nucleus ambiguus 
or an action on neuronal pathways from the CVLM to nucleus 
(Macrae and Reid, 1988).
The dose-related reduction in blood pressure and heart rate 
observed following injection . of clonidine into the RVLM, is 
consistent with an analogous microinjection studies carried out 
by Granata et al (1984; 1986), in anaesthetised and paralysed 
Sprague-Dawley rats.
A reduction in sympathetic nerve activity to the heart and 
blood vessels together with a facilitation of the vagal 
baroreceptor reflex was proposed to mediate the central 
cardiovascular actions of clonidine (Sun and Guyenet, 1986; 
Schmitt et al, 1967). More recently, Willette et al (1987),
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observed that chemical stimulation of the neuronal pools in the 
CVLM and RVLM, using L-glutamate, resulted in a differential 
regulation of regional blood flow. Microinjection of L-glutamate 
into the CVLM produced a decrease in sympathetic nerve activity, 
blood pressure and heart rate, associated with a reduction in 
mesenteric and hindquarter vascular resistance. In contrast, the 
opposite effects were observed in the RVLM, namely an increase in 
sympathetic nerve activity, blood pressure and heart rate with a 
concomitant increase in the resistance of all vascular beds 
monitored. Since regulation of sympathetic outflow mediates the 
effects of L-glutamate stimulation in the RVLM and CVLM, it is 
possible that the effects of clonidine in these regions may 
involve a similar mechanism of action. However, the congrous 
effects of clonidine observed in the RVLM and CVLM in the present 
study, are in apparent conflict with the differing actions of L- 
glutamate, demonstrated in both areas by Willette and colleagues. 
It is therefore necessary to find an alternative explanation in 
order to understand this anomaly.
Controversy exists concerning the possible interference of 
anaesthesia in the haemodynamic responses of clonidine. Vlahakos 
et al (1985) reported that in conscious animals clonidine 
injected into the nucleus tractus solitarius of the medulla 
produced pressor responses instead of the reported depressor 
responses observed in anaesthetised animals (Gurtu et al, 1982). 
Thus it was suggested that central forebrain pressor effects of 
clonidine are attenuated in the anaesthetised rat. However 
Punnen et al (1987) were unable to confirm these observations
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since the hypotensive action of clonidine in the ventrolateral 
medulla was qualitively identical in the conscious mid-collicular 
decerebrate rats and rats anaesthetised with pentobarbital or 
urethane. In the present study urethane was used to provide a 
prolonged and stable anaesthesia since, at least in the latter 
study, it did not appear to alter the cardiovascular response to 
clonidine.
Although the antihypertensive actions of clonidine have been 
considered to be due to an action at central OL  ^ adrenoceptors, 
the synaptic location of these receptors has not been clearly 
established. Unnerstall et al (1984) demonstrated that the 
distribution of OL2  adrenoceptors in the brainstem correlates 
well with the location of central noradrenergic and adrenergic 
neurones. A post synaptic site of action for clonidine has been 
suggested by Haeusler (1974). This author observed that 
clonidine was still able to reduce sympathetic outflow following 
depletion of central noradrenaline stores with reserpine plus OL - 
methyl-p-tyrosine implying that a tonic release of noradrenaline 
is not a prerequisite for the hypotensive action of clonidine 
(Starke and Montel, 1973). In addition, prior treatment with 6 - 
hydroxydopamine, to destroy noradrenergic nerve terminals in the 
hindbrain and spinal cord, showed that clonidine was still 
hypotensive although bradycardia was attenuated indicating the 
involvement of noradrenergic terminals at least in the latter 
action of clonidine (Korner and Head, 1983; Connor and Finch, 
1981). Ligand binding studies have further revealed that
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pretreatment with 6 -hydroxydopamine does not alter the binding of 
3
( H) clonidine in the central nervous tissue (U'Prichard et al, 
1977). Indeed substantial evidence exists to show clonidine- 
mediated lowering of blood pressure by an action at postsynaptic 
receptors and may explain the mechanism by which clonidine lowers 
blood pressure in the CVLM (Kobinger, 1978; Bousquet and 
Schwartz, 1983).
Nevertheless a presynaptic mechanism in which clonidine 
inhibits the release of adrenaline has been proposed (Scatton 
et al, 1979; Atkinson et al, 1984). This is supported by the 
indirect evidence that adrenergic neurones are resistant to the 
neurotoxic effects of 6 -hydroxydopamine administration and that 
pretreatment with this agent does not reduce the hypotensive 
actions of intracisternal clonidine (Reid et al, 1976). Thus, 
the hypotensive action of clonidine shown in the vasopressor RVLM 
may be a consequence of a presynaptic action on the adrenergic 
terminals of colaterals, or interneurones in this region, rather
than a direct postsynaptic effect. This would result in the
inhibition of transmitter release, leading to a reduction in the 
activity of the vasopressor neurones and subsequent hypotension. 
Consistent with this hypothesis is the observation that the blood 
pressure lowering effect of clonidine is accompanied by a 
decreased capacity to synthesise adrenaline in the ventrolateral 
medulla (Atkinson et al, 1986). Moreover, Ward-Routledge et al 
(1988) demonstrated that intracisternal administration of
idazoxan, the Q^"adrenoceptor antagonist, enhanced the pressor 
effects of stimulation supporting the existence of a q ^"
autoreceptor involved in blood pressure control. Local 
brainstem networks containing gamma-amino butyric acid, glutamate 
and acetylcholine can modify the actions of ventrolateral 
medullary neurones and may also account for the similar actions 
of clonidine in both regions (Section 1.3.4).
Recently, Bousquet et al (1984) showed that imidazoles, such 
as cirazoline which lack adrenoceptor selectivity, are
hypotensive when applied to the ventrolateral medulla Thus the 
hypotensive action of these agents, and even clonidine itself, 
may be effected through binding at non Oi^-adrenergic receptors 
in this area. This has been confirmed by Ernsberger et al 
(1986), who have shown, using radioligand binding studies, that 
clonidine binds with high affinity not only to -adrenergic
receptors but also to a population of imidazoline binding sites 
in the ventrolateral medulla. The natural ligand for the 
imidazole receptors is unknown. One possibility is an endogenous 
clonidine displacing substance isolated from bovine brain (Atlas 
and Burstein, 1984). Like clonidine, this substance binds both 
to adrenergic and imidazole receptors in the VLM (Ernsberger 
et al, 1986) and produces hypotension when injected into the RVLM 
of the rat (Meeley et al, 1986). Thus the hypotensive action of 
clonidine in both areas studied may in part be mediated through 
these imidazoline receptors. ;
To summarise, a fall in blood pressure and heart rate was 
demonstrated after NPY and clonidine administration in the CVLM 
and for clonidine alone in the RVLM. Further characterisation in
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terms of neuronal pathways and localisation of terminals and 
receptors in the ventrolateral medulla is necessary to resolve 
the apparent discrepancies and elucidate the action of NPY and 
clonidine in this region. The definition of the postulated 
receptor populations will be facilitated by the development of 
receptor isolation and purification techniques, as well as more 
specific ligands for these receptor subtypes.
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Chapter Four
Coadministration of Neuropeptide Y and Clonidine in the 
Ventrolateral Medulla
4.1 Introduction
The colocalisation of neuropeptide-Y (NPY) with 
catecholamines in central nuclei associated with cardiovascular 
control implicates this peptide in the modulation of 
catecholamine pathways and haemodynamic regulation (Hokfelt 
et al, 1983a; Everitt et al, 1984). It has previously been shown 
that clonidine, the Q^-adrenoceptor agonist, as well as 
adrenaline and noradrenaline reduce blood pressure following 
central administration, most likely by an action on central 
adrenoceptors (Section 3.3; Zandberg et al, 1979; Kubo and Misu, 
1981). Injection of NPY into similar areas also produces a 
hypotensive effect (Section 3.3). The similarity of the actions 
of catecholamines and NPY suggest that the coexisting peptide may 
cooperate with the endogenous transmitter(s) in blood pressure 
regulation. The possibility of central functional interactions 
between catecholamines and NPY has been further encouraged by 
reports of an NPY-mediated increase in dopamine turnover in the 
rat striatum and a reduction in noradrenaline turnover in the rat 
brainstem subsequent to the central injection of NPY (Flint-Beal 
et al, 1986; Vallejo et al, 1987).
More direct evidence of a central interaction between 
adrenoceptors and NPY binding sites derives from a series of 
quantitative autoradiographical experiments by Harfstrand et al
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(1989). They reported that NPY in vitro or after 
intraventricular administration in conscious rats significantly 
reduced the density of C i^'adrenergic binding sites (using
tritiated para-amino clonidine as a radioligand) in the medulla 
oblongata. In the same area, comparative studies revealed a 
decrease in the binding of iodinated NPY in the presence of
in vitro or in vivo clonidine (Fuxe et al, 1986; Harfstrand
et al, 1989). These findings indicate the existence of a 
receptor-receptor interaction and support earlier observations, 
using radioligand binding techniques, that NPY in vitro can alter 
the binding characteristics of Oi^-adrenergic receptors. Using 
membrane preparations from the medulla oblongata, Agnati et al 
(1983) previously observed an increased number of C 2^ "acfrenergic 
binding sites in the presence of NPY. In subsequent experiments 
however, the only consistent observation in this area was an NPY- 
evoked reduction in the affinity of the OL^~adrenergic binding 
sites for tritiated para-amino clonidine (Fuxe et al, 1986). 
Alteration of experimental conditions and concentrations of 
radioligands used between studies may account for these 
discrepancies.
Thus evidence of a reciprocal modulation of ^ 2 " 
adrenoceptors and NPY binding sites exists in the medulla and it 
is proposed that this interaction may operate physiologically. 
In agreement with this view, Harfstrand et al (1984) 
demonstrated that simultaneous intracisternal injection of 
clonidine and NPY in anaesthetised rats does not lead to any 
additional lowering of blood pressure compared to that seen with
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either drug alone, implicating a negative interaction between 
these receptors. Furthermore an inhibitory regulation was 
observed by Harfstrand and Fuxe (1987) who found that 
intraventricular coadministration of equi-potent doses of 
adrenaline and NPY significantly counteract the hypotensive 
effects of one another in conscious rats.
Based on the haemodynamic responses obtained for the 
individual microinjections of NPY and clonidine into the 
ventrolateral medulla presented in the preceding section 
(Section 3.3), the present study explored the prospect of a 
functional interaction between NPY and -adrenoceptors in the 
same regions. Thus in the caudal (CVLM) and rostral (RVLM) 
ventrolateral medulla, the response to simultaneous 
microinjection of NPY and clonidine was investigated.
4.2 Methods
4.2.1 Coadministration of Neuropeptide Y and Clonidine in the
Rostral and Caudal Ventrolateral Medulla
Groups of 6 - 1 2  male Wistar-Kyoto rats (250- 3 2 0  g), 
anaesthetised with a combination of urethane and G'-chloralose 
suspension (Section 2.2) were utilised for the studies contained 
within this chapter. The animals were prepared and unilateral 
microinjections into the RVLM or CVLM implemented as described in 
Section 2.3. A submaximal concentration of clonidine (10 nmol) 
and NPY (25 or 50 pmol) was co-administered in a total volume 
of O.ljul, over a time period of 20 seconds, consistent with the
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individual injections of each agent.
4.2.2 Statistics
Analysis was carried out on the changes in mean arterial 
pressure (AMAP) and heart rate (AHR). The statistical test 
used - Repeated Measures Analysis of Variance - compared interval 
estimates for the change in response following coadministration 
of NPY and clonidine with the interval estimates for the sum of 
the individual changes in response reported in the previous
chapter (Section 3.3). * P < 0.05 represents significant
difference. All results are expressed as mean + s.e.mean.
4.3 Results
4.3.1 Effect of Neuropeptide Y and Clonidine Co-
administration in the Caudal Ventrolateral Medulla 
The hypotensive ' effect produced by clonidine (10 nmol) in 
the CVLM was not altered by simultaneous injection of NPY 
(25 pmol), which alone had no significant effect on blood 
pressure (Figure 4.1). However, the bradycardia observed
following the dual injection of NPY (25 pmol) and clonidine 
( 1 0  nmol) was significantly less than the sum of the individual 
heart rate responses between 20 and 120 minutes (Figure 4.1).
Co-administration of clonidine (10 nmol) and the higher dose 
of NPY (50 pmol) evoked a fall in blood pressure which was 
similar in the time course and magnitude to the sum of their 
individual responses (Figure 4.2). The associated reduction in 
heart rate following this dual injection in the CVLM could also
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Figure 4.1
Effect of coadministration of neuropeptide Y (NPY) together with 
clonodine into the caudal ventrolateral medulla on (a) mean 
arteries pressure (MAP) and (b) heart rate (HR).
A  NPY (25 pmol)
□ Clonidine (10 nmol)
O  NPY (25 pmol) + clonidine (10 nmol)
Points represent mean changes from preinjection value; vertical bars 
show s.e.mean; * significant difference from sum of the individual 
values.
Preinjection values 
(means + s.e.mean)
25 pmol NPY; n.= 9 
10 nmol Clonidine; n 
Combination; n = 8
=  10
MAP (mmHg)
101.0 + 1.9
96.8 + 2.5
94.8 + 2.9
HR (bpm)
338.0 + 11.3
373.0 + 8 . 6
376.0 + 6.0
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Figure 4.2
Effect of coadministration of neuropeptide Y (NPY) together with 
clonidine into the caudal ventrolateral medulla on (a) mean arterial 
pressure (MAP) and (b) heart rate (HR).
A NPY (50 pmol)
□  Clonidine (10 nmol)
•  NPY (50 pmol) + clonidine (10 nmol)
Points represent mean changes from preinjection value; vertical 
bars show s.e.mean.
Preinjection values 
(means ±. s.e.mean)
50 pmol N P Y ; n = 9 
10 nmol Clonidine; n 
Combination; n = 8
=  10
MAP (mmHg)
102.0 + 2.7
96.8 + 2.5
94.8 + 2.9
HR (bpm)
368.0 + 9 . 2
373.0 + 8 . 6
376.0 + 6.0
be considered additive (Figure 4.2).
4.3.2 Effect of Neuropeptide-Y and Clonidine Co­
administration in the Rostral Ventrolateral Medulla 
Although NPY (25 and 50 pmol) alone produced no significant 
haemodynamic effect in the RVLM, it is still possible that the 
peptide could modulate the response to other agents. Therefore 
the cardiovascular changes induced by simultaneous injection of 
NPY (25 pmol) and clonidine (10 nmol) in the RVLM were 
investigated. The blood pressure and heart rate response to the 
co-administered NPY (25 pmol) and clonidine (10 nmol) had a 
similar profile and was not significantly different from the 
response to clonidine alone in the RVLM (Figure 4.3).
4.4 Discussion
The current, study demonstrates that in the CVLM of
anaesthetised rats, the reduction in blood pressure 
produced by coadministration of clonidine and 
NPY was not significantly different from the sum of their 
individual actions. Furthermore in the RVLM NPY (25 pmol), which 
alone had no significant effect on blood pressure, also failed to 
modify the hypotensive action of clonidine. This lack of 
interaction between G!2 -adrenoceptors and NPY-binding sites, with 
reference to blood pressure in the VLM, is contrary to a report 
by Carter et al (1985) who demonstrated that the hypotensive 
response to noradrenaline (20 nmol) injected into the NTS of 
anaesthetised rats, was significantly modified by prior or 
simultaneous injection of an ineffective dose of NPY (47 fmol).
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Figure 4.3
Effect of coadministration of neuropeptide Y (NPY) together with 
clonidine into the rostral ventrolateral medulla on (a) mean 
arterial pressure (MAP) and (b) heart rate (HR).
A  NPY (25 pmol)
□ Clonidine (10 nmol)
O  NPY (25 pmol) + clonidine (10 nmol)
Points represent mean changes; vertical bars show s.e.mean, 
preinjection values + s.e.mean are as follows:-
Preinjection values 
(means + s.e.mean)
25 pmol NPY: n = 7 
10 nmol Clonidine; n 
Combination; n = 6
= 5
MAP (mmHg)
97.9 + 4.9 
88.0 + 6.0 
91.5 + 2.51
HR (bpm)
382.8
347.0 + 29.1
385.8 + 11.1
In addition, the same authors also observed that in the locus 
coeruleus co-administration of NPY (which itself was 
inefficacious) also blocked the haemodynamic responses to 
noradrenaline and clonidine (Vallejo and Lightman, 1986b).
The reason for the disparity between the above reports and 
the current study is not clear since NPY-immunoreactivity has 
been shown to be co-localised with catecholamines in the cell 
bodies and terminals of all the regions described (Hokfelt et al, 
1983; Everitt et al, 1984; Harfstrand et al, 1987a). However, 
co-localisation of transmitters is not always indicative of a 
functional interaction. In the striatum, NPY and somatostatin 
are co-stored but have additive, rather than synergistic or 
antagonistic actions on dopamine turnover when co-injected, 
suggesting a separate mechanism of action (Kowall et al, 1985; 
Vincent and Johansson, 1983; Flint-Beal et al, 1986). 
Furthermore, an independent mechanism of action for NPY and 
clonidine has been proposed by Harfstrand e t al (1984). They 
observed that prior intracisternal injection of RX 781094, an 
O'2 -adrenoceptor antagonist, prevented the hypotensive actions of 
clonidine, but not the hypotensive action of NPY, indicating that 
NPY can exert its cardiovascular actions in the presence of G ^ - 
adrenoceptor blockade. Indeed Vallejo and Lightman (1986a) found 
that intracerebroventricular administration of NPY still induced 
a pressor response after the depletion of central catecholamines 
by 6 -hydroxydopamine. In contrast, the involvement of ^ 2 ” 
adrenoceptors in the response to NPY is supported by Chen et al
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(1988) who demonstrated that intravenous pre-treatment with the 
C^ 2 -adrenoceptor antagonist can prevent the hypotensive actions 
of intrathecal injections of NPY in the anaesthetised rat. Thus 
interactions between co-stored transmitters may be present in 
some central areas but cannot be considered ubiquitous.
Although the hypotensive response to clonidine in the CVLM 
was not altered by simultaneous injection of a low dose of NPY, 
combined injection of clonidine (10 nmol) and NPY (25 pmol) did 
produce a fall in heart rate which was significantly less than 
the sum of their individual heart rate responses. Therefore it 
appears that an antagonistic interaction exists between NPY- 
binding sites and -adrenergic receptors, possibly linked to 
noradrenergic synapses in the CVLM associated with the control of 
heart rate. In agreement with this postulate, Fuxe et al (1986) 
also observed that the bradycardia evoked by the combined 
intracisternal administration of submaximal doses of NPY and 
clonidine was attenuated compared to the summed responses of each 
drug.
The participation of the peptide and catecholamines in the 
regulation of haemodynamic responses may occur at the post- 
synaptic site either at the level of the recognition site and/or 
the level of the coupling device (Fuxe et al, 1984; 1987b). More 
recently a presynaptic interaction has also been indicated. 
Martire et al (1986) demonstrated that NPY (1 nmol) enhanced the 
inhibitory effects of the OL^ agonist clonidine, on the potassium 
induced release of ( H)-noradrenaline in synaptosomes from the 
rat medulla oblongata. This modulation of catecholamine turnover
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has been corroborated by In vivo studies by Fuxe et al (1987b) 
where it was reported that intraventricular administration of NPY 
(7.5 pmol) reduced adrenaline release in the caudal dorsomedial 
medulla. Furthermore a tendency for an increased release of NPY 
was observed in the rostral dorsomedial medulla subsequent to 
intracisternally administered clonidine (3.75 nmol) in rats (Fuxe 
et al, 1987b). These data suggest a reciprocal presynaptic 
regulation exists between (X^ adrenoceptors and NPY receptors in 
this region. The relative importance of the presynaptic and 
post-synaptic receptor interactions in the medulla oblongata 
requires further investigation and may vary between regions or 
depend on the concentration of exogenous agent used (Harfstrand 
et al, 1987b).
In conclusion no apparent interaction was demonstrated for 
the combined administration of clonidine and neuropeptide Y with 
regard to the blood pressure response, in the ventrolateral 
medulla of anaesthetised rats. In the CVLM an antagnostic action 
on the heart rate response was observed following co- 
administration of clonidine and NPY. Further experiments are 
warranted to elucidate the exact mechanisms and possible subtypes 
of receptors involved in the modulatory response between 
clonidine and NPY illustrated here and previously reported in the 
medulla oblongata.
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Chapter Five
Effect of Neuropeptide Y on cAMP Levels in Slices 
of Rat Medulla Oblongata
5.1 Introduction
Despite the proposed functional role for neuropeptide Y
(NPY) in the central nervous system, corroborated by the results
presented in Section 3.3, the mechanism(s) of its haemodynamic
action has not been clearly established. High affinity saturable
binding sites for NPY have been characterised throughout the rat
125brain including the lower brainstem, using ( I)-NPY as a
radioligand (Unden et al, 1984; Nakajima et al, 1986; Harfstrand
et al, 1986). The equilibrium binding of the NPY radioligands in
the rat central nervous system has been shown to be altered by
guanine nucleotides (Unden and Bartfai, 1984). Chang et al
(1985) demonstrated that GppNHp (a stable analogue of GTP), GTP
and GDP inhibited, in a concentration dependent manner, the
125specific binding of ( I)-NPY to rat hippocampal membranes. A 
maximal decrease in NPY binding of approximately 50% of the 
control value was obtained in the presence of GppNHp (10~^M). 
Moreover this inhibitory effect is not restricted to hippocampal 
membranes since a significant number of NPY binding sites, in the 
rat cerebral cortex and area postrema have also been reported to 
be sensitive to guanine nucleotides (Unden and Bartfai, 1984;’ 
Nakajima et al, 1986). These observations are of particular 
interest since guanine nucleotide binding proteins (G-proteins) 
have been implicated in the coupling of neurotransmitter or
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hormone receptor complexes to intracellular second messenger 
systems (Section 1.4; Rodbell, 1980; Joseph, 1985). For 
example, guanine nucleotides have been shown to lower the binding 
affinity of agonists such as noradrenaline and acetylcholine in 
several systems (Kent et al, 1980; Berrie et al, 1979), as well 
as mediating the hormonal stimulation and inhibition of adenylate 
cyclase (Rodbell, 1980).
Recently it was reported that NPY inhibits forskolin- 
stimulated cAMP accumulation in feline cerebral blood vessels 
(Fredholm et al, 1985). This repressive action of NPY on the 
cAMP system was also later observed in membrane preparations of 
rat hippocampus and cortex (Petrenko et al, 1987; Westlind- 
Danielsson et al, 1987). In the former region, a GTP dependence 
for the NPY-attenuation of adenylate cyclase activity was also 
demonstrated, giving indirect evidence of the involvement of an 
inhibitory G-protein in the coupling of the NPY receptor complex 
to adenylate cyclase (Petrenko et al, 1987). The object of the 
present study therefore was three-fold. First to examine the 
effect of NPY on cAMP accumulation in slice preparations from rat 
medulla oblongata, an important area in the regulation of blood 
pressure (Section 1.3). Second, since other investigators have 
shown inhibitory effects of NPY on the cAMP system in the cortex 
using different techniques, the present study will also examine 
the effects of NPY on cAMP levels in the frontal cortex to allow 
comparison with those studies and with the proposed investigation 
of the effects of NPY in the medulla oblongata. Previous 
investigations have also observed that the inhibitory action of
NPY in other brain areas was best investigated in the presence of 
an activator of adenylate cyclase. Forskolin, a diterpene 
derivative as shown in Figure 5.1, which directly stimulates the 
catalytic subunit of the adenylate cyclase enzyme without 
involving the regulatory guanine binding proteins, was utilised 
for this purpose (Seamon et al, 1981). Assuming that NPY alters 
the levels of cAMP in the medulla oblongata, the third aim of the 
study was to examine the involvement of inhibitory guanine 
nucleotide binding proteins in the transduction mechanism 
associated with NPY-regulation of adenylate cyclase. Pertussis 
toxin (PTX) is known to uncouple the receptors for inhibitors of 
adenylate cyclase by ADP-ribosylation of a subunit of the 
inhibitory guanine nucleotide binding component of adenylate 
cyclase (Burns, 1988; Katada and Ui, 1982). Pretreatment with 
this toxin (intracisternal administration to concentrate the 
toxin around the medulla oblongata) would therefore attenuate or 
abolish the effect of inhibitory signals on adenylate cyclase. 
Thus, a more direct and specific approach was employed than 
observing the GTP-dependence of NPY on inhibition of cAMP levels
(Petrenko et al, 1987), which would give insight into the mode of
the hypotensive action of NPY in the medulla oblongata.
5.2 Methods
5.2.1 Preparation and Preincubation of Brain Slices
This procedure for the preparation and . preliminary 
incubation of the medullary or cortical slices is described in
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Figure 5.1 
Structure of the diterpene forskolin
Section 2.8.1.
5.2.2 Drug Treatment of Slices
After the preliminary incubation stage, NPY or vehicle 
saline, in a volume of 2 0  p i  was added to the appropriate tubes 
and incubated for five minutes. Forskolin or the vehicle ethanol 
( 2 0  p i )  was added after this stage and the tissue incubated for a 
further ten minutes (Figure 5.2). The reaction was terminated, 
tissue cAMP released and measured as detailed in Sections 2.8.2 
and 2.8.3.
5.2.3 Pretreatment with Pertussin Toxin
Each animal was anaesthetised with methohexitone sodium 
- 1(60 mgs kg , i.p.) and an area of skin above the atlanto-
occipital membrane shavpd and cleaned with a sterile swab. The 
rat was then placed in a stereotaxic frame, with the head flexed 
approximately 45°C down from the horizontal position. The 
atlanto-occpital membrane was located by touch and a 30-gauge 
needle connected to a length of polyvinyl tubing filled with 
sterile saline was implanted into the cisterna magna. Access to 
cerebrospinal fluid confirmed by the movement upwards and 
downwards of the miniscus when the column of fluid was lowered 
and raised in relation to the animal. The needle was left in 
position and a second length of tubing filled with either 
Pertussis Toxin or saline was connected. The toxin (2 >ig; 5 p g )  
or vehicle saline (0.9% w/v) was then microinjected into the 
cisterna magna in a volume of 10 p i ,  using a Hamilton syringe, 
over a period of two minutes. Both groups of animals (control
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Figure 5.2
Protocol for the investigation of the effect of neuro­
peptide Y (NPY) on basal and forskolin-stimulated cAMP 
levels in slices of the rat medulla oblongata.
and PTX-treated) were allowed to recover for a period of 24 hours 
before continuing with the study.
5.2.4 Statistics
All values are expressed means + s.e.mean. Statistical
analysis was carried out using Repeated Measures Analysis of 
Variance (ANOVA) with the Bonferroni correction for multiple 
comparisons. * P < 0.05 denotes significant difference from 
basal values or as indicated by the bar.
5.3 Results
5.3.1 Effect of Neuropeptide Y on Basal and Forskolin-
stimulated cAMP Accumulation in the Medulla Oblongata 
-5Forskolin (10 M) significantly increased cAMP accumulation
in the slice preparation of the medulla oblongata compared to
control (basal) values, as demonstrated in Figure 5.3. The
magnitude of the response to forskolin varied between
- 7 - 5experiments. NPY (10 - 10 M) alone, did not have any
significant effect on the basal levels of cAMP. However NPY in 
the presence of forskolin appeared to be inhibitory with a 
significant attenuation of the forskolin-stimulated cAMP 
production observed at 10 ^M NPY.
5.3.2 Effect of Neuropeptide Y on basal and forskolin-
stimulated cAMP accumulation in the cortex
- 6In the frontal cortex NPY (10 M) again did not alter the 
basal levels of cAMP (Figure 5.4). Although these basal levels
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Effect of neuropeptide Y (NPY) on basal and forskolin- 
stimulated cAMP levels in the medulla oblongata.
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of cAMP were similar to the levels observed in the medulla
oblongata, the magnitude of the elevation in cAMP accumulation in
-5response to forskolin (10 M), was greater in the cortex. A 
significant reduction in the forskolin-stimulated cAMP levels was 
demonstrated in the presence of NPY (10 ^M) in the cortex, which 
is in agreement with the results obtained in the medulla 
(Figure 5.4).
5.3.3 Effect of Pertussis Toxin Pretreatment on the 
Neuropeptide Y-mediated Inhibition of cAMP Accumulation 
in the Medulla Oblongata 
The influence of NPY on basal and forskolin-stimulated cAMP 
levels was re-examined following intracisternal PTX (2 jug or 
5 jug) treatment and compared to the control situation where the 
animals were pretreated with saline (Figure 5.5). NPY (10’^M) 
had no effect on basal levels of cAMP in both the vehicle and PTX 
(2 jug) treated animals. Although intracisternal pretreatment 
with a higher dose of PTX (5 jug) elevated basal levels of cAMP 
compared to vehicle treated animals, NPY (10~^M) again had no 
effect on this basal value. In contrast to the reduction of 
forskolin-stimulated cAMP accumulation afforded by NPY in the 
control animals pretreated with saline, no reduction in 
forskolin-stimulated cAMP levels was evident after PTX (2 jug or 
5 jug) pretreatment (Figure 5.5).
5.4 Discussion
Investigations have shown that NPY administered 
intracisternally or injected into discrete regions of the medulla
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oblongata in the rat produces a decrease in blood pressure and
heart rate (Fuxe £t al, 1983; Section 3.3). The present results
suggest this effect may be mediated by a reduction in cAMP
accumulation. This inhibitory action of NPY in the medulla
oblongata was apparent when adenylate cyclase activity was
-5stimulated by forskolin (10 M). Forskolin directly activates 
the catalytic subunit of this enzyme without involving the 
regulatory G-proteins and is therefore an invaluable tool for 
assessing the inhibitory action of agents on cAMP levels (Gehlert 
et al, 1985; Nelson et al, 1988; Seamon et al, 1981; Seamon and 
Daly, 1981).
In agreement with the present study, Petrenko et al (1987) 
observed in rat hippocampal membranes, that the inhibitory effect 
of NPY on adenylate cyclase activity was more evident when the 
enzyme was stimulated by forskolin. Furthermore, these authors 
demonstrated a maximal inhibition with 10 NPY which
corresponded to a 2 2 % decrease in forskokin stimulated adenylate 
cyclase activity. Although a direct comparison cannot be made 
since the techniques and expression of results differ between 
studies, a maximal inhibition corresponding to a 30% 
(approximate) reduction in forskolin-stimulated cAMP levels was 
observed in the present study. Moreover NPY was not observed to 
completely attenuate either the stimulated levels of cAMP in the 
present study or the stimulated adenylate cyclase activity in the 
study by Petrenko and colleagues. This finding probably reflects 
the view that not all adenylate cyclase molecules accessible to
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forskolin are also coupled to NPY receptors. This view is
supported by the finding that adenylate cyclase molecules, 
3localised by [ H]-forskolin binding sites, quantitatively exceed 
typical transmitter receptor protein concentrations 1 0  to 1 0 0  
fold, consistent with the role of both a messenger and an 
amplifier of receptor signals (Worley et al, 1986). The cognate 
peptide PYY and the classical transmitter acetylcholine in the 
rat striatum as well as adenosine (A^ receptor) in the 
hippocampus have also have also been observed to reduce adenylate 
cyclase activity and indicate that like NPY these agents also 
appear to be negatively coupled to the adenylate cyclase enzyme 
(Westlind-Danielsson et al, 1988; Dunwiddie, 1985).
The absence of NPY-induced changes in cAMP accumulation 
under basal conditions is in accord with Harfstrand et al 
(1987c). Using slices from the NTS region of the medulla they 
also observed that the inhibitory effect of NPY on cAMP levels 
was apparent only in the presence of forskolin. Therefore it is 
presumed that at least in the medulla a regulatory mechanism 
exists in- which the inhibitory effects of NPY appear only under 
conditions of elevated cAMP production. In contrast, Westlind- 
Danielsson et al (1987; 1988) demonstrated an NPY-attenuation of
basal adenylate cyclase activity in membranes from rat cortex and 
striatum. This disparity between studies may either in 
differences in the region studied, or in the technique used. 
Therefore, the effect of NPY on cAMP levels in cortical slices 
was examined in the present study and compared to the 
investigation by Westlind-Danielsson et al (1987) who utilised
rat cortical membranes. The inhibition of basal cAMP levels by 
NPY, previously reported by Westlind-Danielsson et al (1987) in 
membrane preparations of the rat cortex, could not be 
demonstrated in a slice preparation from the same area under the 
present conditions. The discrepancy between the studies could 
derive from a variation in experimental conditions which may 
include the tissue preparation. Although the brain slice could 
be considered a more physiological preparation than membranes, 
perhaps diffusion barriers presented by the brain slice result in 
the bioavailability of NPY being lower compared to the membrane 
preparation. Consequently the 'responsiveness' of the slice 
preparation would be reduced making it more difficult to observe 
an NPY-evoked reduction of basal cAMP levels. However a more 
likely explanation for Westlind-Danielsson and colleagues to be 
able to demonstrate an inhibitory effect of NPY on basal cAMP 
levels could be due to the fact that these authors observed a 
higher basal level of cAMP at the outset. Thus detection of the 
inhibitory action of NPY on this parameter would be easier. The 
higher basal values in that study may be the result of a 
stimulating factor present under the basal conditions after using 
the membrane preparation technique or the result of a higher 
assay sensitivity. Although an analogous method to the present 
study was employed to measure cAMP levels (competitive protein 
binding assay), these authors did not utilise the Amersham kit 
for this purpose.
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It is interesting to note that in the present study although 
the basal levels of cAMP in the medulla and cortex were similar, 
the response to forskolin was greater in the cortex compared to 
the medulla. This phenomenon was also observed by Daly et al 
(1982) in the same preparations. Since forskolin activates 
adenylate cyclase directly, one might expect this agent to 
increase the basal levels of cAMP to the same extent in different 
regions (Seamon and Daly, 1981). It has been reported by Bahner 
et al (1989) in the rat that although the basal levels of cAMP 
were similar in each brain region, the amount of adenylate 
cyclase and its basal activity varied from area to area. It is 
therefore possible that variation in the amount of adenylate 
cyclase accessible to forskolin may account for the differences 
observed between the medulla and cortex. Indeed, it has been 
observed that the density of tritiated-forskolin binding sites in 
the rat cortex is greater than in the rat medulla (McAuley,
unpublished observations). This suggests that a greater amount 
of adenylate cyclase is present in the cortex and may account for 
the enhanced forskolin-stimulated levels of cAMP observed in this 
region.
As discussed previously an essential component of 
neurotransmitter regulation of adenylate cyclase involves G- 
proteins (Section 1.4). The involvement of an inhibitory G- 
protein, in the NPY reduction of forskolin-stimulated cAMP, was 
investigated using pertussis toxin. This toxin ADP-ribosylates 
the -subunit of the inhibitory G-protein. The inhibitory 
receptors are consequently uncoupled from the adenylate cyclase
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complex, thereby preventing receptor-mediated inhibition of cAMP 
(Katada and Ui, 1982; Katada et al, 1986). A salient feature of 
PTX is the latency which exists between toxin administration and 
the induction of its biochemical effects. This lag period, which 
varies between tissues, has been proposed to be due to a slow 
penetration of the toxin into the cell membrane (Burns, 1988). 
PTX (2 jug; 5 jug) was therefore injected centrally 20 - 24 hours 
prior to the start of the study to accommodate for the delay in 
the onset of action. These parameters were similar to those 
employed in previous investigations concerned with the central 
effects of PTX (Nomura et al, 1987; Aghajanian and Wang, 1986).
In the absence of pertussis toxin NPY (10 ^M) as expected 
from previous data (Section 5.3.1), reduced the forskolin- 
stimulated cAMP accumulation. When the animals were pretreated 
with PTX, the ability of NPY to inhibit the elevated cAMP levels 
was abolished. This is consistent with the toxin inactivating 
the inhibitory G-protein by ADP ribosylation, thus preventing the 
transduction of inhibitory signals to adenylate cyclase. 
Motulsky and Michel (1988) demonstrated a comparable action of 
PTX on the NPY-inhibition of forskolin-stimulated adenylate 
cyclase activity in human erythroleukaemia cells.
In agreement with other workers, PTX (5 jug) also enhanced 
the basal levels of cAMP as well as rendering the tissue more 
sensitive to forskolin, suggesting that PTX alleviates the 
restraining action of the inhibitory G-protein on basal activity 
(Kassis et al, 1987; Katada £t al, 1982). Using gel
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electrophoresis and autoradiographical techniques, PTX has been 
shown to ADP-ribosylate a 41-KDa protein in membranes from rat 
atrial cells (Kassis et al, 1987). This protein corresponds to 
the C^-subunit of one of the inhibitory G-proteins, the Gi- 
protein. This suggests that the NPY attenuation of cAMP 
formation observed in rat atrial membranes by Kassis et al (1987) 
may be mediated via the Gi-protein. However, it is not clear at 
present whether the same form of inhibitory G-protein mediates 
the reduction of adenylate cyclase in both the rat atrial 
membranes and in slices from the rat medulla oblongata.
NPY receptors in the central nervous system have been shown 
to be coupled to other effector molecules including 
'phospholipases, protein kinases and calcium channel by means of 
G-proteins (Hinson et al, 1988; Perney and Miller, 1988). Thus 
the central haemodynamic actions of NPY may be regulated by more 
than one second messenger system. However, the coupling of the 
NPY receptors to effector molecules such as phospholipases 
(involved in inositol phosphate production, Section 1.4) has not 
been demonstrated to date in central regions associated with 
haemodynamic regulation. Perney and Miller (1989) have reported 
a small increase in the production of inositol trisphosphate and 
diacylgycerol as well as an increase in the mobilisation of 
calcium from intracellular stores in the sensory rat dorsal root 
ganglion (DRG) neurones following NPY. The stimulatory effect of 
NPY on inositol trisphosphate formation was attenuated by PTX 
indicating the involvement of a PTX substrate such as Go or one 
of the forms of Gi in the response. An involvement of inositol
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phosphate production in the enhancing effects of NPY on 
noradrenaline-induced contractions in the periphery has 
previously been proposed (Section 1.5.6). Perney and Miller 
(1989) also reported that NPY can attenuate the depolarisation- 
induced influx of calcium ions and release of substance P from 
DRG cells. They also suggested that the NPY receptor is coupled 
to the voltage-dependent calcium channels via an inhibitory-like 
G-protein, Go.
The coupling of NPY receptors to two or more second 
messenger systems purports the involvement of more than one 
receptor subtype. Indeed as discussed in Section 3.4 the 
existence of more than one NPY receptor subtype has been proposed 
based on the differential efficacy of an NPY analogue (NPY^ ^5 ) 
for the binding to central NPY receptors and for eliciting 
central hypotensive effects (Sheikh et al, 1989; Fuxe et al, 
1987a). However, this issue remains controversial since several 
other reports have found only one NPY binding site in the various 
central regions (Chang et al, 1985; Saria et al, 1985; Goldstein 
et al, 1986). Hinson et al (1988), utilising rat cortical, 
striatal hippocampal miniprisms, have demonstrated an increase in 
inositol phosphate production in the presence of NPY. Wahlestedt 
(1987) proposed that at least in the cortical tissue this 
response was a result of Y^ receptor activation since N P Y ^  
was ineffective. However, a contradictory report was published 
by Perney and Miller (1989). These authors found that ^ P Y ^  3 5  
was an effective agonist in stimulating inositol trisphosphate
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production in DRG neurones, implying that the putative was
involved in phosphoinoside hydrolysis. It is not known whether
the same G-protein mediates both the inhibition of adenylate
cyclase and the stimulation of phosphate production or whether
separate G-proteins regulate each effect. Perney and Miller
2 +(1989) have reported that the reduction in Ca currents evoked 
by NPY in the DRG neurones was mediated via the G protein, Go, 
suggesting that NPY receptors are coupled to more than one G- 
protein. The clarification of receptor(s) and second messenger 
system(s) involved in the central and peripheral actions of NPY 
requires further work and awaits the development of an NPY 
antagonist.
In summary, this chapter describes one of the possible 
second messenger systems, coupled to NPY receptors in the medulla 
oblongata. It is proposed that the previously discussed 
hypotensive action of NPY may involve the reduction of cAMP 
mediated via an inhibitory G-protein. The exact nature of the G- 
protein and the type(s) of receptor involved in the biochemical 
and functional responses demonstrated remain to be elucidated.
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Chapter Six
Possible Interactions between Neuropeptide Receptors and 
Adrenoceptors on cAMP Levels in Rat Medulla Oblongata
6.1 Introduction
The purported functional interactions between neuropeptide Y 
(NPY) , and adrenoceptors located in the central nervous system 
have been postulated to exist at the level of the recognition 
site, and/or at the level of the coupling device (Fuxe et al, 
1984; 1987b). Evidence for the former comes from radioligand
binding data which describe a small increase in the number of NPY 
binding sites in cerebral cortical membranes after chronic 
intraperitoneal treatment of rats with the Q? 2 _adrenoceptor 
agonist clonidine (Goldstein et al, 1986). Although these 
results are in contrast to the reduction in iodinated NPY binding 
sites in the medulla oblongata, observed using autoradiographical 
techniques, following the in vitro or intraventricular 
administration of clonidine in rats, the potential for receptor- 
receptor interactions is highlighted (Fuxe et al, 1986; 
Harfstrand et al, 1989). In addition, the modulation between NPY 
receptors and adrenoceptors may take place at post-receptor 
processes. Current evidence, including the work presented in the 
preceding chapter, indicates that NPY can inhibit the adenylate 
cyclase, via a guanine nucleotide binding protein (Section 5.3., 
Petrenko et al, 1987; Westlind-Daniellson et al, 1988). A 
similar mechanism of action has been proposed for peripheral C^' 
adrenoceptors, which are also thought to be negatively coupled to
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adenylate cyclase (Jakobs, 1985).
These findings, together with the demonstration of guanine
nucleotide-induced changes in the equilibrium binding
characteristics of both NPY and alpha-adrenoceptor agonists 
previously discussed in Section 5.1, suggest the possibility of 
an interaction between NPY receptors and Q^-^tenoceptors with 
regard to the inhibitory regulation of adenylate cyclase and cAMP 
production. Indeed, Harfstrand et al (1989) reported that in 
membrane preparations of the rat medulla oblongata, the reduction 
in the affinity of the C^-^renoceptor binding sites evoked by
the view that NPY affects the binding of c 2^ ‘aSonists v^a
mechanisms that involve guanine-nucleotide binding proteins. 
Whether the modulation between these receptors can in turn 
regulate cAMP production has not been investigated to date in the 
central nervous system. However, it has been demonstrated in 
atrial and ventricular cardiomyocytes that NPY can inhibit 
isoprenaline-stimulated cAMP accumulation, suggesting a 
functional antagonism between neuropeptide Y and the 
adrenoceptor agonist isoprenaline in these tissues (Kassis e t al, 
1987; Cherie Miller £t al, 1988).
In view of the obvious importance of gaining further insight 
into the understanding of the molecular mechanism of action and 
interaction of NPY and adrenoceptor agonists in the central 
nervous system, the current chapter is concerned with their 
possible interrelationship in the regulation cAMP in the medulla 
oblongata. Firstly, the actions of the C^'^renoceptor agonists
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clonidine and moxonidine as well as the j3 "adrenoceptor agonist 
isoprenaline on cAMP accumulation were established. Secondly, 
the response to these agents in the presence of NPY was examined.
6.2 Methods
6.2.1 Preparation and Preincubation of Brain Slices from the
Medulla Oblongata
The methodology used in the preliminary stages of the 
incubation experiments is as described in Section 2.8.1.
6.2.2 Drug Treatment of Slices Alpha^-Adrenergic Agonists
Following the initial incubation stage, the effect of
clonidine on cAMP formation in slices of the medulla oblongata 
was investigated. The appropriate concentration of clonidine or 
vehicle was added to each tube in a volume of 2 0  ;ul and incubated 
for five minutes. This incubation was continued for a further 
ten minutes in the absence (basal values) or presence (forskolin- 
stimulated levels) of forskolin ( 1 0  ^M) as depicted in 
Figure 6.1. A congruous method was employed to examine the 
effects of moxonidine on basal and forskolin-stimulated cAMP 
formation. Furthermore, where the interaction between moxonidine 
(10”^M) and NPY (10 ^M) was investigated, NPY was added 
simultaneously with moxonidine at the appropriate stage.
6.2.3 Drug Treatment of Slices ^ Beta-Adrenergic Agonists
At the end of the preliminary incubation stage, propranolol, 
NPY or appropriate vehicle was added and incubated for five
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Figure 6.1
Protocol for the investigation of the effect of clonidine 
on basal or forskolin-stimulated cAMP levels in slices of 
the rat medulla oblongata.
Time (mins)
minutes. Isoprenaline or vehicle (20 jul) was subsequently added 
and the incubation continued for a further ten minutes 
(Figure 6.2).
In all the experiments detailed above the reaction was 
terminated and cAMP levels measured as described in 
Sections 2.8.2 and 2.8.3.
6.2.4 Statistics
All values are expressed as means + s.e.mean. The 
statistical test used to analyse this data was described 
previously in Section 5.2.3.
6 .3 Results
6.3.1 Dose-Response Relationship of Clonidine on Basal and
Forskolin-Stimulated cAMP Levels
The alpha2 -adrenoceptor agonist clonidine, over a range of
- 8  -5
concentrations from 10 - 10 M, did not significantly modify
the basal cAMP levels in slices of the medulla oblongata 
(Figure 6.3). The effects of clonidine (10 ^M) were further 
examined on the elevated levels of cAMP produced by forskolin 
(Figure 6.4). Forskolin (10 ^M), as expected from previous data, 
significantly raised the levels of cAMP formation above control 
values. Clonidine (10 ^M), as well as having no effect on basal 
cAMP accumulation, did not alter the response to forskolin 
(Figure 6.4).
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Protocol for the investigation of the effects of neuro­
peptide Y (NPY) or propranolol on basal or isoprenaline- 
stimulated cAMP levels in slices of the rat medulla oblongata.
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basal cAMP levels in the medulla oblongata.
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Lack of effect of clonidine (10 M) on basal and forskolin- 
stimulated cAMP levels in the medulla oblongata.
Results are expressed as mean + s.e.mean; n = 6 .
* significant difference from basal values (p < 0.05).
6.3.2 Dose-Response Relationship of Moxonidine on Basal and 
Forskolin-Stimulated cAMP Levels
-8 -5As shown in Figure 6.5, moxonidine (10 - 10 M) had no
significant effect on the basal levels of cAMP accumulation
However, prior incubation with moxonidine (10 ^) significantly
-5reduced the elevated levels of cAMP evoked by 10 M forskolin 
(Figure 6 .6 ).
6.3.3 Possible Interaction Between the Effects of Moxonidine 
and NPY on Forskolin-Stimulated cAMP Levels
The incubation of moxonidine (10 ^M) in combination with NPY 
(10 ^M) had no effect on the basal levels of cAMP formation in 
slices of the medulla oblongata (Figure 6.7). Forskolin (10 ^M)
again, significantly raised cAMP levels compared to basal values.
-  6 -  6Prior’ incubation of moxonidine (10 M) plus NPY (10 M) before
the introduction of forskolin ( 1 0  ^M) did not significantly
reduce the forskolin response (Figure 6.7).
6.3.4 Lack of Effect of NPY on Isoprenaline-Stimulated cAMP 
Formation
-  6The adrenergic agonist isoprenaline (10 M) significantly 
increased the formation of cAMP in slices of the rat medulla 
oblongata as depicted in Figure 6 .8 . This effect of isoprenaline 
was significantly attenuated in the presence of propranolol 
(1 0 ’^M) a specific ^-adrenoceptor antagonist, which alone had no 
effect on basal cAMP accumulation (Figure 6 .8 ). NPY (10 ^M) had 
no significant effect on basal levels of cAMP formation 
(Figure 6.9) and the incubation of NPY (10 ^M) prior to the
145
cA
MP
 
(p
m
ol
s 
m
g-
1 
pr
ot
ei
n)
CONTROL
Figure 6.5
Lack of effect of moxonidine (10 ^ - 10 ^M) on basal 
cAMP levels in the medulla oblongata.
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Effect of moxonidine (10 M) on basal and forskolin- 
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Figure 6.9 
— 6
Lack of effect of NPY (10 M) on basal and isoprenaline-
: \
stimulated cAMP levels in the medulla oblongata.
Results are expressed as mean + s.e.mean, n = 6 .
* significant difference from basal value (p < 0.05).
addition of isoprenaline did not significantly modify the
response to the latter agent (Figure 6.9).
6.4 Discussion
Although the negative coupling of -adrenoceptors is well 
established in the peripheral tissues (Jakobs, 1985), the 
relation between cAMP and a  -adrenoceptors in the central nervous 
system is more confusing. Initially it was reported that o i ~
adrenergic agonists have little effect on cAMP accumulation in
brain slices themselves but that they augment the response to
substances that stimulate the enzyme (Daly et al, 1980; Pile and 
Enna, 1985). This effect was later attributed to the stimulation 
of both O i and OL^ -adrenoceptors (Pile and Enna, 1986). More 
recently, Duman and Enna (1986) demonstrated that while the
inhibitory effect of QJ2 'aSon^sts on basal levels of cAMP was 
difficult to observe, it was possible to show the inhibitory
response in the cerebral cortical slice when adenylate cyclase 
was stimulated directly with forskolin. The data obtained in the 
present study with the O'2 -adrenoceptor agonist clonidine, 
indicates that in the medulla oblongata slice preparation this 
agent does not alter either the basal cAMP accumulation or the
elevated levels of cAMP produced by forskolin. The inactivity of 
clonidine in this cAMP system may reflect its low intrinsic 
activity, since at least in the peripheral nervous system
imidazolines such as clonidine (Figure 6.10) have been shown to 
be partial agonists at O i^ -adrenergic receptors (Medgett et al, 
1978; Armah, 1986). Indeed, a similar lack of effect of
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Figure 6 .10
Structure of the alpha^-adrenoceptor agonist clonidine
-5clonidine (10 M) was observed by Etgen and Petitti (1987) in the
rat hypothalamic slice preparation. However, Duman and Enna
(1986) observed that selective stimulation of OL 2 -adrenoceptors
with clonidine, inhibited the forskolin-stimulated formation of
cAMP in the cerebral cortex slice. In addition a similar
- 5inhibitory response to clonidine (10 M) which was reversed by 
the a  2-adrenoceptor antagonist yohimbine, was observed by 
Kitamura (1986) in particulate membrane fractions from the same 
area.
This implies that a regional variation in receptor 
populations may account for the inconsistency between 
investigations. Furthermore, intraperitoneal administration of 
clonidine in the rat has been observed to increase cAMP levels in 
the cerebellum, hypothalamus and medulla oblongata (Nakamichi 
et al, 1987). Due to the route of administration used by these 
authors the concentration of clonidine in the various brain 
regions cannot be determined and compared to the other studies. 
However, the fact that the CX^-adrenoceptor antagonist prazosin 
attenuates the response to clonidine in that particular study 
suggests that high concentrations of clonidine are present, which 
would reduce the selectivity for q ^ -adrenoceptors and enable 
clonidine to act at -adrenoceptors (U'Prichard et al, 1977; 
Timmermans et al, 1980).
Moxonidine, an imidazoline derivative (Figure 6.11), is a 
centrally acting antihypertensive agent, which, like clonidine, 
is considered to reduce blood pressure by an action on central
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Figure 6.11
Structure of the alpha^-adrenoceptor agonist moxonidine.
Oi -adrenoceptors (Armah and Stenzel, 1981; Planitz, 1987).
Bergerhausen (1985), demonstrated that moxonidine was a full
agonist at receptors on human platelet membranes with high
potency and -selectivity. Furthermore, in the isolated rabbit
pulmonary artery moxonidine exerts a full oj 2 -agonist' action, in
contrast to clonidine which is shown to be a partial agonist in
this model (Armah, 1986; 1987). Moxonidine in the present study,
had no effect on the basal levels of cAMP but in contrast to the
lack of effect observed with clonidine, moxonidine significantly
reduced the elevated levels of cAMP produced by forskolin. A
greater hypotensive effect has been observed following
intracisternal administration of moxonidine compared to clonidine
in anaesthetised rabbits (Armah, 1987).
The reason for the difference between the actions of
clonidine and moxonidine on cAMP accumulation is curious since
radioligand binding studies in cerebral cortex membranes have
3demonstrated the value for displacement of ( H) rauwolscine
from C^-binding sites was 3.48 x 10 for moxonidine, compared 
- 8to 2.06 x 10" M for clonidine, thus indicating that clonidine is 
the more potent agent (Armah, 1987). However, the discrepancy 
may be attributed to differences in the synaptic location of the 
site of action of these agonists. Indeed BDF 6143, an OL2 " 
adrenoceptor antagonist with a higher presynaptic selectivity and 
potency than yohimbine, antagonised the hypotensive effects of 
intracisternally administered moxonidine in anaesthetised rabbit 
to a greater extent than the hypotension evoked by clonidine. 
Similarly, catecholamine depletion with 6 -hydroxydopamine reduced
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the hypotensive action of moxonidine but not clonidine in 
anaesthetised rabbits. This suggests that moxonidine elicits its 
hypotensive action via activation of presynaptic Q^-adrenoceptor 
sites (Armah, 1987), while clonidine may require post-junctional 
(X 2 -adrenoceptors to elicit its hypotensive effect. In guinea- 
pig spinal cord slices where the OL^ -adrenergic receptors are 
proposed to be located post-synaptically, clonidine reduced 
forskolin-stimulated cAMP production (Wikberg and Hajos, 1987; 
Uhlen and Wikberg, 1988). However, a presynaptic action of 
clonidine may be a possibility if the OL ^-adrenoceptors are 
located on non-noradreneric neurones (Haeusler, 1982; 
Section 3.4.2).
To evaluate the possible functional interaction between NPY 
receptors and Q^-adrenoceptors, NPY and moxonidine were added to 
the system in concert. This combination had no effect on basal 
cAMP levels. Moreover the significant reduction of forskolin- 
stimulated cAMP levels in the medullary slices produced 
individually by both the CX2  adrenoceptor agonist moxonidine and 
NPY, as demonstrated in Figures 6 . 6  and 5.3, was no longer 
apparent when these agents were incubated together (Figure 6.7). 
However, in the combination experiment the basal levels of cAMP 
and data variability were higher than in either of the individual 
studies, perhaps making it more difficult to observe a reduction 
in the forskolin-stimulated cAMP levels. Further studies to 
examine the correlation between the degree of forskolin- 
stimulated cAMP levels (above basal) and the magnitude of the
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inhibition observed may be warranted. These biochemical data,
although modest in degree, suggest an inhibitory interaction
exists between NPY and moxonidine at the adenylate cyclase level
and augment previous autoradiographical studies that purport a
recipricol modulatory relationship between the respective
receptors. Harfstrand et al (1989) reported that NPY (10 nM),
in vitro or after intraventricular administration in consious
rats significantly decreased the OL^ -adrenergic binding sites
(tritiated para-amino clonidine as a radioligand) in the NTS
region of the medulla oblongata. Analagous studies in the same
area revealed a decrease in the binding of iodinated NPY in the
presence of 10 nM clonidine In vitro studies and in vivo studies
subsequent to intraventricular administration (Fuxe et al, 1986;
Harfstrand et al, 1989). Using radioligand binding techniques it
was further demonstrated that in vitro the most consistent change
in the, binding characteristics of tritiated para-amino clonidine
in the presence of NPY was a reduction in the affinity of the
binding sites. This is in contrast to the previously reported
increase in the number of O'2 -adrenergic binding sites
(Harfstrand et al, 1989; Agnati et al, 1983 Fuxe et al, 1986). It
125is presently unknown if the observed reduction of the ( I)-NPY
binding represents a reduction of the number or a reduction in
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the affinity of the ( I)-NPY binding sites. The reduced 
affinity of the -adrenergic receptor induced by NPY may
reflect a diminished efficiency of this receptor. This view 
corroborates the present findings, since an antagonism of the 
individual inhibitory actions on forskolin-stimulated cAMP
accumulation was observed when NPY and moxonidine were added in 
concert, thus implying the existence of a receptor-receptor 
interaction between NPY and ( X adrenoceptors.
While the existence of ^-adrenoceptors in the rat central
nervous system and their involvement in central cardiovascular
regulation is known (Bylund and Snyder, 1976; Stone and
U'Prichard, 1981; Borkowski and Finch, 1979; Peres-Polon and
Correa, 1987), most studies investigating the central interaction
of NPY and catecholamines have centered on the relationship
between NPY and Qf2 _a^renocePtors• However, it has been
demonstrated in ventricular myocytes isolated from the rat heart, 
- 9 - 6that NPY (10 - 10 M) can reduce the magnitude of cAMP
accumulation elicited by the ^-agonist isoprenaline suggesting 
an interaction in this tissue between NPY receptors and f t -  
adrenoceptors (Cherie Millar et al, 1988).
In slices of the rat medulla oblongata isoprenaline (10 ^M) 
increased cAMP accumulation through stimulation of -
adrenoceptors. The prospect of a functional interaction between 
NPY receptors and |3-adrenoceptors was subsequently explored by 
adding NPY to the incubation prior to isoprenaline. The 
elevation in cAMP levels achieved by isoprenaline was not altered 
by NPY (10 ^M). It would therefore appear that at least in this 
system, NPY does not interact directly with ^-adrenoceptor 
function. In agreement with the present study the binding
characteristics of the radioligand dihydroalprenolol to - 
adrenoceptors in membranes of the medulla oblongata were not
modified in the presence of NPY (Agnati et al, 1983). These
results differ from the studies of a human neuroblastoma SK-N-MC
cell line as well as cardiac atrial and ventricular cell lines, 
-  6where NPY (10 M) significantly inhibited the response to 
isoprenaline suggesting an interaction between the respective 
receptors (Olasmaa et al, 1987; Kassis et al, 1987; Cherie Millar 
et al, 1988). Moreover, in the latter study it was shown that 
NPY was able to prevent both the accumulation of cAMP stimulated 
by isoprenaline in the ventricular cardiomyocyte and to reduce a 
pre-elevated cellular content of cAMP. However, the ability of 
NPY to inhibit isoprenaline-stimulated adenylate cyclase is not a 
ubiquitous occurrence since in addition to the present study the 
peptide had no effect on j0 -adrenergic stimulation of adenylate
cyclase in membranes from certain cultured cells including rat
glioma C 6  (Kassis et al, 1987). The variation between studies
may be explained by the hypothesis that not all cell types
possess both NPY and {$ -receptors that can interact. In this 
respect it has been demonstrated that in rat frontal cortex 
membrane preparations fused with Friend erythroleukemia cells, 
NPY was not able to inhibit the vasoactive intestinal 
polypeptide-induced elevation of cAMP production (Olasmaa and 
Terenius, 1986). Furthermore, these authors reported that in 
pilot experiments, NPY does not interfere with the function of 
PGE^ receptors again suggesting that the juxtaposition of 
receptors does not always result in an interaction (Olasmaa and 
Terenius, 1986).
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In summary, these studies demonstrate the (y 2 _ac^ renocePtor 
agonist moxonidine but not clonidine reduces forskolin-stimulated 
cAMP levels in slices of the rat medulla oblongata. Furthermore, 
a modest functional antagonism exists between NPY and the 
moxonidine in this system. However, an interaction between NPY 
and the ^-adrenoceptor agonist, isoprenaline was not observed.
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Chapter Seven
Haemodynamic Actions of Endothelin-1
7.1 The Haemodynamic Effects of Intravenous Administration 
of Endothelin-1 in the Anaesthetised and Conscious Rat
7.1.1 Introduction
The present chapter is principally concerned with the 
possible central cardiovascular actions of the novel peptide 
endothelin-1 (ET-1). At the inception of this study a very 
limited amount of information was available pertaining to the 
haemodynamic effects of the peptide in vivo. In the inaugural 
report by Yanagisawa et al (1988a) which described the isolation 
and identification of ET-1, the authors also demonstrated that in 
the anaesthetised chemically denervated Sprague-Dawley rat, 
intravenous injection of ET-1 caused a transient decrease of 
systemic arterial pressure followed by a pronounced and sustained 
elevation in blood pressure. Although a biphasic cardiovascular 
response to systemic administration of ET-1 has since been 
reported by other groups in both the anaesthetised and conscious 
Wistar rat, the composition of this response to ET-1 appears to 
be influenced by such factors as the route of administration, 
anaesthetic state and basal blood pressure of the animal (de 
Nucci et al, 1988; Gardiner et al, 1989; Winquist et al, 1989). 
The aim of the current study was therefore to obtain preliminary 
data on the intravenous dose-response relationship to ET-1 in the 
anaesthetised and conscious Wistar-Kyoto rat. In the initial 
absence of data on the central actions of ET-1, this study would
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provide a basis from which a reasoned dose range for the central 
administration of ET-1 could be estimated. Furthermore, the 
information obtained would enable comparison to be made between 
the peripheral and potential central cardiovascular actions of 
this peptide in the Wistar-Kyoto rat.
7.1.2 Methods
7.1.2.1 Intravenous Administration in Anaesthetised Animals 
Experiments were carried out on male Wistar-Kyoto rats 
weighing between 270 - 285g. Anaesthesia was induced in a 
perspex box with halothane (5%) and maintained with (0.5 - 1%) 
halothane in a nitrous oxide/oxygen mixture (70 : 30%). A 
tracheostomy was performed and the animals' ventilation
controlled by a small animals respirator. Polyethylene 
catheters, filled with heparinised saline ( 8  units ml were 
inserted into both femoral arteries, one for continuous blood
pressure and heart rate measurement and the other for blood
sampling. Using the same methodology a femoral vein was also 
catheterised for intravenous (i.v.) drug administration.
Arterial blood samples were withdrawn for measurement of blood 
gases prior to drug administration. Ventillation was altered to 
maintain arterial carbon dioxide tension and arterial oxygen 
tension within normal limits. Body temperature was kept constant 
at 37°C with an homeothermic blanket.
A stabilisation period of 30 minutes was then allowed before 
proceeding with the investigation. I.v. injections of ET-1
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(1 nmol/rat) and saline (0.9% w/v) were given in a randomised 
order to each rat. All injections were delivered in a volume of 
0 . 1  ml over a period of one minute.
7.1.2.2 Intravenous Administration in Conscious Animals
The conscious animal studies were performed on male Wistar- 
Kyoto rats weighting between 270 - 280g. The animals were 
prepared as detailed in Section 2.5 with arteries catheterised 
for arterial blood pressure recording and blood sampling, and 
vein for drug administration.
The animals were allowed to recover for three hours
following surgery before commencing with the experiment. I.v. 
injections of ET-1 (0.1 - 1.0 nmol/rat) and saline (0.9% w/v) 
were administered in a randomised order, each animal receiving 
all the doses. The injection was given over a time period of one 
minute in a total volume of 0 . 1  ml.
7.1.2.3 Measurement of Plasma Catecholamines
Plasma catecholamine levels were determined (as described in 
Section 2.7) before and after (at the maximum blood pressure 
response) i.v. drug administration. This permitted an indirect 
measurement of sympathetic nerve activity.
7.1.2.4 Statistical Analysis
All results are expressed as mean + standard error. 
Analysis of the data was carried out using Repeated Measures 
Analysis of Variance and where appropriate a Bonferroni
correction was included for multiple comparisons.
157
7.1.3 Results
7.1.3.1 Effect of Intravenous Administration of Endothelin-1 on 
Blood Pressure and Heart Rate in the Anaesthetised Rat
Mean arterial pressure (MAP) and heart rate (HR) before ET-1 
administration in the anaesthetised was 77 + 4.4 mmHg and 
237 + 11.8 bpm, respectively. I.v. administration of ET-1 
( 1  nmol) produced a biphasic cardiovascular response as 
illustrated in Figure 7.1. An initial transient depressor 
response (64.0 + 1.9 mmHg) occurred almost immediately but was 
not significantly different from the saline control value 30 
seconds after the start of the injection. The phase was 
proceeded by a rapid and marked rise in blood pressure. The 
maximum response (142.4 + 5 . 7 mmHg) was evident five minutes 
subsequent to i.v. ET-1 and the pressor effect was sustained for 
about two hours. The tachycardia associated with the initial 
hypotension varied in magnitude between animals, with the mean 
response (245.0 +9. 2  mmHg) at 30 seconds post-injection not 
significantly different from the control values. The heart rate 
response returned to control values within 30 seconds and was not 
significantly different from the control value during the 
hypertensive stage of the blood pressure response. An example of 
a trace displaying the effect of i.v. ET-1 on arterial pressure 
and heart rate is shown in Figure 7.2.
7.1.3.2 Effects of Intravenous Administration of Endothelin-1 
on Plasma Catecholamine Levels in the Anaesthetised Rat
Plasma noradrenaline and adrenaline levels following
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Figure 7.1
The effect of intravenous (i.v.) administration of ET-1 
(1.0 nmol) on (a) blood pressure (MAP) and (b) heart rate 
(HR) of the anaesthetised rat.
Points represent mean data + s.e.mean, n = 5 
* significant difference from control value (p <  0.05)
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■ ET-1 (1.0 nmol).
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Figure 7.2
A representative trace of the (a) arterial blood 
pressure (mmHg) and (b) heart rate (bpm) following 
intravenous (i.v.) administration of ET-1 (1.0 nmol) 
in the anaesthetised rat.
1.0 nmol i.v. ET-1 were not significantly different from pre- 
injection values as demonstrated in Table 7.1. As expected, 
plasma catecholamine levels were not altered by i.v. saline 
injection (Table 7.1).
7.1.3.3 Effect of Intravenous Administration of Endothelin on 
Blood Pressure and Heart Rate in the Conscious Rat 
The haemodynamic response to ET-1 was biphasic and dose- 
related over a range of 0.1 - 1 nmol (Figure 7.3). The MAP and 
HR were allowed to return to baseline values and stabilise 
between drug or vehicle injections. No significant difference 
was observed between the pre-injection values. The initial 
effect of the peptide was a transient dose-related fall in MAP. 
At the highest dose of ET-1 (1 nmol) this value (95 + 5.1 mmHg) 
was significantly different from vehicle (127.8 +.1.9 mmHg) 30 
seconds after the start of the injection. The hypotension was 
followed by a gradual increase in MAP which reached a maximum 
between five and fifteen minutes depending on the dose and 
returned to control values within 60 minutes (Figure 7.3) The 
maximum blood pressure response to ET-1 (1 nmol), which occurred 
15 minutes after administration was 151 + 3.4 mmHg and was 
significantly different from vehicle (126.0 + 4.0 mmHg).
A significant dose related elevation in HR was associated 
with the initial hypotensive phase (Figure 7.3). This response 
was greatest 30 seconds after i.v. ET-1 (0.3 - 1 nmol) and 
returned to control values within 2-5 minutes. At the highest 
dose of ET-1 investigated (1.0 nmol) the maximum HR observed was
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Table 7.1
Lack of Effect of Intravenous Administration of Endothelin-1 (ET-1) 
on Plasma Catecholamine Levels in the Anaesthetised Rat
Noradrenaline (nM ) Adrenaline (nM )
pre-injection 
values
post-inj ection 
values
pre-injection 
values
post-injection 
values
Saline 1.94 + 0.91 1.68 + 0.63 1.56 + 0.84 1.71 ±  0.76
ET-1
(1 . 0  nmol) 1.61 +0.69 0.65 + 0.19 2.97 ±0.57 1.77 + 0.56
Results are expressed as means + s.e.mean
n = 5
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Effect of intravenous administration of ET-1 (0.1 - 1.0 nmol) on 
(a) blood pressure (MAP) and (b) heart rate (HR) in the conscious 
rat.
Points represent the mean blood pressure (mmHg) and heart rate 
(bpm) response + s.e.mean, n = 5; * Significant differences from 
saline control value (p < 0.05).
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O ET-1 (0.1 nmol)
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■ ET-1 (1.0 nmol)
467 + 7 . 0  bpm compared to the control value of 309 +19.5 bpm. 
The haemodynamic effect of intravenous ET-1 in the conscious rat 
are illustrated in a representative response to 1 nmol ET-1 in 
Figure 7.4.
7.1.3.4 Effects of Intravenous Administration of ET-1 on Plasma 
Catecholamine Levels in the Conscious Rat
Plasma catecholamine levels were not significantly affected 
by i.v. injection of saline (Table 7.2) Similarly ET-1 had no 
effect on the levels of noradrenaline or adrenaline in the plasma 
(Table 7.2).
7.1.4 Discussion
A biphasic cardiovascular response to i.v. ET-1 was 
demonstrated in both the anaesthetised and conscious Wistar-Kyoto 
rat. These results corroborate those of Yanagisawa et al (1988a) 
in the chemically denervated, anaesthetised Sprague-Dawley rat. 
The mechanism underlying the initial depressor response has not 
been conclusively established. However, recent studies have 
reported that as well as eliciting a vasodilation in isolated 
blood vessels, ET-1 produces a transient regional increase in 
blood flow in vivo (Warner et al, 1989). The vascular beds 
dilated by this peptide include the hindquarters and carotid but 
the vascular reactivity and region affected appears to be 
dependent on the dose and route of administration (Gardiner 
et al, 1989; Han et al, 1989). In the present study, although 
ET-1 (1.0 nmol) elicited an initial decrease in blood pressure, a 
low dose of ET-1 (0.3 nmol) administered to the conscious rat
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Figure 7.4
Representative trace showing (a) arterial blood pressure 
(mmHg) and (b) heart rate (bpm) following intravenous (i.v.) 
administration of ET-1 (1.0 nmol) in the conscious rat.
Table 7.2
Lack of Effect of Intravenous Administration of Endothelin-1 (ET-1) 
on Plasma Catecholamine Levels in the Conscious Rat
Noradrenaline ( n M  ) Adrenaline (n.M )
pre-injection 
values
post-inj ection 
values
pre-injection 
values
post-injection 
values
Saline 1.01 + 0.25 0.91 + 0.18 0.70 + 0.29 0.78 + 0.33
ET-1
(0.1 nmol) 0.87 + 0.15 0 . 8 5 + 0 . 2 1 0.72 + 0 . 1 2 0.46 + 0 . 1 9
ET-3
(0.3 nmol) 0.90 + 0.12 0.60 + 0.11 0.43 + 0.08 0.71 + 0.50
ET-1
(1.0 nmol) 0.79 + 0.12 0.88 + 0.19 0.93 + 0.29 0.84 + 0 . 2 2
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evoked only a significant vasopressor response, indicating that 
at this dose vasoconstriction predominates.
The release of vasodilator substances by ET-1 has been 
proposed to account for the vasodilation observed in isolated 
tissues and may explain the depressor effect observed in vivo. 
In the rat perfused mesentery and lung preparations ET-1 has been 
shown to release endothelium-derived relaxing factor (EDRF) and 
prostacyclin (de Nucci et al, 1988). Moreover, the eicosanoid 
inhibitor indomethacin potentiates the pressor response to 
intravenous ET-1 in the pithed rat indicating the removal of a 
vasodepressor action of the peptide in vivo (de Nucci et al, 
1988).
In the present study the observed tachycardia in the 
conscious rat was proportional to the initial fall in blood 
pressure suggesting it was reflex in origin and thus due to a 
reduction in vagal tone or increase in sympathetic nerve activity 
(Stornetta et al, 1987). Direct cardiac effects of ET-1 have 
also been reported including positive inotropic and chronotropic 
activity, ET-1 is also a potent secretagogue of atrial 
natriuretic peptide from rat atria (Ishikawa et al, 1988a; b; Hu 
et al, 1988)> The latter action has also been postulated to 
contribute to the vasodepressor effect.
A difference was observed in the extent of the vasodepressor 
response elicited by intravenous ET-1 in the conscious rat 
compared to the anaesthetised rat. The smaller magnitude in the 
latter may be a consequence of the influence of anaesthesia on 
the factors, discussed above and/or result from the prior
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depression of vasomotor outflow by the anaesthetic, thus making 
it more difficult for the peptide to further reduce arterial 
pressure. Although the maximum pressor response to ET-1 (1 nmol) 
was similar in both groups, the magnitude of the rise in blood 
pressure was much smaller in the conscious animal. This may 
reflect activation of compensatory mechanisms in the conscious 
animal. Winquist et al (1989), have reported that the pressor 
response to i.v. ET-1 in the conscious animal was attenuated 
compared to the anaesthetised animal. These authors suggested 
that the vasoconstriction induced by ET-1 in the conscious animal 
may be offset by substantial decreases in cardiac output. De 
Nucci et al (1988), demonstrated that the pressor response 
subsequent to i.v. administration was more marked in the 
anaesthetised rat with low blood pressure (130/85 mmHg) compared 
those with high blood pressure (185/135 mmHg). These data 
further suggest that anaesthesia influences the vascular response 
to ET-1 in vivo.
A striking feature of the pressor phase of the in vivo 
response to ET is its time course. At least two hours were 
required for the return to pre-injection values after ET-1 
(1 nmol i.v.) in the anaesthetised rat. In the conscious animals 
the hypertensive effect was sustained for a shorter period (one 
hour). The prolonged nature of the response is in agreement with 
other studies and has been shown to be associated with a time 
dependent vasoconstriction of a number of vascular beds including 
mesenteric, renal and hindquarter (Wright and Fozard, 1988; Han
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et al, 1989). In the present study plasma catecholamine levels, 
3 n indirect determinant of sympathetic nerve activity, were not 
significantly altered in either the anaesthetised or conscious 
rat following i.v. ET-1. This would suggest that at least in the 
periphery this peptide acts directly on the vascular beds rather 
than interfering with sympathetic tone. Indeed, as discussed in
Section 1.6, this direct effect on vascular smooth muscle cells
2+ 2+ may involve Ca . However, the source of this Ca remains
controversial (Section 1.6.6). Specific receptors for ET-1 have
been demonstrated on vascular smooth muscle cells (Hirata et al,
1988). The dissociation of the endothelin radioligand 
125( I)-ET-1 from cultured rat aortic smooth muscle cells was very 
slow with 85% of the initial cell bound radioactivity still 
present after two hours (Hirata et al, 1988). Although 
internalisation of the peptide may contribute to this 
observation, the slow dissociation from the putative receptor may 
partly explain the long-lasting response in vivo.
Thus, in confirmation of the epoch study by Yanagisawa et al 
(1988a) in anaesthetised ganglion-blocked rats, ET-1 (1 nmol/rat) 
given intravenously elicits a biphasic cardiovascular response in 
both the conscious and anaesthetised Wistar-Kyoto rat. However, 
the composition of this response depends on the anaesthetic state 
of the animal. Moreover, in the absence of published data on the 
central activity of ET-1, an estimated range for the proposed 
studies on the central activity of the peptide (Sections 7.2 and 
7.3) can be extrapolated from the doses utilised in the present 
study. In addition, a comparison of the peripheral and potential
central actions of ET-1 can be undertaken.
7.2 Haemodynamic Effects of Intracisternal Administration
of Endothelin-1 in the Conscious Rat
7.2.1 Introduction
The first report of ET-1 constricting porcine coronary 
artery strips provoked a plethora of studies examining the 
peripheral acivity of this novel peptide (Yanagisawa et al, 
1988a). Almost unnoticed in that initial study was a similar 
dose-response relationship to ET-1 in isolated cat basilar 
arteries, implying that endothelin may also regulate cerebral 
vascular function. Although the potent and prolonged 
vasoconstrictor activity of endothelin has since been extensively 
investigated in peripheral systems (Section 1.6.4), only a very 
limited number of reports have appeared concerning its effect on 
cerebral blood vessels.
Asano e_t al (1989) demonstrated in isolated canine basilar
-11 -  8arteries, that ET-1 (10 - 3 x 10 M) induced a sustained dose-
dependent vasoconstriction. The characteristic long-lasting 
nature of this response pointed to possible damage of the tissue 
by endothelin. However, the vasoconstriction was counteracted by 
the intracellular calcium antagonist, HA 1077, providing evidence 
that the vascular response was not due to irreversible damage 
(Asano et al, 1989). ET-1 binding sites have been localised very 
recently on cerebral vessels and it is possible that the observed 
slow dissociation of the endothelin from the putative receptor in
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vascular smooth muscle cells may be instrumental in the prolonged 
response in cerebral as well as peripheral tissues (Hirata et al, 
1988) . An influx of calcium ions has been proposed as the 
mechanism for the slowly developing contractile response in the 
isolated middle cerebral arteries of the cat (Saito et al, 1989). 
In tjiis tissue endothelin did not produce a vasoconstrictor 
response in a calcium-free solution. Moreover nicardipine and 
diltiazem, calcium channel blockers, attenuated the effect of 
endothelin by reducing the maximum responses but not the ED^q 
values implicating a non-competitive antagonism. Extracellular 
calcium ions are also required in certain peripheral blood, 
however, differences may exist in the mechanisms of channel 
opening between cerebral and peripheral blood vessels (Saito 
et al, 1989; Kurihara et al, 1989).
More recently, Koseki et al (1989a), using receptor
autoradiographical techniques, observed that the distribution of
binding sites for ET-1 subsequent to systemic administration of
radiolabelled ET-1 were located only in the circumventricular
structures of the median eminence and subfornical organ and
choroid plexus located outside the blood-brain barrier. This is
consistent with ET-l's inability to cross the blood brain
barrier. A single class of specific high affinity binding sites 
-10(Kd = 4-5 x 10 M) for ET-1 have however been demonstrated m  
membrane preparations from the rat brainstem (Koseki et al, 
1989b). Moreover, these authors observed that in the brainstem, 
ET-1 binding was not displaced by various receptor agonists, 
toxins, peptides, and calcium channel blockers suggesting that
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this peptide binds to a novel receptor.
As previously mentioned in Section 1.6.3, quantitative 
autoradiographical studies by Hoyer et al (1989) have revealed a 
differential pattern of ET-1 distribution in various brain areas 
studied. High densities of binding sites were observed in the 
hypothalamus and cerebellum with lower densities in the 
neocortex. The non-homogenous distribution within the rat brain 
regions indicate that the endothelin receptors may not only be 
located in blood vessels. The view that ET-1 binding has a 
neuronal rather than a vascular distribution is purported by 
Jones et al (1989). These authors have shown that regions of rat 
brain with a similar vascular supply display a differential 
pattern of distribution. Although there was no real evidence to 
support the assumption made by these authors, that ET-1 binding 
in the vascular tissue of each region is equivalent thereby any 
differences observed are due to parenchymal binding, the broad 
range of binding sites observed in central areas would suggest a 
more extensive role than control of vascular tone.
Thus, ET-1 could act in the central nervous system as a 
neurotransmitter or neuromodulator to control a variety of 
functions. The recent finding that ET-1 binding sites are 
present in the rat brainstem, an area of cardiovascular 
significance is worthy of particular attention since it suggests 
that this peptide may be involved in the central regulation of 
cardiovascular function (Koseki e t al, 1989b). The present study 
investigated the cardiovascular actions of ET-1, by examining the
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haemodynaraic response to intracisternal administration of the 
peptide in the conscious rat. At the onset of this study no data 
was available concerning central administration of endothelin, 
therefore as a starting point, concentrations extrapolated from 
the intravenous dose-response relationship established in 
Section 7.1.3 were utilised in the proceeding experiments.
7.2.2 Methods
Conscious unrestrained male Wistar-Kyoto rats weighing 
between 275 - 300g were used in the experiments carried out in 
this section.
7.2.2.1 Preparation of Animals
Intracisternal guide cannulae were implanted prior to the 
study day as detailed in Section 2.6. On the day of the 
experiment, the femoral arteries were cannulated to monitor blood 
pressure throughout the procedure and to sample arterial blood 
(Section 2.5). Using the same methodology a catheter was also 
implanted in the femoral vein for i.v. administration of a fatal 
dose of pentobarbitone sodium (180 mg kg , to kill the animal 
at the end of the procedure or it experienced any distress during 
the procedure.
7.2.2.2 Intracisternal Drug Administration
Intracisternal injections of vehicle saline (0.9% w/v) or
0.01 - 0.03 nmol/rat of ET-1, one injection per rat, were given 
via an injector, placed in the guide cannula, which was connected 
by tubing to a Hamilton syringe (5 jjlI) . The injectate volume was
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2.5 p i  administered over 30 seconds. The lowest concentration 
(0 . 0 1  nmol) used in this dose range represents a 1 0 -fold lower 
dose than the 0 . 1  nmol dose which was ineffective when given 
intravenously (Section 7.1.3). The narrow dose range in the 
current study reflects the difficulties experienced in finding 
endothelin concentrations producing cardiovascular effects 
without more profound centrally mediated effects.
7.2.2.3 Plasma Catecholamine Determination
Arterial blood samples were taken to measure plasma 
noradrenaline and adrenaline levels before and at the maximal 
blood pressure response to ET-1/vehicle administration 
(Section 2.7). This would allow an indirect determination of 
changes in sympathetic nerve activity following drug 
administration.
7.2.2.4 Statistical Analysis
The statistical test used to analyse the mean haemodynamic 
data was the Repeated Measures Analysis of Variance with a 
Bonferroni correction for multiple comparisons included where 
appropriate. Analysis of the changes in plasma catecholamine 
levels utilised the Kruskal-Wallis (non-parametric one way 
analysis of variance) statistical test.
7.2.3 Results
7.2.3.1 Effect of Intracisternal Administration of Endothelin-1
on Blood Pressure and Heart Rate 
Intracisternal administration of ET-1 in conscious rats
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evoked complicated haemodynamic responses. Marked elevations in 
blood pressure in response to ET-1 (0.01 - 0.03 nmol) were 
observed in some but not all of the animal studies. Individual 
blood pressure and heart rate responses before and at the maximum 
(1-5 minutes) response after intracisternal injection are shown 
in Table 7.3. Data were not subdivided on the basis of blood 
pressure responses at this point. The mean data for each group 
is depicted in Figure 7.5. The pre-injection values of the 
control and treatment groups did not significantly differ from 
each other. As expected, intracisternal administration of saline 
did not significantly effect either blood pressure or heart rate. 
A prominent and significant rise in blood pressure was observed 
following administration of ET-1 (0.02 and 0.03 nmol) by the same 
route (Figure 7.5). In the animals where the increase in blood 
pressure to ET-1 exceeded 40 mmHg, this hypertension had a 
latency of onset between 0.5 - 1 minute. This hypertensive event 
was usually preceded by an increased activity of the animal which 
could develop into longitudinal rolling of the body (Table 7.3). 
If these events occurred or if the animal was in obvious 
discomfort, a fatal intravenous dose of anaesthetic was given. 
No consistent change in heart rate was demonstrated following 
intracisternal ET-1 (Figure 7.5). An example of a trace from an 
animal where administration of ET-1 (0.03 nmol) resulted in a 
dramatic rise in blood pressure is shown in Figure 7.6. In this 
animal the dose of ET-1 itself was lethal.
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Table 7.3
Individual Blood Pressure Responses and Corresponding Heart Rate Values
before and at the Maximum Response Following Intracisternal Inlection
of ET-1 (0.01 - 0.03 nmol) or Saline in the Conscious Rat
Blood Pressure (mmHg) Heart Rate (bpm)
Pre- injection Post-injection Pre-injection Post-injection
Saline 131 135 305 310
n - 6 130 134 350 320
130 140 315 370
130 140 330 340
115 120 410 410
125 125 430 290
0.01 nmol 123 132 330 350
n - 5 115 125 270 270
127 145 326 310
125 165 300 270
125 210* 320 -
0.02 nmol 124 135 300 330
n - 5 125 145 405 300
118 220 315 390
110 220 245 480
118 200* 270 260
0.03 nmol 137 150 325 330
n - 7 120 145 300 300
123 200* 345 290
125 218* 320 270
115 195 310 370
125 215* 350 150
130 180 300 330
* represents animals that experienced a concomitant barrel-rolling response
172
220 n
200 -
X  1 8 0 "
E
£  160 -
120 -
100
post-injectionpre-injection
400 n
_  350 -
E
CL
S3
DC
X  300 -
250 -*■-------------------------------------------------------------- ------- -------------
pre-injection post-injection
Figure 7.5
Effect of intracisternal administration 0.01 - 0.03 nmol 
endothelin-1 (ET-1) on blood pressure (MAP) and heart  
rate (HR) in the conscious rat.
Results are expressed as mean values + s.e. mean, before 
and at the maximum response to intracisternal administration 
of saline or peptide; n = 5-7.
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Figure 7.6
Representative trace of the (a) arterial blood pressure 
(mmHg) and (b) heart rate (bpm) following intracisternal 
(i.e.) administration of ET-1 (0.03 nmol) in the conscious 
rat.
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7.2.3.2 Effects of Intracisternal Administration of Porcine
Endothelin-1 on Plasma Catecholamine Levels in the 
Conscious Rat
Plasma catecholamine levels were determined before and at 
the maximum response to ET-1 or saline injection (Figure 7.7). 
An increase in plasma noradrenaline and adrenaline levels was 
evident following administration of the peptide and this reached 
significance with the highest dose of ET-1 (0.03 nmol). The 
variation in the data reflects the fact that catecholamine levels 
were increased only in those animals where the marked elevation 
in blood pressure was accompanied by marked changes in behaviour. 
The frequency of this response was previously shown in Table 7.3.
7.2.4 Discussion
Evidence has been presented in this section that ET-1 
induces a pronounced hypertension following intracisternal (i.e.) 
administration in the conscious rat. The profile of this 
response differs from the previously demonstrated biphasic blood 
pressure response to i.v. injected ET-1, in both the conscious 
and the anaesthetised rat (Section 7.1.3). These data and the 
fact that 10-fold higher doses of ET-1 were required to elevate 
blood pressure when given by the i.v. route, imply that the 
hypertensive action of i.e. administered ET-1 is unlikely to be 
due to leakage of the peptide into the peripheral circulation. 
Since the completion of these studies a few reports have been 
published addressing the possible central activity of the 
peptide. Kawano et al (1989) demonstrated a similar difference
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Effect of intracisternal administration of endothelin 
-1 (0.01 - 0.03 nmol) on plasma catecholamine levels in the
conscious rat.
Data expressed as means ± s.e. mean, before and at the 
maximum response to intracisternal administration of saline 
or peptide; n = 5-7
■  Saline
^ET-1 (0.01 nmol)
HET-1 (0.02 nmol) 
Eg ET-1 (0.03 nmol)
* Significant difference from saline control value ( p < 0.05)
between the doses needed to produce a rise in blood pressure via 
the intracerebroventricular (i.c.v.) compared to those needed via
i.v. route, in conscious Wistar rats. These authors observed 
that i.c.v. administration of ET-1 at a dose of 100 ng/kg 
(0.04 nmol) produced an increase in blood pressure, whereas 
1000 ng/kg (0.40 nmol) i.v. was needed to elicit a hypertensive 
effect. A tachycardia was observed following i.c.v. ET-1 in the 
latter study, however in the present investigations no clear-cut 
effect on heart rate was evident. The disparity between studies 
may be related to the dose of peptide used or the route of 
administration, i.c.v. concentrating the peptide's effects more 
rostrally.
Centrally mediated behavioural effects of ET-1 have also 
been demonstrated. Moser and Pelton (1989) have reported that 
ET-1 (0.005 nmol) injected into the right lateral ventricle 
produced a longitudinal rolling of the body analogous to that 
previously described for somatostatin (Cohn and Cohn, 1975). 
Cardiovascular parameters were not measured in the former study. 
However, it was reported that higher doses of ET-1, 0.01 and
0.02 nmol/rat, were lethal. In the current investigation 
intracisternal administration of the peptide (0 . 0 1  -
0.03 nmol/rat) elicited an increase in the blood pressure in some 
but not all of the animals. This response was variably 
accompanied by intense barrel-rolling movements and death. The 
consistent effects on motor coordination demonstrated by Moser 
and Pelton (1989) after i.c.v. injection, could be due to a 
greater concentration of the peptide around the cerebellum, the
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area of motor coordination where a high density of endothelin 
binding sites have been reported (Jones et al, 1989). However, 
intracisternal administration of the peptide, although focusing 
the peptide's effects around the medulla, would still also 
concentrate the peptide's effects around the cerebellum. In 
contrast to the results of Moser and Pelton (1989) no overt 
behavioural activity was reported by Kawano et al (1989) 
following injection of the peptide by the same route. The lower 
concentration of ET-1 utilised in the latter study may explain 
the discrepant results.
The wide variation in the haemodynamic responsiveness to
i.e. ET-1 is curious. However, a similar phenomenon has been
reported by Wiklund et al (1988) in the femoral arteries from the
guinea-pig. These authors observed only nine of 21 preparations
-9 - 8contracted to endothelin (10 - 10 M) and again there was no
obvious explanation. In the present study problems associated 
with the activity of the peptide can be excluded since the same 
batches of endothelin were used in the intravenous experiments 
carried out at the same time (Section 7.1.3). Although the 
patency of the cannula was confirmed before injection of the 
peptide (as described in Section 2.6) and the position of the 
cannula examined at the end of the procedure, it is possible that 
in some cases the delivery of the peptide from the cannula into 
the cerebral spinal fluid was impaired. This would account for 
the 'all or none' phenomenon observed. However as will be 
discussed in Section 7.3.4 further experiments are required to
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verify this view.
An increase in sympathetic tone has been associated with the 
increase in blood pressure following injection of ET-1 into the 
ventricles of the conscious rat. Kawano et al (1989) 
demonstrated that pretreatment with intravenous hexamethonium (a 
ganglion blocker) significantly attenuated the rise in blood 
pressure produced by i.c.v. administration of ET-1. In the
present study, plasma catecholamine levels were determined as an 
indirect measurement of sympathetic nerve activity. At the 
highest dose of ET-1 studied, a significant increase of both 
adrenaline and noradrenaline levels compared to control values, 
was observed. This would suggest that an increased sympathetic 
nerve activity mediated via central cardiovascular regulatory 
pathways was responsible for the hypertensive response evoked by 
the peptide. Ho.wever, further examination of the data revealed 
that catecholamine levels were only elevated in the animals that 
experienced intense activity (longitudinal rolling) together with 
the hypertensive response. Therefore the interpretation of the 
catecholamine results is not straightforward and requires further 
and perhaps more direct investigation.
Autoradiographical studies in the brainstem have revealed 
ET-1 binding sites in areas corresponding to nuclei associated 
with cardiovascular regulation and body fluid homeostasis (Koseki 
et al, 1989a). These regions include the nucleus of the solitary 
tract, the rostral ventrolateral medulla, the parabrachial 
nucleus as well as the paraventricular and supraoptic nuclei of 
the hypothalamus. Kawano et al (1989) also observed that
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intravenous administration of a vasopressin antagonist, 
attenuated the hypertensive response to the i.c.v. administration 
of ET-1, suggesting the involvement of vasopressin in the central 
effects of the peptide. Although the distribution of ET-1 
binding sites in the brain was distinct from those of 
vasopressin, an additional link between these peptides has been 
proposed since the circumventricular structures bound by the 
systemic administration of ET-1 also contain binding sites for 
atrial natriuretic peptide. This latter peptide has been shown 
to be involved in the regulation of vasopressin secretion and its 
release is stimulated by ET-1 in guinea pig atria (Koseki et al, 
1989b; Fukuda cit al, 1988). Further evidence for a neuropeptide 
role for ET-1 in the central nervous system is suggested by the 
finding that ET-l-like immunoreactivity is present in certain 
types of neurones such as motor neurones and primary sensory 
neurones in the porcine spinal cord (Yoshizawa et al, 1989a). 
Moreover ET-1 has been shown to depolarise a ventral root 
potential in the rat spinal cord giving further support to a 
neuronal function for this peptide (Yoshizawa et al, 1989b). The 
distinctive hypertensive and behavioural responses seen in the 
present study could also be mediated via the previously described 
binding sites on cerebral blood vessels. Shigeno et al (1989) 
have demonstrated that intracisternal administration of ET-1 (5- 
500 pmol) resulted in a potent vasoconstriction of the feline and 
canine basilar artery as measured by angiographic techniques. 
Thus the present data can only be regarded as a starting point in
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the investigation of the central haemodynamic actions of ET-1. 
Further detailed experiments are necessary to ascertain the exact 
mechanisms(s) involved in this putative role of ET-1. This issue 
is considered in the following section.
7.3 Effect of Intracisternal Administration of Endothelin-1
on Cerebral Blood Flow in the Anaesthetised . and 
Conscious Rat
7.3.1 Introduction
The results of the preceding section (Section 7.2) 
demonstrate that intracisternal administration of ET-1 in the 
conscious rat evokes a marked elevation in blood pressure, with 
no consonant change in heart rate. This marked increase in blood 
pressure which accompanied the central administration of 
endothelin, may. be secondary to an action on brainstem nuclei 
associated with cardiovascular control or a consequence of 
cerebral vasoconstriction. Indirect autoradiographic evidence 
supporting the former postulate has emerged very recently and has 
been discussed previously in Section 7.2.4.
An alternative mechanism for the distinctive hypertensive 
event might be a causal relation to the constriction of cerebral 
blood vessels. Asano et al (1989) demonstrated, using 
angiographic techniques, that intracisternal administration of 
ET-1 (10 - 1000 pmol) in anaesthetised dogs produced a sustained 
basilar artery vasoconstriction with an increase in blood 
pressure observed at the highest concentration, These in vivo 
findings, combined with in vitro studies on isolated cerebral
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vessels, which demonstrate a prominent vasoconstrictor activity 
of ET-1 (Section 7.2), suggest that the dramatic changes in 
blood pressure and motor coordination observed following 
intracisternal injection of endothelin in rats (Section 7.2) may 
be a consequence of the reported potent and prolonged cerebral 
vasoconstrictor activity of ET-1.
The present study addressed this hypothesis by determining 
the regional cerebral blood flow following intracisternal 
administration of ET-1 in the rat.
7.3.2 Measurement of Cerebral Blood Flow in Anaesthetised and 
Conscious Rats Methodology 
Male Wistar-Koyoto rats weighing between 270 - 310 g on the 
study day, were utilised in the proceeding investigations.
7.3.2.1 Preparation of Animals
Anaesthesia was induced in a perspex box with halothane (5%) 
in a nitrous oxide/oxygen mixture (70% : 30%) and maintained with 
0.5 - 1% halothane. A tracheostomy was performed when cerebral 
blood flow (CBF) was to be measured in anaesthetised animals. 
The animal's ventilation was controlled by a small animal 
respirator.
Polyethylene cannulae containing heparinised saline ( 8  units 
ml”^) were inserted into both femoral arteries to monitor 
arterial blood pressure and sample arterial blood. Both femoral 
veins were also catheterised for administration of the 
radioactive tracer and where necessary, intravenous
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administration of a fatal dose of anaesthetic. Arterial blood 
samples were withdrawn for measurement of blood gases prior to 
tracer administration. In anaesthetised animals, ventilation was 
adjusted to maintain arterial carbon dioxide tension (PaCC^) 
between 32 and 40 mmHg. Animals with an arterial oxygen tension 
(Pa0 2 ) of below 80 mmHg were excluded from the study. Rectal 
temperature was maintained at 37°C with an automated heating box.
When measurement of CBF was to be carried out on conscious 
animals the rats were anaesthetised and femoral cannulae 
implanted as above. The wounds were then infiltrated with 
lignocaine, a local anaesthetic and sutured. The animals were 
restrained in a plaster cast which extended from the front to the 
hind legs. The latter were further restricted from movement and 
the possible displacement of the cannulae, by taping to a fixed 
platform on which the animal was placed. The rats were then 
allowed to recover from the anaesthesia for a period of three 
hours before commencing with the experiment. Arterial blood 
samples were withdrawn as described above with the same blood gas 
criteria needed for entry into the study.
7.3.2.2 Intracisternal Drug Administration
Intracisternal injections of saline (0.9% w/v) or endothelin 
(30 pmols/rat) were made via an injector inserted into the 
implanted guide cannula, as described in Section 2.6. The dose 
of endothelin chosen for intracisternal injection, represented a 
concentration which evoked the most consistent hypertensive 
response in the previously described study on conscious rats
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(Section 7.2.3). In accordance with the methodology used in 
Section 7.2.3, each rat received one injection of either the
peptide or saline in a volume of 2.5 j i l  over a time period of 30 
seconds.
14
7.3.2.3 Cerebral Blood Flow Measurements with the [ CJ^  jr 
Io do ant ipyrine Autoradiographic Technique 
The effects of E-l on cerebral blood flow (CBF) were first 
determined in anaesthetised rats. Since the timing of this 
procedure is critical and the end point timed exactly by 
decapitation using a guillotine, anaesthesia prevents any
possible delays in the kill time due to movement of the animal. 
However, the results obtained from the first series of
experiments on anaesthetised animals necessitated further 
examination of the effects of endothelin on cerebral blood flow 
in conscious animals. Since some of the animals were likely to 
experience behavioural effects which affected movement as
described earlier, the procedure was terminated and the animal 
killed by bolus injection of euthetal ( 1  ml) rather than 
decapitation by guillotine.
The procedure utilised to measure CBF was initiated 2 - 5
minutes subsequent to drug administration (Section 7.3.2.2) using
a modified method of Sakurada et al (1978). This time delay
corresponded to the maximum hypertensive response to i.e. ET-1
previously described in Section 7.2.3.1. A ramped infusion over 
1 A-30 seconds of [ C]-iodoantipyrine (50 juCi in 1.5 ml saline) was 
administered whilst simultaneously collecting timed arterial
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blood samples (a total of 14 - 18) from the femoral cannula onto
pre-weighed filter papers. At the end of the infusion period and
for reasons discussed previously the animal was killed either by
decapitation or an overdose of anaesthetic. The drop rate and
precise time of death were noted. The brain was then removed
rapidly for freezing by immersion in 2-methyl butane at -45°C.
Coronal brain sections were cut (20 ^ un thick) in a cryostat at
22°C, three in every ten sections were mounted on glass
coverslips and immediately dried on a hot plate for
autoradiographic processing. The next section in each cycle was
stained with cresyl violet to facilitate neuroanatomical
identification of brain nuclei. Autoradiographs were prepared by
exposing the appropriate sections, with a set of plastic
14standards of known C concentrations (44 - 1175 nCi/g) to X-ray 
film. Tissue optical density (OD) measurements from the 
autoradiographs were measured on a computer based densitometer 
with reference to the pre-calibrated standards. In the first 
series of experiments on anaesthetised animals the minimum tissue 
OD was measured in a general brain area from at least six 
sections in which this area was present. In the second study 
utilising conscious animals, tissue OD measurements were taken 
from at least six sections in which the discrete anatomical areas 
of interest could be accurately defined. The tissue OD 
measurements from both studies were converted with reference to 
the precalibrated standards into equivalent tracer 
concentrations.
The regional cerebral blood flow was then calculated by
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solving the operational equation (Figure 7.8) derived originally 
by Kety (1951), using the concentration of the [^C]- 
iodoantipyrine in the discrete regions of the brain, the blood- 
brain partition coefficient for the tracer (0 .8 ), and the history 
of the tracer in arterial blood during the experimental period 
(Sakurada et al, 1978).
7.3.2.4 Statistical Analysis
The nature of the results obtained from the present study 
necessitated that the individual data sets for the haemodynamic 
studis were displayed for clarity. Where appropriate statistical 
analysis of these haemodynamic parameters was carried out on mean 
results using Repeated Measures Analysis of Variance with a 
Bonferroni correction included for multiple comparisons. The 
cerebral blood flow data was analysed using an unpaired students 
T-test.
7.3.3 Results
7.3.3.1 Effect of Intracisternal Administration of ET-1 on 
Blood Pressure and Heart Rate in the Anaesthetised Rat 
The effect of intracisternal administration of ET-1 
(0.03 nmols/rat) on blood pressure and heart rate in the 
anaesthetised rat is shown in Figure 7.9. Due to variation in 
the data these results are initially presented as individual 
values taken before and at the maximum blood pressure and heart 
rate response to intracisternal administration of ET-1. The 
haemodynamic response to intracisternal administration of ET-1
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where Ci(T) equals the tissue concentration of the tracer at a 
time T after the introduction of the tracer into the circulation;
X equals the tissue : blood partition coefficierlt; is the
concentration of the tracer in the arterial blood; t equals the 
variable, time; and K equals a constant that incorporates within 
it the rate of blood flow in the tissue.
The constant K is defined as follows:
K = mF/wX
where F/W equals the rate of blood flow per unit mass of tissue 
and m equals a constant between 0  and 1  that represents the 
extent to which diffusion equilibrium between blood and tissue is 
achieved during passage from the arterial to the venous 
capillaries.
Figure 7 . 8
Operational equation to determine cerebral blood flow using 
14the [ C]-iodoantipyrine autoradiographic technique
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Figure 7.9
Individual blood pressure responses and corresponding heart 
rate values before and at the maximum response following 
intracisternal injection of ET-1 (0.03 nmol) or saline in 
the anaesthetised rat.
• Saline, n = 5 
■ ET-1 (0.03 nmol), n = 8
(0.03 nmols), with one exception, did not appear to markedly vary 
from the control values (Figure 7.9). Indeed the maximum blood 
pressure and heart rate response for this group did not differ 
significantly from the pre-injection values (Table 7.4). 
Although, for obvious reasons a statistical test could not be 
applied, in the one animal that did respond to the peptide a 
maximum rise in blood pressure of 85 mmHg was observed two 
minutes after administration of ET-1 with no marked change in the 
corresponding heart rate (Table 7.4). This hypertensive event was 
similar to the haemodynamic effects of ET-1 previously 
demonstrated in the conscious rat (Section 7.2.3).
7.3.3.2 Effect of Intracisternal Administration of ET-1 on 
Cerebral Blood Flow in the Anaesthetised Rat 
Regions of minimum cerebral blood flow (CBF) in three sites 
of neuroanatomical interest were examined in the animals 
described in Section 7.3.3.1. As shown in Table 7.5 the mean CBF 
values for the group of animals that did not respond to 
intracisternal administration of ET-1 were not significantly 
different from the control saline group. Although statistical 
analysis could not be carried out for obvious reasons, the CBF 
was markedly reduced, in all the brain regions shown in 
Table 7.5, in the animal which produced a hypertensive response 
to intracisternal administration of the peptide.
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Table 7.4
Effect of Intracisternal ET-1 (0.03 nmol) on Blood Pressure (HAP)
and Heart Rate (HR) in the Anaesthetised Rat
Drug/
Vehicle
MAP
Pre-injection
(mmHg)
Post-inj ection
HR
Pre-injection
(bpm)
Post-injection
Saline 
(n - 5)
83.0 + 4.9 84.0 + 4.0 227.0 + 1 3 . 0 246 + 14.4
ET-1 
(n - 7)
82.1 + 4.3 95.7 + 3.5 223.6 + 9.8 242.1 + 5.33
ET-1 
(n - 1)
75 160 190 200
Results are expressed where appropriate as mean values + s.e.mean before 
and at the maximum response to intracisternal administration of saline
or Peptide
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Table 7.5
Effect of Intracisternal ET-1 (0.03 nmol) on Cerebral Blood
Flow (CBF) in the Anaesthetised Rat
CBF Values (ml lOOg • -l^m m  )
Region Saline (n = 5 ) ET-1 (n = 7) ET-1 ( n 
A  MAP =
- 1 )
85 mmHg
Lateral
Medulla
89 + 4 89 + 6 1 0
Inferior Olives 125 + 9 125 + 7 1 1
Cerebellar 
White Matter 37 + 7
3 1  ± 3 19
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7.3.3-. 3 Effects of Intracisternal Administration of ET-1 on
Blood Pressure and Heart Rate in the Conscious Rat 
In the conscious rat, intracisternal administration of 
saline, as expected, had no effect on either blood pressure or
heart rate as shown by the individual blood pressure and heart
rate responses presented in Figure 7.10; In contrast, injection 
of ET-1 (0.03 nmols) by the same route, elicited differential 
effects on blood pressure. The individual haemodynamic responses 
before and at the maximum response to administration of the
peptide are shown in Figure 7.10. It is clear from these results
that in some, but not all animals, ET-1 (0.03 nmols) produced a 
distinct elevation in blood pressure. This hypertensive response 
had a latency of onset between 0.5 - 2 minutes reaching a maximum 
between 2-5 minutes. In this respect, the present results 
resemble those .obtained in the previous haemodynamic study on 
conscious animals in Section 7.2.3. Increased activity of the 
animal prior to the hypertensive event was evident. However, 
since the animal was restrained the incidence of barrel-rolling 
could not be established. The blood pressure response has been 
subdivided into two groups based on whether or not a discernible 
(> 10 mmHg) increase in blood pressure occurred (Table 7.6). 
Statistical analysis was carried out to determine if the maximum 
(post-injection) blood pressure and heart rate responses of these 
subgroups differed significantly from their pre-injection values. 
In the group that 'responded' (A BP > 10 mmHg) to ET-1
(0.03 nmol), a significant increase in blood pressure was 
observed (Table 7.6). However, no significant alteration in the
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Figure 7.10
Individual blood pressure responses and corresponding heart 
rate values before and at the maximum response following 
intracisternal injection of ET-1 (0.03 nmol) or saline in 
the conscious rat.
O Saline, n = 5 
■ ET-1 (0.03 nmol), n = 9
blood pressure response was observed either in the saline group 
or the subgroup of animals that were unresponsive 
(A BP < 10 mmHg) to the peptide (Table 7.6). No significant 
changes in heart rate were observed in any of the subgroups 
(Table 7.6).
7.3.3.4 Effects of Intracisternal Administration of ET-1 on 
Cerebral Blood Flow in the Conscious Rat 
Analysis of the regional cerebral blood flow (CBF) from the 
conscious rats described above was carried out in three 
neuroanatomically defined regions of the medulla. The results 
revealed that CBF was consistently and significantly reduced, 
compared to the control (saline) group, in all medullary regions 
examined from the subgroup of animals where administration of the 
peptide produced the distinctive elevation in blood pressure 
(Table 7.7). Blood flows in the same regions from the subgroup 
of animals that did not 'respond' to i.e. ET-1 were not 
significantly different from the control group (Table 7.7). 
Representative autoradiographs from sections of the brains of two 
conscious rats are shown in Figure 7.11. A clear reduction in 
regional CBF is demonstrated in the section from an ET-1 treated 
animal that experienced a hypertensive event after administration 
of the peptide compared to a corresponding section from a control 
(saline)-treated animal.
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Table 7.6
Effect of Intracisternal ET-1 (0.03 nmol) on Mean Arterial Pressure (MAP)
and Heart Rate (HR) in the Conscious Rat
Drug/
Vehicle
MAP
Pre-injection
(mmHg)
Post-injection
HR
Pre-injection
(bpm)
Post-injection
Saline 128.0 + 3.2 128.0 + 3.6 371.0 + 2 8 376.0 + 26
(n - 5)
ET-1
( BP < 10 mmHg)
(n - 4) 135.0 + 2 : 0 1 3 9 . 3 + 2 . 5 423.8 + 8,3 418.8 + 11.3
ET-1
( BP > 10 mmHg)
(n - 5) 129.0 + 1.0 169.0 + 11* 404.0 + 22 369.0 + 27
Results are expressed as mean values + s.e.mean before and at the 
maximum response to intracisternal saline or peptide administration
* significant difference from saline control
* p < 0.05
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Table 7.7
Effect of Intracisternal ET-1 (0.03 nmol) on Cerebral Blood
Flow (CBF) in the Conscious Rat
Region
Saline (n
CBF Values (ml lOOg" 1
= 5) ET-1 (n = 4)
BP < 10 mmHg
. - 1  ' min )
ET-1 (n = 5)
BP > 10 mmHg
Nucleus of
the Solitary 103 + 4 116 + 13 40 + 13***
Tract
Caudal
Ventrolateral 109 + 4 130 + 15 31 + 20**
Medulla
Rostral
Ventrolateral 116 + 7 1 2 7 + 1 5 49 + 25*
Medulla
results are expressed as means s.e.mean
* significant difference from saline control
* p < 0.05 ** p < 0.005 *** p < 0.001
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Figure 7.11
Representative autoradiographs showing a reduction in 
cerebral blood flow in sections from an animal that ex­
perienced hypertension after administration of ET-1 (0.03 nmols) 
compared to a corresponding section from a saline-treated animal, 
a = control - caudal medulla oblongata
b = ET-1 (0.03 nmols) - caudal medulla
oblongata
c = control - rostral medulla oblongata and pons
d - ET-1 (0.03 nmols) - rostral medulla oblongata
and pons
7.3.4 Discussion
In conscious rats the marked elevation in arterial blood 
pressure, observed in some of the animals examined, subsequent to 
ET-1 administration, was associated with a pronounced reduction 
in cerebral blood flow (CBF). Indeed the extent and magnitude of 
this effect was far greater than any other peptide previously 
examined including neuropeptide Y (Tuor et al, 1987). The 
ability of this putative transmitter to modify CBF most likely 
results from a direct vasoconstrictor action on the cerebral 
vasculture but it could be a consequence of alterations in 
cerebral energy consumption. Evidence to support the former 
hypothesis derives from studies which described the constriction 
of isolated feline and canine basilar arteries in response to 
ET-1 (Yanagisawa et al, 1988a; Asano et al, 1989). In the same 
report, Asano et al (1989) also demonstrated, using angiographic 
techniques, a reduction in basilar artery diameter following 
intracisternal administration of ET-1 in anaesthetised dogs. 
Changes in the degree of vasoconstriction by ET-1 (10 pmols) 
could be observed in the absence of alterations in blood 
pressure. However this effect was dose-related and prominent but 
transient increases in blood pressure (40 mmHg) were observed at 
higher concentrations (100 pmol) of the peptide (Asano et al, 
1989).
Thus, in the present study, the marked reduction in CBF most 
likely arises from intense cerebral vasoconstriction. It is 
proposed that the resultant ischemia and concomitant increase in 
PCO2  levels, due to insufficient perfusion of the brain, would
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then stimulate central chemosensitive regions (Dampney and Moon, 
1980; Grady and Blaumanis, 1988). The dramatic increase in 
arterial pressure which ensues may therefore be an attempt 
(reflex) to maintain commensurate cerebral perfusion pressure. 
Neurones in the medulla oblongata, in particular the previously
discussed cell group located in the ventrolateral regions, are
thought to participate in the reflex responses to reduction in
blood flow and oxygen perfusion of the brain. Indeed lesions of
the area in the rabbit abrogate the prominent pressor response 
evoked by cerebral ischemia (Dampney and Moon, 1980). Moreover 
these neurones are ideal candidates as oxygen sensors since they 
contain abundant mitochondria, are in close proximity to 
capillaries and can influence spinal preganglionic vasomotor 
outflow (Milner et al, 1987; Ross et al, 1984b).
The event described above is similar to Cushing Response 
(Cushing, 1901). This phenomenon, characterised by a marked rise 
in arterial pressure and bradycardia, occurs when intracranial 
pressure approaches the levels of arterial pressure and prevents 
sufficient cerebral perfusion. Controversy surrounds the exact 
mechanism responsible for the stimulation of sympathetic nerve 
outflow and consequent increase in arterial pressure in the 
Cushing Response. However, ischemia with the associated increase 
in PCO2 , direct pressure and mechanical distortion of the 
brainstem have all been implicated (McGillicuddy et al, 1978; 
Grady and Blaumanis, 1988; Thompson and Malina, 1959).
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Thus, the ET-l-induced cerebral vasoconstriction which has 
been proposed to result in the observed attenuation of CBF, may 
have a physiological or pathophysiological role in the control of 
cerebral blood flow. Indeed, the disturbances in the control of 
ET-1 production or metabolism could also be instrumental in the 
pathogenesis of cerebral vasospasm. This condition, in humans, 
can occur after subarachnoid haemorrhage secondary to rupture of 
an intracranial aneurysm. Although a number of agents such as 
arachidonic acid metabolites, noradrenaline and serotonin have 
been proposed as contributing factors, ET-1 may also participate 
(Asano et al, 1989).
A second mechanism by which ET-1 could alter cerebral blood 
flow is through modification of cerebral energy consumption 
namely oxidative metabolism or glucose consumption. The 
relationship between CBF and cerebral metabolism emanates from 
the requirement of a continuous blood supply to maintain cerebral 
function. This is necessary since the brain only contains small 
amounts of energy generating substances. A number of agents have 
been shown to influence these parameters in parallel. Central 
administration of serotonin reduces cerebral functional activity 
as determined by oxygen and glucose utilisation as well as 
evoking a parallel reduction in CBF (Harper and MacKenzie, 1977). 
Opposite effects are elicited by vasoactive intestinal 
polypeptide (McCulloch and Edvinsson, 1980). This peptide 
increases cerebral energy requirements with an associated 
increase in CBF. Moreover, neuropeptide Y has been observed to 
reduce glucose utilisation in brainstem areas (Macrae et al,
1990, in press). In view of the lack of data concerning the 
alterations in cerebral metabolic activity following 
intracisternal administration of ET-1, a contribution from this 
source to the reduction in CBF cannot be excluded, although it 
is unlikely that a decrease in metabolic activity alone could 
account for the massive reductions in CBF observed.
The differences observed between conscious and anaesthetised 
rats in the frequency of the haemodynamic and parallel CBF 
response to intracisternal ET-1 may, reflect confounding effects 
of general anaesthesia on metabolic activity and CBF. Halothane 
anaesthesia elicits a reduction in total cerebral energy 
consumption associated with a reduction in consciousness (Shapiro 
et al, 1978). A direct action of halothane on cerebral blood 
vessels has also been suggested since vasodilation and not 
vasoconstriction, as expected from the metabolic data, has been 
reported (McCulloch, 1988). However, this proposed influence of 
anaesthesia on the central effects of ET-1 is not supported by 
the results obtained following intravenous administration of the 
peptide (Section'7.1.3). In that study, halothane anaesthesia 
altered the magnitude but not the frequency of the hypertensive 
response. Differences between the effects of halothane on the 
peripheral and cerebral circulation cannot be excluded. Perhaps 
the response to ET-1 varies with the activity of the animal. 
Thus, in the conscious animals, active head movement enabled the 
peptide to mix in the cerebral spinal fluid and reach the large 
and more distant blood vessels such as the basilar artery, on the
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ventral surface of the brain. Indeed a time-lag (0.5 - 2
minutes) in the haemodynamic effects of intracisternal
administration of ET-1 was observed in the present study implying
a delay in reaching the site of action. This explanation
however, does not account for the fact that some of the conscious
animals did not respond to intracisternal administration of
endothelin. In these animals the CBF resembled control values.
This would suggest that distribution to the cerebral blood
vessels was impeded in these animals. Shigeno ejt al (1989) have
demonstrated a consistent reduction in basilar artery diameter
following intracisternal administration of ET-1 in both cats and
dogs under halothane anaesthesia. However, a large injectate
volume ( 3 - 6  mis) was used in this study, possibly assisting
distribution. Despite the fact that access to the cerebral
spinal fluid (CSF) via the cannula was tested before each
injection as described in Section 1.6 and the position of the
cannula verified in certain animals at the end of the procedure
it is feasible that there are problems associated with the
technique in the present study. Since the completion of the
studies contained within Chapter Seven, experiments have been
undertaken to address the possibility that the inactivity of ET-1
(0.03 nmols) in some animals is a consequence of obstructed flow
of the peptide through the cannula. Preliminary data from pilot
experiments utilising the coadministration of unlabelled ET-1
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(0.03 nmols) and [ I]-radiolabelled ET-1 to trace the 
distribution of the peptides have demonstrated that in an animal 
that did not respond to the intracisternal coadministration, ET-1
binding sites could not be detected in the autoradiographs of
brain tissue. This would suggest that in this case the passage
of the peptide through the cannula was impaired. Moreover, ET-1 
binding sites were observed throughout the brain tissue of an 
animal that responded with a hypertensive event to the
coadministration regime. While further experiments are obviously 
needed to confirm this finding other explanations cannot be 
excluded. Interestingly, Wiklund et al (1988) reported a
similar ambiguity in the effect of ET-1 on isolated femoral 
arteries. In this study, nine out of 21 preparations did not 
respond to the peptide. Although an interpretation was not 
advanced by these authors it is unlikely that restricted access 
would account for the unresponsiveness of some of the
preparations.
The complications discussed above do not detract from the 
major finding of the current investigation that a reduction in 
cerebral blood flow is consistently associated with the 
hypertensive response following intracisternal administration of 
ET-1. Thus, ET-1 may have physiological relevance in the control 
of cerebral vascular tone as well as pathological importance in 
condiions such as cerebral vasospasm. However, further 
experiments are needed to resolve the apparent anomalies.
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CHAPTER EIGHT
GENERAL DISCUSSION
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Chapter Eight 
General Discussion
The intention of this final chapter is to coalesce and 
abridge the findings of the individual studies contained within 
this thesis, which investigate the central cardiovascular 
activities of the recently discovered peptides, neuropeptide Y 
(NPY) and endothelin-1 (ET-1). The physiological and 
pathological implications of these findings will also be 
considered along with proposals for future work.
In Chapter One the putative role of NPY in the central 
haemodynamic regulatory mechanisms was examined in the 
anaesthetised rat, using a discrete microinjection technique. 
This permitted the investigation of two distinct regions of the 
medulla oblongata namely, the caudal ventrolateral medulla (CVLM) 
and the rostral ventrolateral medulla (RVLM). These areas both 
contain NPY-like immunoreactive cell bodies as well as terminals 
and are considered pivotal in the tonic and reflex control of the 
cardiovascular system (Harfstrand et al, 1987a). NPY (25 pmol 
and 50 pmol) injected into the CVLM of the anaesthetised rat 
evoked a dose-related hypotension which, it is proposed, may be 
associated with the stimulation of a group of noradrenergic 
vasodepressor (A^) neurones located in this region. NPY also 
elicited a pronounced fall in heart rate, which was not dose- 
related. One explanation for this finding may be the close 
proximity and possible involvement of the nucleus ambiguus, an 
area with cardioinhibitory vagal projections (Ciriello and
198
Calaresu, 1980c; Macrae and Reid, 1988). This central 
vasodepressor effect of NPY in the CVLM is in accordance with 
another study which described a hypotensive response following 
intracisternal administration of this peptide (Fuxe et al, 1983). 
Since administration by this latter route concentrates the 
peptide around the medulla oblongata, it is possible that the 
neurones in the CVLM contribute to this response following 
intracisternal administration of NPY.
Although in the present study, injection of NPY (25 and 
50 pmol) into the RVLM did not elicit any significant 
haemodynamic response, spinally projecting NPY-containing 
neurones in this area have been purported to be involved in the 
haemodynamic response elicited from A^ neurones. This conjecture 
has arisen from pharmacological and neuroanatomical studies which 
have indicated that the sympathoexcitatory neurones in the RVLM 
receive a tonic inhibitory input from the CVLM (Granata et al, 
1986; Chan et al, 1986). Moreover when neurones in the CVLM are 
inhibited (or neurones in the RVLM directly stimulated) an 
increase in both blood pressure and the release of NPY-like 
immunoreactivity from the spinal cord ensue (Pilowsky et al, 
1987; Chalmers et al, 1986). Whether NPY is the endogenous 
transmitter responsible for stimulating the sympathetic 
preganglionic neurones and consequently elevating blood pressure 
is unclear, since intrathecal injection of NPY has been shown to 
evoke a vasodepressor response (Westfall et al, 1988). It is 
apparent that further work is needed before the potential of NPY 
to regulate blood pressure and heart rate in these regions is
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fully explored. This research is hindered by the absence of a 
specific NPY antagonist.
In addition to the proposed role for NPY in the normal 
functioning of central cardiovascular dynamics, supported by the 
studies, dysfunction of mechanisms regulating this peptide may be 
involved in the development and/or maintenance of hypertension. 
Indeed radioimmunoassay studies by Maccarrone and Jarrott (1985) 
have shown that lower levels of this vasodepressor peptide are 
present in the brainstem and spinal cord of spontaneously 
hypertensive rats (SHR). Moreover the hypotension elicited by 
intrathecal injection of NPY is attenuated in SHR rats (Westfall 
et al, 1988). Other alterations in NPY functioning have been 
observed in the SHR rat including increased binding sites in the 
area postrema (Nakajima et al, 1987). It is of considerable 
interest that many of the central neuronal systems containing 
catecholamines, which are considered to be of fundamental 
importance in the central regulation of blood pressure and whose 
function is altered in experimental hypertension, also contain 
NPY (Chalmers, 1975). NPY is costored, for instance, with 
noradrenaline in the cell group of the CVLM and in the more 
rostrally located C^ adrenergic cell group (Harfstrand et al, 
1987a). The functional implications of this coexistence with 
regard to haemodynamic regulation, was investigated in 
Chapter Four where the possible interaction between NPY receptors 
and C^2 "Adrenoceptors was examined. The involvement of ^ 2 " 
adrenoceptors in the central neural regulation of the
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cardiovascular system has been recognised and it has been 
proposed that the catecholamines, adrenaline and noradrenaline 
are the endogenous ligands for these brainstem G^-^tenoceptors 
(Unnerstall et al, 1984; Hausler, 1982). In Chapter Three it was 
previously demonstrated that the -adrenoceptor agonist
clonidine (10 and 20 nmol) produced hypotension and bradycardia 
following microinjection into both the CVLM and RVLM. 
Coadministration of NPY (25 or 50 pmol) together with a 
submaximal dose of clonidine (10 nmol) into the CVLM, produced a 
hypotensive response which was similar to the sum of their 
individual blood pressure responses. This indicated that no 
interaction occurred between the separate blood pressure 
responses evoked by the agents through their respective 
receptors. A similar lack of interaction was observed in the 
RVLM. NPY (25 pmol) which alone had no effect on blood pressure 
did not alter the haemodynamic effects of clonidine. It is 
interesting that in the CVLM although the hypotensive response to 
clonidine was not affected by NPY, simultaneous injection of NPY 
(25 pmol) and clonidine (10 nmol) produced a bradycardia which 
was less than the sum of the individual heart rate responses. 
The functional significance of this apparent antagonistic 
interaction remains to be determined. However, the general 
absence of functional interaction between O i^ -adrenoceptors and 
NPY receptors, with regard to the blood pressure response, 
differed from a report by Carter et al (1985) who demonstrated 
that the hypotensive response to 20 nmol noradrenaline in the 
nucleus of the solitary tract (NTS), was significantly modified
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by both prior and simultaneous injection of an ineffective dose
(47 fmol) of NPY. The reason for the differences between studies
*
is not clear since colocalisation of NPY and catecholamines has 
been observed in the neuronal groups of the ventrolateral aspects 
of the medulla as well as in the NTS. However, colocalisation 
may not always denote a probable functional interaction. Indeed, 
the classical transmitter somatostatin and NPY are costored in 
the striatum but do not appear to interact in the regulation of 
dopamine turnover when coadministered, implying a separate 
mechanism of action (Kowall et al, 1985). In some regions 
colocalisation may reflect a provision for separate functions 
which are required or evoked under different conditions. In 
sympathetic neurones in the periphery where NPY and noradrenaline 
are costored, differential release of these agents has been 
observed lending support to this postulate. Low frequency 
stimulation preferentially releases noradrenaline whereas high 
frequency stimulation is needed to release both noradrenaline and 
NPY (Lundberg et al, 1986). Thus, it has been proposed that NPY 
may only be released under conditions of high frequency 
stimulation such as 'stress' to support the classical transmitter 
and improve transmitter economy.
The molecular mechanism involved in the hypotensive action 
of NPY and possible interactions with adrenoceptors were examined 
in Chapters Five and Six. Since NPY was previously shown to 
modulate cAMP levels in cerebral blood vessels and cortex 
(Fredholm et al, 1985; Westlind-Danielsson, 1987), experiments
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were devised to test whether this second messenger system could 
also participate in the central cardiovascular activities of NPY 
observed in the medulla. A significant reduction of forskolin- 
stimulated but not basal cAMP levels was demonstrated with 10 
NPY in slices of the rat medulla oblongata as well as in the 
cortex. In addition, the ability of NPY to inhibit forskolin- 
stimulated cAMP levels in medullary slices was abolished 
following intracisternal pre-treatment with pertussis toxin (2 or 
5 jug). This toxin inactivates a family of inhibitory G-proteins 
which are known to mediate the reduction of adenylate cyclase 
activity and consequently a reduction in cAMP levels. It is 
therefore postulated that the reduction in cAMP levels produced 
by NPY in the medulla is regulated through an inhibitory G- 
protein.
Consistent .with the hypothesis that the hypotensive effect 
of NPY in the medulla is mediated via a reduction in adenylate 
cyclase activity and cAMP levels, a very recent publication by 
Fuxe et al (1989) demonstrates that intraventricular pretreatment 
with PTX inhibits the hypotensive and bradycardic effects of NPY 
injected into the lateral ventricles. Interestingly in this 
study the hypotensive but not the bradycardic effect of clonidine 
was also attenuated by PTX pretreatment. Although the central 
hypotensive properties of clonidine were confirmed in the current 
studies, this OL adrenoceptor agonist was not observed to reduce 
forskolin-stimulated or basal cAMP levels in slices of rat 
medulla oblongata. It is noteworthy that while the inhibitory 
coupling of 012-adrenoceptors to adenylate cyclase is established
in the peripheral nervous system, the situation is less clear and 
results more variable in the central nervous system. Thus, 
clonidine has been observed to either decrease, increase or have 
no effect on cAMP levels in central regions (Duman and Enna, 
1986; Nakamichi et al, 1987; Etgen and Petitti, 1987). 
Differences in concentrations of the agonist used in these 
studies and variations in receptor populations between regions 
may contribute to these variations in response.
Moxonidine, another centrally acting OL adrenoceptor 
agonist with hypotensive properties, was observed to reduce 
forskolin-stimulated cAMP levels in medullary slices. In 
addition to being a full agonist at OL adrenoceptors (Clonidine 
is a partial agonist) another reason for its disparate effects 
from clonidine may be a consequence of its higher presynaptic 
0^2-adrenoceptor selectivity. Although haemodynamic interactions 
between NPY and OL^-adrenoceptors were generally absent in the 
ventrolateral medulla, a functional interaction has been reported 
between these receptors in the NTS (Carter et al, 1985). This 
receptor interaction may exist at the level of the recognition 
site as suggested by Fuxe et al (1987b) or at post-receptor 
processes. Evidence has been presented in Chapter Six which 
indicates that an interaction between the Q£ 2 •adrenoceptor 
agonist moxonidine and NPY can be detected at the second 
messenger level. Thus, the previously discussed individual 
inhibitory effects of these agents on forskolin-stimulated cAMP 
levels in the medulla oblongata were attenuated when these agents
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were coadministered, suggesting an interaction between OL 
adrenoceptors and NPY receptors can be distinguished at the level 
of the second messenger system. In vivo microinjection studies on 
the haemodynamic effects of NPY and moxonidine alone and in 
combination are necessary to establish if an interaction is also 
evident at the circulation level. The. cardiovascular effects of 
catecholamines which are found costored with NPY in medullary 
neurones may also be mediated through j(3-adrenoceptors located in 
this region (Stone and U'Prichard, 1981). However, an 
interaction between ^-adrenoceptors and NPY receptors at the 
adenylate cyclase level was not evident in slices of medulla 
oblongata. In vivo microinjection studies observing the 
haemodynamic responses of these agents alone and when 
coadministered are proposed. Moreover, development of a method 
to microinject into the medullary regions of conscious rats would 
circumvent the possible confounding effects of anaesthesia and 
would therefore be beneficial in such studies.
The haemodynamic actions of another peptide, endothelin-1 
(ET-1), a member of the recently identified endothelin family was 
examined in Chapter Seven. Intracisternal administration of ET-1 
(0.01 -0.03 nmols) in the conscious rat evoked a distinctive 
response consisting of a dramatic elevation in blood pressure, 
accompanied in some cases by intense motor activity (barrel- 
rolling), but no consistent alteration in heart rate. This 
haemodynamic profile, following intracisternal ET-1
administration, occurred at lower concentrations than those 
needed to elicit a response in the periphery and also differed
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qualitatively from the biphasic haemodynamic response produced 
following intravenous ET-1 (0.1 -1 nmol) administration. This 
data would suggest the response to intracisternal administration 
of ET-1 is central in origin and not due to leakage of the 
peptide into the periphery. An autoradiographic approach was 
utilised to elucidate the possible sites and mechanisms of the 
central action of ET-1. The distinctive cardiovascular response 
(reminiscent of Cushing Syndrome) and the now rapidly 
accumulating publications which assert a vasoconstrictor action 
of ET-1, suggest that the dramatic hypertensive event may be 
mediated via an action on cerebral blood vessels rather than an 
action in the brain parenchyma.
This hypothesis was investigated in the third section of 
Chapter Seven using [.^C] iodoantipyrene autoradiography for 
measurement of regional cerebral blood flow (CBF). The data 
obtained, indicated that the prominent increase in blood pressure 
following intracisternal administration of ET-1 was in all cases 
accompanied by a decrease in CBF in the brain stem to ischaemic 
levels. Moreover, this reduction in brainstem CBF was greater in 
magnitude than that previously observed with other putative 
endogenous transmitters. This data supports an angiographic 
study which was published subsequent to the present investigation 
and described cerebral vasoconstriction following intracisternal 
administration of ET-1 in dogs (Asano et al, 1989). Aberrations 
were in evidence in the present study. The hypertensive event 
was not present in all animals (conscious or anaesthetised)
206
investigated, moreover in those animals that did not respond to 
intracisternal endothelin-1 CBF was comparable to control values. 
The frequency of the hypertensive response in these animals was 
apparently reduced in the presence of anaesthesia. While an 
effect of anaesthesia per se on the frequency of the response to 
ET-1 is possible (though unlikely considering anaesthesia does 
not alter the frequency of the peripheral response), further work 
is required to resolve the 'non-response' of some animals to 
intracisternal administration of the peptide. Despite these 
anomalies considerable evidence has been presented which purports 
an involvement of ET-1 in centrally mediated haemodynamics and 
cerebral vascular function. It has also been speculated that a 
breakdown of the regulatory mechanisms of ET-1 production could 
lead to various pathological conditions such as cerebral 
vasospasm. Although there is no direct evidence to confirm this 
supposition, the potent and prolonged nature of the contracture 
observed following intracisternal administration of ET-1 in the 
present study and in the angiographic study by Asano et al (1989) 
suggest that this peptide may contribute to chronic cerebral 
vasospasm and its sequelae. Moreover that cerebral vasospasm can 
occur after subarachnoid haemorrhage secondary to rupture of an 
intracranial aneurysm and that the expression of ET-1 is 
stimulated in the presence of factors which are present at the 
site of endothelial injury (thrombin, TGF-F, shear stress) 
indicate an association of this peptide with the pathogenesis of 
vasospasm. In addition to its direct vasoconstricting action 
ET-1 may also participate in neural cardiovascular regulatory
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mechanisms acting as a neuropeptide or neuromodulator. This 
putative role of ET-1 remains to be established. However Asano
et al (1989) have shown that a low dose of ET-1 (10 pmol i.e.) 
evoked angiographic vasospasm with no elevation in blood 
pressure. This indicates that the first line of action of this 
peptide in the modulation of cerebral circulation in vivo appears 
to be the cerebral vessels.
In conclusion, both NPY and ET-1 have been observed to alter 
haemodynamic parameters following central administration in the 
rat. Some insight into the possible mechanisms of these actions 
have been presented. However, as discussed, further work is 
required to elucidate fully the potential role of both peptides 
in central cardiovascular regulatory mechanisms. The development 
of specific antagonists to NPY and ET-1 would undoubtedly 
expediate this research.
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